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Abstract 
Regenerative medicine is a multidisciplinary effort to regenerate or replace a deficiency 
of functional cells/tissues, such as deteriorated vasculature in cardiovascular pathologies 
or depleted 𝛽-cell mass in diabetes. The transplantation of pro-regenerative progenitor 
cell populations has demonstrated therapeutic benefits in pre-clinical models, although 
translation to clinical efficacy is limited by the paradoxical balance between cell 
expansion ex vivo and loss of regenerative functions in vivo. Herein, this thesis 
encompasses two distinct approaches to circumvent translational deficiencies; 1) 
prevention of hematopoietic progenitor cell differentiation during ex vivo expansion and 
2) utilizing the secretome of pancreas-derived multipotent stromal cell as a biotherapeutic 
agent. Across the first two studies, I investigated whether the inhibition of retinoic acid 
(RA)-signaling would limit HPC differentiation and retain pro-vascular and islet 
regenerative functions in vivo. These studies identified a bias of HPC towards 
megakaryopoiesis with prolonged culture; however, also demonstrated that the reversible 
inhibition of RA-signaling enhances the expansion of HPC progeny that retain a primitive 
phenotype and multifaceted pro-regenerative functions in vivo. Albeit, cell 
transplantation is limited by transplanted cell survival and subsequent secretion of pro-
regenerative stimuli. Accordingly, we have demonstrated the transplantation of 
conditioned media generated by therapeutic cells by-passes these limitations while 
stimulating endogenous mechanisms of tissue regeneration. To this end, I isolated a 
heterogenous Panc-MSC population during culture of human islets in vitro.  Using label-
free mass spectrometry and flow cytometry analyses, I provide the first in-depth 
characterization of human Panc-MSC in comparison to BM-MSC. Specifically, I 
demonstrated the proteome of Panc-MSC restricts adipogenesis and RA-signaling; albeit, 
is competent to pro-neural stimuli and primed for robust expansion ex vivo. Next, I 
determined that Panc-MSC secrete pro-angiogenic and islet regenerative stimuli which 
are harbored within extracellular vesicles. Collectively, this body of work provides novel 
insights towards multifaceted therapeutic cell populations and lays a foundation to 
explore the cell-free biotherapeutics for applications of regenerative medicine.  
ii 
Summary  
This body of work undertakes a broad experimental approach to identify “stem cell” 
populations cells from human post-natal or adult tissues, such as umbilical cord blood, 
bone marrow, or pancreas. Specifically, I sought to identify cells which may be used as a 
biological agent to activate endogenous (self-) regeneration to treat diabetes and life-
threating complications of blood vessels. In diabetes, a loss or dysfunction of insulin-
producing β-cells leads to elevated blood sugars that damage blood vessels in organs 
throughout the body. In the first half of this thesis, I developed a method to increase the 
number of blood lineage-specific stem cell populations that can regenerate beta-cells and 
blood vessels in mouse models. Albeit, I present early evidence that cells of the 
megakaryocyte (platelet-producing)-lineage may have therapeutic potential. The second 
half of this thesis characterized a mesenchymal progenitor population from human 
pancreas tissue using high-sensitive equipment to detect over >7000 proteins in an effort 
to establish a “proteomic fingerprint” of therapeutic cell populations. Accordingly, I 
proceeded to show that cell transplantation can be avoided, and media conditioned by 
mesenchymal progenitors can be concentrated for use as a biological cocktail to stimulate 
blood vessel and β-cell regeneration in mouse models. This body of work provides 
foundational evidence to further explore the use of post-natal and adult stem/progenitor 
cell populations as a therapeutic tool to treat diabetes and/or vascular complications. 
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Chapter 1  
1 Introduction 
1.1 Diabetes Mellitus 
Over 2000 years ago, physicians in India provided the first ‘clinical’ diagnosis of 
“madhumeha” or “honey urine” when excessive urine excretion (polyuria) from patients 
attracted an unexpected infestation of insects1,2. Today, madhumeha is diagnosed as 
diabetes mellitus (DM) or ‘passing through of honey’ which more accurately segregates 
the glucose-rich polyuria of diabetes mellitus from non-related polyuria conditions (i.e. 
diabetes insipidus)3. Although DM has challenged scientists and clinicians for over 2000 
years, only in the last century has clinical interventions that mitigate early death become 
available4. At the root of disease, DM is the dysregulation of blood glucose homeostasis 
and/or peripheral insulin sensitivity; ultimately leading to system-wide cardiometabolic 
imbalances that contribute to secondary pathologies.  
DM can be further segregated based on etiology and central pathology, albeit both 
types of DM will ultimately succumb to comparable cardiovascular comorbidities5-9. 
Briefly, DM is made-up of individuals with autoimmune Type 1 and insulin-resistant 
Type II pathologies; although, other forms of DM, such as gestational diabetes, also 
exist10-13.  Presently, DM has reached epidemic proportions (>400 million individuals 
globally) and has financially burdened the international healthcare system (>700 billion 
USD per year) without a foreseeable plateau13. Throughout this chapter, I will discuss the 
etiology, pathology and common cardiovascular comorbidities of DM. Specifically, I will 
focus on the limitations of therapeutic approaches aiming to provide long-term glucose 
control and how regenerative medicine is progressing towards novel therapies to treat 
diabetes and vascular comorbidities. 
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1.1.1 Human Pancreas Development 
Organogenesis of the human pancreas occurs at anatomical region of the endoderm-
derived distal foregut morphogenesis followed by subsequent budding of the FOXA2+ 
(Forkhead Box A2)/PDX1+ (Pancreatic and Duodenal Homeobox 1) dorsal and ventral 
pancreatic epithelium at 4-5 weeks post-conception14,15 (Figure 1.1). Accordingly, the 
larger dorsal bud and common bile duct rotate and fuse to the smaller ventral bud, 
creating the common pancreatic duct network that drains exocrine secretions towards the 
duodenum around embryonic week 7. During these morphological changes, PDX1+ 
progenitor cells within pancreatic buds undergo robust proliferation and differentiate into 
either duct-supported exocrine tissue or endocrine-functioning islets of Langerhans. In a 
brief summary, SOX9+ (SRY-box 9)/PDX1+ progenitors will acquire an exocrine fate 
through the acquisition of GATA4 (GATA Binding Protein 4) expression defining ‘tip’ 
progenitor cells committed toward acinar cell fate. In contrast, ‘trunk’ progenitor cells 
serve as a bipotent progenitor cell pool which commits to ductal or endocrine-lineage fate 
through sustained expression of SOX9 or transient expression of NEUROG3, 
respectively15.  Exocrine tissue makes up the vast majority of the adult pancreas (>95%) 
and provide an essential supply of pro-isoform digestive enzymes that are subsequently 
activated in the duodenum of the small intestine. Endocrine tissue makes up ~1-2% of 
total pancreas mass despite containing a unique composition of at least 5 hormone-
releasing islet cell types. In summary, exclusive expression of lineage specific 
transcriptional factors in NEUROG3+ endocrine-lineage progenitors, such as NKX6.1 
(NK6 Homeobox 1) and MAFA (MAF BZIP Transcription Factor A) , lead to the 
differentiation and maturation of insulin-producing β-cells15. Similarly, the balance 
between ARX (Aristaless Related Homeobox) and PAX4 (Paired Box 4) expression 
regulates α-cell versus β-cell identity16, respectively. The coordinated development of  
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Figure 1.1 Overview of Human Pancreas Development and Lineage-specification. 
Organogenesis of pancreas begins in distal foregut endoderm at 3-4 weeks post-
conception. FOXA2 and PDX1 expression defines Distal Foregut Endoderm commitment 
to the pancreatic lineage. High GATA4 expression commits PDX1+ pancreatic bipotent 
progenitors towards acinar-cell fate. Sustained NKX6.1 expression commits bipotent 
progenitors towards ductal cell fate through sustained expression of SOX9. Alternatively, 
endocrine progenitors will lose SOX9 expression and transiently express NEUROG3. 
NEUROG3+ progenitors will give rise to endocrine cells, including insulin-secreting β-
cells and glucagon-secreting α-cells.   
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these specialized cell-types bestows the pancreas as a multifunctional organ which 
provides central components for nutrient absorption and energy homeostasis. 
Acinar cells can be histologically identified by ductal-centric organization, distinct 
cytoplasmic zymogen granules, and basolateral nucleus17,18 (Figure 1.2). During 
development, acinar cells differentiate from PDX1 pancreatic endoderm progenitors 
through the activation of Notch signaling pathways and expression of GATA4, PTF1 
(Pancreas Associated Transcription Factor 1a), and CPA2 (Carboxypeptidase A2)15,17,19-
21. Pancreatic acini are composed of acinar cells centered around centroacinar cells 
located at the terminal end of intercalated ductal epithelium22. Networks of ductal 
epithelium converge to form intralobular ducts that transport digestive zymogens released 
from acinar cells. Exocrine secretions of the pancreas to lead enzymatic breakdown and 
absorption of carbohydrates, lipids, or proteins in the small intestine. Disruption of acinar 
homeostasis can lead chronic inflammation of the pancreas, also known as pancreatitis. 
Towards this end, acinar cells have been proposed to regenerate exocrine pancreas tissues 
via dynamic differentiation and plasticity23,24. Exocrine regeneration by acinar cell 
expansion has been thoroughly investigated24,25, however convincing evidence of acinar 
cell reprogramming towards an endocrine fate has only been demonstrated using 
exogenous vectors26.  
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Figure 1.2 Overview of Exocrine and Endocrine Cell Populations of the Pancreas. 
The pancreas contains exocrine (acinar and ductal cells) and endocrine (islet of 
Langerhans) cell populations, each with unique functions. 
 
 
 
 
6 
The endocrine compartment of the pancreas is composed several cell-types marked by 
specialized hormone secretion27; including ∝-cells (glucagon), 𝛽-cells (insulin), δ-cells 
(somatostatin), ε-cells (ghrelin), PP-cells14,28-30. The ratio of cells within islets of 
Langerhans is estimated around 35-40% ∝-cells and 40-60% β-cells with infrequent 
representation by δ-cells, PP, and ε-cells. Spatial arrangement of endocrine cells within 
islets is distinct between rodents and humans, such that β-cells dispersed through the 
human pancreas and centered at the islet core in rodent models. Nonetheless, the 
architecture of mammalian pancreatic islets is integrated with a dense microvascular 
network, that serves to transport secreted hormones to peripheral tissues31. In the context 
of diabetes, reciprocal balance of ∝- and β-cell function maintains glucose homeostasis 
by controlling the glucose release from the liver and uptake from the circulation32-35. 
Briefly, ∝-cells release of glucagon in response hypoglycemic or energy-demanding 
conditions. Activation of the glucagon receptor on hepatocytes increases glycogenolysis 
and gluconeogenesis to elevate blood glucose levels. In contrast, insulin functions to 
reduce blood glucose levels by stimulating glucose uptake into peripheral tissues after 
ingestion of food. In the context of diabetes, the loss of functional β-cell mass and/or 
peripheral insulin sensitivity leads to damaging hyperglycemia36.  
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1.1.2 Insulin Secretion and Glucose Homeostasis 
Following the ingestion of food and absorption of carbohydrates in the small 
intestine, systemic blood glucose concentration can rapidly elevate nearly 2-fold in a 
healthy adult32. In order to counteract toxicity from prolonged hyperglycemia, β-cells 
sense hyperglycemia and rapidly restore normoglycemia (within ~60 minutes) through 
the hormonal actions of insulin (Figure 1.3). β-cells are equipped with bidirectional 
glucose transporter, GLUT2 (Glucose Transporter 2), that allows β-cells to gauge 
systemic glycemia levels and regulate glucose metabolism37,38. Homeostatic blood 
glucose levels are maintained by a fine-tuned balance of glucagon or insulin secretion. In 
periods of normoglycemia, the low affinity of GLUT2 transporter facilitates glucose 
uptake from circulation at concentrations that maintains membrane potential in β-cells38. 
In contrast, hyperglycemia elevates glucose uptake via GLUT2 and increases the 
production of cytosolic ATP, ultimately leading to insulin secretion (Figure 1.3). ATP 
generated by glycolytic activities of the β-cell will inhibit ATP-sensitive K+-channel 
function, and in return, indirectly open voltage-gated Ca++ channels38-40. Decreased K+ 
efflux leads to rapid depolarization of the plasma membrane and increased cytosolic 
calcium concentrations mediate insulin release. The initial pool of insulin released via 
exocytosis by β-cells is replenished by the glucose-sensitive regulation of pro-insulin 
translation. During this period, glucagon secretion from α-cells  
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Figure 1.3 Overview of Insulin Secretion and Glut4 Translocation in Response to 
Hyperglycemia. Glucose uptake through GLUT2 transporters leads to increased 
cytosolic ATP in beta-cells. Inhibition of ATP-sensitive K+ channels will lead to an 
influx of Ca++ and insulin vesicle release and translation. Insulin will activate INSR1/2 
on peripheral cells (i.e. adipocytes) and translocation of GLUT4 to the plasma membrane 
will occur. Subsequently, glucose will be up taken through GLUT4 transporters to satisfy 
metabolic demands. 
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is dampened, and glucose storage is promoted within the liver by the inhibition of 
glucagon-regulated glycogenolysis enzymes and activation of glycogen synthase to 
promote glycogen formation33. Circulating insulin activates insulin-receptors to stimulate 
translocation of GLUT4 transporters to the plasma membrane of competent (i.e. liver, 
adipose, skeletal muscle) cells to increase the glucose clearance from systemic circulation 
and meet the metabolic demands of tissues35,41,42.  In type 2 DM, insulin-dependent 
GLUT4-translocation is disrupted in peripheral cells.  
Insulin secretion and/or function is also regulated by additional effectors which either act 
in a positive or negative manner. Incretins hormones including Gastric Inhibitory 
Polypeptide (GIP) and Glucagon-like Peptide 1 (GLP-1) are released from the intestinal 
mucosa shortly after oral nutrient ingestion43,44. Both GIP and GLP-1 potentiate insulin 
secretion from the pancreas, whereas the later also reduces glucagon secretion. Ghrelin-
secretion from epsilon-cells also increases insulin secretion from β-cells in rodent model, 
although the relevance of this in humans is not completely understood29,30.  In contrast, 
effectors such as glucagon, catecholamines, growth hormone, cortisol, and free fatty 
acids dampen the secretion or peripheral actions of insulin32,34. Intra-islet hormones, such 
as somatostatin and PP, also provide overlapping regulation of glucagon and insulin 
secretion45,46. In the context of diabetes, disruption of insulin production and/or 
peripheral sensitivity leads to dysregulated systemic glucose homeostasis. As a result, a 
wide spectrum of cardiometabolic pathologies develop leading to life-threatening 
complications. 
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1.1.3 Type 1 Diabetes  
Accounting for ~10% of individuals with DM, Type 1 DM affects roughly >40 
million individuals internationally and is most prominent in populations of Northern 
European descent13,47. Type 1 DM is commonly referred to as juvenile diabetes, although 
this terminology may be viewed as a misnomer as symptoms occasionally manifest in 
adults as latent autoimmune DM or ‘Type 1.5’48. The international rates of Type 1 DM 
have gradually increased over time47,49,50, which has only complicated our understanding 
of the etiology of Type 1 DM47,50-55. Although genetic mutations (i.e. HLA-DR3/4) have 
been identified in a proportion of individuals with Type 1 DM, other studies have 
suggested in utero or post-natal environmental insults, combined with genetic 
predisposition, may trigger initiation of autoimmunity in Type 1 DM51,54,55. Common 
models of Type 1 DM, include NOD mice which spontaneously develop autoimmune 
diabetes and reflect the human pathophysiology of inflammatory cell infiltration into 
islets56. Other genetic and chemical-induced models have also been used to further our 
understanding the pathophysiology of Type 1 diabetes and/or facilitate the transplantation 
of human islets and/or regenerative cell populations for the development of novel 
therapies57,58.  
The underlying pathology of Type 1 DM is targeted T-cell mediated destruction of 
pancreatic β-cells (Figure 1.4). Specifically, CD4+ T-helper Cells and CD8+ cytotoxic T-
cells are responsible for the targeted destruction of β-cells following the  generation of 
autoantibodies by activated B cells, respectively54,59. Although mechanisms are not 
completely understood, autoantigen presentation is initially mediated by B-lymphocytes 
and antigen-presenting cells of the innate immunity, such as macrophages and/or 
dendritic cells. Interestingly, 𝛼-cells, 𝛿-cells, PP cells, and 𝜖-cells of the islet are not 
targeted by cytolytic CD8+ T-cells, thus suggesting the autoantigen is exclusive to the β-
cell lineage. Recent studies have suggested early senescence of a β-cell population may 
be the root of autoantibody generation60, eventually leading to the destruction of 
functional β-cells. The destruction of insulin-generating β-cell leads to systematic 
complications, such as neuropathy, nephropathy, retinopathy and gastrointestinal 
disorders, as a result of prolonged periods of hyperglycemia8,61-64.  
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Figure 1.4 Overview of Autoimmune-induced Type 1 Diabetes and Insulin-
dependent Hyperglycemia.  Autoantigens, generated by antigen presenting cells of the 
innate and adaptive immune system, activate cytolytic T-cells. Activated T-cells will 
selectively induce apoptosis in β-cells, leading to a loss of insulin-producing cell mass. 
The loss of β-cell mass will lead to sustained hyperglycemia and insulin-dependence.  
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In a clinical setting, individuals with Type 1 diabetes present with a spectrum of 
symptoms59; however, the initial diagnosis typically following the rapid onset of severe 
hyperglycemia-induced coma. In addition to severe hyperglycemia, patients with Type 1 
diabetes may present with sub-average muscle mass, chronic fatigue, polyuria, and/or 
secondary infections of oral and genital orifices. Ultimately, individuals diagnosed with 
Type-1 diabetes are insulin-dependent and require daily exogenous injection or 
automated pump therapies.   
 
1.1.4 Type 2 Diabetes 
The prevalence of Type 2 diabetes has increased at an alarming rate. With an estimated 
>30% increase of afflicted individuals in next 5 years, Type 2 diabetes continues to 
burden the global healthcare system due poor diet, central obesity, and sedentary 
lifestyles65-71. In 2015, Type 2 diabetes patients numbered >400-million individuals 
globally and despite a notable number of individuals remaining undiagnosed, Type 2 DM 
and related health issues caused the global healthcare system >$800 billion13,67,70,71. 
Unfortunately, in many cases this financial burden is placed on the afflicted individuals 
who struggle to secure and retain employment due to complications of the disease67.  
Notably, Type 2 diabetes is largely preventable through proper diet and exercise 
regimens, which outlines the importance of public educational programs and individual 
care65,66,72-77. Furthermore, both proactive and preventative measures must be taken to 
counteract the alarming rate of Type 2 diabetes presently diagnosed in children and 
adolescents61.  Several genetic pre-dispositions have been proposed by genome-wide 
association studies and have correlated variations in genetic loci to the onset and 
progression of Type 2 DM in human tissues68,71,78. To this end, evidence from epigenetic 
studies following gestational insufficiency have demonstrated important non-genetic 
contributions towards β-cell maturation and susceptibility to disease later in life15,79,80. 
Without effective management of hyperglycemia, individuals with Type 2 DM will 
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eventually become insulin-dependent (Figure 1.5); although, early diagnosis could 
prevent this outcome.  
Skeletal muscle and adipose tissues are the primary targets for circulating insulin to 
stimulate the rapid removal of glucose from the blood35. Insulin binds to insulin receptor 
1/2 (INSR1/2) on the membrane of target cells, in return leading to a cascade of 
downstream effectors that stimulate translocation of GLUT4 transporter to the plasma 
membrane42,81. Chronic activation of INSR1/2 can lead sustained receptor internalization 
leading to a global decrease in the expression of GLUT4 on peripheral tissues. As a 
result, when β-cells increase the production and secretion of insulin, in an attempt to 
combat prolonged periods of hyperglycemia, peripheral tissues, such as skeletal muscle, 
become desensitized to chronic exposure of circulating insulin and fail to facilitate the 
uptake of glucose from systemic circulation. As a result of concurrent obesity, individuals 
with Type 2 DM are prone to elevated level of free fatty acids which additionally 
compromise β-cell function82. This paradoxical dysfunction of glucose homeostasis 
eventually leads to β-cell exhaustion, free-radical generation, and β-cell death83,84. 
Ultimately, the capacity of the pancreas in Type 2 diabetics to produce enough 
endogenous insulin is compromised, thus individuals with late-stage Type 2 DM will 
require exogenous insulin therapy similar to individuals with Type 1 DM70,71,83.  
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Figure 1.5 Overview of Insulin-resistant Type 2 Diabetes and Insulin-dependent 
hyperglycemia. Sustained periods of elevated glucose levels and cardiometabolic 
imbalances lead to peripheral insulin desensitization. As a result, insulin demand will 
increase and eventually lead to beta-cell exhaustion and apoptosis. In late stages of Type 
2 diabetes, the loss of beta-cell mass leads to insulin-dependence.  
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1.1.5 Clinical Strategies to Combat Diabetes 
Insulin-dependence in Type 1 and Type 2 DM is a result diminished β-cell mass where 
insulin secretion is no longer sufficient to maintain glucose homeostasis. Interestingly, 
rodent models that received >90% excision of the pancreas did not become insulin-
dependent despite a considerable loss of β-cell mass25,85. In contrast, a 40-50% resection 
of the pancreas in human patients has led to insulin-dependence following surgery86. 
These differences reflect genetic and physiological differences between species, such as 
architectural organization and distribution of islets of Langerhans87-92. Nonetheless, 
current therapies must supplement the loss of insulin-secreting β-cells by providing 
sufficient exogenous insulin to counteract chronic hyperglycemia93,94. However, 
exogenous insulin therapy can lead to fluctuations in blood glucose that lead to diabetic 
complications, which reduces the life expectancy of individuals with DM by ~15 years 
despite current clinical intervention. Briefly, I will highlight the current clinical strategies 
and limitations encountered during the treatment of Type 1 or Type 2 DM.  
 
1.1.5.1 Clinical Therapies for Type 1 Diabetes 
From a pioneering studies performed in Canada, the discovery of insulin by Fredrick 
Banting, Charles Best, and John McLeod has prolonged the survival of Type 1 DM 
patients95,96. Insulin, a 29 a.a. peptide, was first discovered through intravenous 
administration of pancreatic extracts which temporary alleviated hyperglycemia in 
diabetic dogs. The first human patient to demonstrate clinical improvements was injected 
with purified insulin from bovine pancreas97.  Today, insulin is primarily synthesized and 
purified from bacteria or yeast98,99; although this has not limited the considerable 
financial burden placed on insulin-dependent patients67,100,101. Moreover, there exists 
several types of insulin that differ based on their pharmacological onset and duration of 
therapeutic effect. Endogenous insulin is packages as a hexameric molecule within 
cytoplasmic vesicles and cleaved into monomers upon secretion. Exogenous insulin has 
exploited these properties to engineering insulin subunits which only exist as monomers 
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to longer-lasting insulin subunits. Despite these advancements, insulin therapy fails to 
recapitulate the fine-tuned physiological response observed in healthy subjects, thus 
replacement of functional β-cell mass is sought to achieve sustained reversal of insulin-
dependence in individuals with Type 1 DM.  
The Edmonton protocol provided pioneering evidence that replacement of functional β-
cell mass could reverse severe Type 1 DM102,103. Specifically, Shapiro and colleagues 
demonstrated the infusion of human islets from 2-3 donor pancreas into the portal vein of 
the liver could alleviate insulin-dependence for up to 1-year in patients with Type 1 
DM104. This procedure is still performed today yet is severely limited by the lack of 
donor pancreases and continued autoimmunity and islet rejection despite a parallel 
immunosuppressive regimen which leaves patients vulnerable to secondary infections105. 
These studies set the foundation for current regenerative medicine approaches which aim 
to either replace or regenerate endogenous β-cell mass. Current evidence suggests the 
orchestration of endocrine cell regeneration may entail a combination of endocrine-cell 
replication, transdifferentiation, and/or islet neogenesis22,23,58,106-110. Therefore, effective 
therapies entail a broad activation pro-regenerative signaling pathways, possibly in 
multiple cell targets. Albeit, the true effectiveness of either replacement or regeneration 
strategies will also depend upon the dampening of autoimmunity111. Accordingly, several 
strategies are currently being investigated to mitigate autoimmunity112-114. 
 
1.1.5.2 Clinical Therapies for Type 2 Diabetes 
Individuals with Type 2 diabetes are commonly treated with pharmaceutical agents which 
aim to lower hyperglycemia independent of exogenous insulin administration. For 
example, Metformin is commonly prescribed to reduce blood glucose by dampening 
gluconeogenic activity of the liver and increasing peripheral insulin sensitivity115. In 
contrast, other pharmaceuticals, such as Sulfonylureas, act to lower blood glucose by 
enhancing the secretion of insulin from β-cells116. Recently, pharmaceutical inhibitors of 
SLGT2 (sodium-glucose co-transporter 2) aim to reduce glucose reuptake in the proximal 
tubule of the kidney117. For example, Empagliflozin administration reduced 
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hyperglycemia and Hemoglobin A1c by promoting the excretion of glucose through 
urination. Nonetheless, early diagnosis of Type 2 diabetes may permit reversal the 
disease through dietary and lifestyle changes65,73,75,76,93,118,119. As previously noted, public 
education is crucial to circumvent the epidemic progression of Type 2 DM. In contrast to 
Type 1 diabetes, undiagnosed Type 2 DM does not produce an immediate threat to 
survival; however, Type 2 DM occurs frequently with hyperlipidemia and leads to life-
threatening cardiovascular comorbidities5-7,9. Therefore, individuals with Type 2 DM 
often require therapeutics to simultaneously combat cardiometabolic syndromes and 
peripheral insulin-resistance. 
 
1.2 Cardiovascular Comorbidities of Diabetes 
Individuals with DM are highly susceptible to developing secondary comorbidities, 
including neuropathy, nephropathy, retinopathy and gastrointestinal disorders5-9,63,64. 
Notably, prolonged periods of hyperglycemia and/or hyperlipemia leads to irreversible 
macrovessel and microvessel damage in 90% individuals with DM. Damage of 
microvasculature has be implicated in stroke, myocardial infarction, and peripheral limb 
ischemia7,120. Likewise, the disruption to microvascular networks can lead to renal121 and 
neurological dysfunction62,122, and loss of vision123. Collectively, loss of vascular 
networks reduces the delivery of oxygen and nutrients to tissues leading to system-wide 
cardiometabolic dysfunction. Thus, restoration of cardiovascular function using 
regenerative medicine approaches are relevant to the treatment of diabetic-related 
cardiovascular comorbidities, such as peripheral artery disease.  
 
1.2.1 Vascular Biology and Architecture 
Tissues in the human body require dynamic microvascular networks to receive vital 
nutrients and oxygen124,125. The cardiovascular system is quickly established during 
embryogenesis, such that embryonic tissues rely on paracrine signaling from endothelial 
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cells during organogenesis126-129. Development of vasculature is initiated during blood 
island formation within the early yolk sac130. Peripheral cells of blood islands generate 
angioblasts or endothelial-lineage committed stem cells131, which migrate to the embryo 
to establish de novo vasculature structures, a process termed vasculogenesis. 
Subsequently, endothelial cell progenitors will undergo extensive proliferation and 
mediate sprouting from pre-existing vessels, i.e. angiogenesis, to establish well-defined 
vascular networks. Gradients of vessel-supportive cytokines, such as VEGF132,133 or 
Angiopoietin family members134-136, are primarily established by secondary cell 
populations 137,138, such as circulating hematopoietic cells131,139,140 that provide stimuli 
which contribute to vasculature development.  
The cardiovascular system is composed of a well-defined hierarchy of macro- and micro-
vessel structures with distinct functions to maintain homeostasis125. At the center of the 
cardiovascular system, the heart continuously pumps oxygenated blood from the left 
ventricle through aorta141 and downstream arteries (0.1-10mm diameter) and arterioles 
(100-300 um diameter) comprised of three distinct anatomical layers142. The tunica 
externa is outer most layer of arterial vessels and is primary composed of elastic fibers 
which function to support vessel stretching when encountering large volumes of blood 
flow. The tunica media is located between the Tunica externa and a basement membrane 
that separates the tunica intima. The tunica media is composed of smooth muscle cells 
which contribute to hemodynamic regulation throughout the body, such as regulation of 
arterial flow142. The tunica intima, found throughout all vessel types, is recognized as the 
continuous layer of endothelial cells that interacts with systemic circulation. Capillaries 
are the smallest vessels of the cardiovascular system and are the primary site of gas and 
nutrient exchange143,144. Depending on the tissue, endothelial cell permeability can 
become fenestrated to facilitate filtration (i.e. kidney glomeruli) or selectively 
impermeable, as seen in the blood brain barrier145,146. Subsequent networks of venules 
and veins return deoxygenated blood from capillaries towards pulmonary circulation for 
reoxygenation147. Similar to arteries, venules and veins contain three layers; however, 
differ by the relative thinness of the outer tunic layers, increased luminal diameter, and 
possess valves that prevent retrograde movement of blood as it is returned through the 
vena cava to the right atrium of the heart.  
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1.2.2 Endothelial Cells 
Endothelial cells line the tunica intima of arterial and venous networks and act as the 
functional units of blood vessel to mediate communication between tissue cells and the 
systemic circulation. Based on the tissue type, endothelial cells receive extrinsic cues that 
guide their phenotype and function, relative to the needs of the tissue145,148. Additionally, 
endothelial cells provide paracrine signals that maintain vital cell populations in a variety 
of tissues, such as β-cells128,149. The symbiotic relationship between endothelial cells and 
adjacent cell populations has been previously demonstrated, such that the depletion of 
one population affects the development and survival of the other. Furthermore, 
revascularization during organ and tissue transplantation is crucial to the integration and 
function of transplanted tissues.   Endothelial cells are in constant communication the 
hematopoietic system during homeostasis and will release chemotactic and pro-
inflammatory upon injury150. Additionally, endothelial cells are the primary source of 
nitric oxide production, a potent vasodilator that acts on adjacent smooth muscle cells 
when endothelial cells encounter elevated hemodynamics151,152.  Endothelial cells are also 
sensitive to elevated lipid and glucose levels in the circulation and succumb to metabolic 
dysfunction153. In the context diabetes, injury-induced signals released from endothelial 
cells accelerate the infiltration of pro-inflammatory monocytes/macrophages, stimulate 
the proliferation and migration of mesenchymal cells, and activate pro-apoptotic 
signaling pathways neighbouring cells5,153-158.   
 
1.2.3 Smooth Muscle Cells and Pericytes 
Within the Tunica media of large vessels, smooth muscle cells function to maintain 
endothelial cell homeostasis and can respond to innervating nervous tissues142,159. Smooth 
muscle cells maintain structural integrity of arterial vessels and regulate blood flow 
through vasomotor responses. As previously mentioned, endothelial cells release nitric 
oxide to stimulate vasodilation through activation of smooth muscle cells, preventing 
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downstream damage on fragile capillary networks. Smooth-muscle cells can be identified 
by the expression of α-SMA and lack markers of the endothelial lineage.  
Related to smooth muscle cells, pericytes also provide structural and paracrine support 
with microvessel endothelial networks143,160. Pericytes support capillary homeostasis by 
maintaining a delicate balance of growth and regression and are recruited to site of 
angiogenesis via a PDGFR𝛽 signaling axis161. Cardiometabolic disorders directly and 
indirectly affect pericyte and smooth muscle cell populations, generally leading to 
aberrant proliferation and fibrosis in response to elevated metabolic stress159. Pericytes 
can be detected by the expression of melanoma cell adhesion molecular (CD146) in the 
absence of hematopoietic or endothelial markers161,162. Crisan et al. demonstrated the 
selection of CD146+ cells from could establish multipotent stomal cell colony formation 
from a variety of postnatal tissues163.   
 
1.2.4 Atherosclerosis 
Disruption of endothelial homeostasis and elevated levels of inflammation can lead to 
narrowing of blood vessels through the progressive formation of atherosclerotic 
plaques138,152,164,165. Specifically, prolonged periods of hyperglycemia or hyperlipidemia 
disturb endothelial permeability by increasing reactive oxygen species and decreasing 
homeostatic nitric oxide production. Subsequently inflammation initiates a cascade of 
monocyte infiltration, proliferation and M1 macrophage specification in response to 
excessive lipid deposition within the intimal layers of large vessels (Figure 1.6). Pro-
inflammatory macrophages will readily scavenge excess lipids from interstitial layers of 
arterial vessels to generate pathogenic foam cells. Progressive accumulation of foam cells 
will develop into the first pathological hallmark of atherosclerosis, the fatty streak. Pro-
inflammatory cytokines stimulate the proliferation and migration of smooth muscle cells 
towards the fatty streak. Activated smooth muscle cells will deposit fibrotic extracellular 
matrix that lead to the formation of a fibrous cap and de novo plaque formation. 
Extensive apoptosis of foam and smooth muscle cells will occur within the core of early 
plagues, accelerating the plaque growth through the deposition of lipids, lipoproteins, and 
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calcified deposits.  Expansion of atherosclerotic plaques can lead to vessel occlusion and 
reduction of distal blood flow, as observed in patients with peripheral artery disease. 
These processes exacerbate over time until aggregation of platelet aggregation and 
infiltration of cytolytic leukocytes disrupts plaque integrity.  Spontaneous rupturing of 
atherosclerotic plaques and subsequent thrombotic events can impose life-threatening 
events, such a myocardial infarction or stroke, by completely occluding arterial blood 
flow to the heart or brain164. Common risk factors that lead to atherosclerosis include: 
hypertension, hyperlipidemia, sedentary lifestyle, smoking, and diabetes.  
 
1.2.5 Cardiovascular Disease 
Cardiovascular disease (CVD) encompasses a broad range of pathophysiological 
conditions that primarily affect the function of the heart and/or vasculature5-7,9. These 
include a broad spectrum of ailments such as several clinical presentations of cardiac 
arrhythmias or myocardial infarction, heart failure, stroke, and peripheral artery disease. 
Collectively, CVD remains one of the leading causes of mortality in the world, 
accounting for ~30% of deaths 166,167. Furthermore, CVD has placed a crippling burden 
on the healthcare system, total costs of $22 billion in Canada per year168. The 
manifestation of CVD is multifactorial and commonly presents in parallel with several 
cardiometabolic syndromes (i.e. diabetes, obesity, atherosclerosis etc.)158,165,169. Although 
genetic pre-dispositions exist, risk factors such as smoking, obesity, etc., are often 
avoidable73,76,77,118,119. Nonetheless, escalating rates of diabetes, hypertension, and obesity 
globally will inevitably lead to increased prevalence of CVD. It is estimated that nearly 
half of the population in the United States will develop CVD in the next decade167, 
leading to a >2-fold increase in annual healthcare costs170.     
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1.2.6 Peripheral Artery Disease and Critical Limb Ischemia 
Atherosclerotic manifestation in the peripheral vasculature can lead to a partial or 
complete occlusion of blood flow to distal tissues (Figure 1.6), as observed in individuals 
with peripheral artery disease (PAD). 1 in 5 individuals with DM will eventually develop 
some form of PAD as a result of diabetes-induced dysfunction of the 
microvasculature13,120,171-173. It is estimated 800,000 individuals in Canada and >8 million 
individuals in the United States are afflicted with PAD120,174; and many patients with 
PAD do not present in the clinic until symptoms are severe. Peripheral artery disease can 
be diagnosed with a combination of physical exam, ankle-brachial index (ABI) 
measurements, ultrasound, blood tests, and/or angiography172. In many cases, non-healing 
wounds or ulcers in diabetic patients lead to diagnosis of PAD, at which point PAD has 
progressed beyond reversible stages (i.e. intermittent claudication) and intervention may 
be required. Critical limb ischemia (CLI) is the most severe form of PAD. Individuals 
with CLI present with resting pain, non-healing ulcers, secondary infections and tissue 
necrosis due to the severe ischemia in tissues distal to occluded vasculature. An estimated 
1 in 3 patients diagnosed with CLI will require limb amputation; and >60% of patients 
will succumb to cardiovascular-related deaths within 5 years175. Current therapeutic 
strategies for PAD and CLI aim to target symptoms, slow disease progression, and/or 
prevent secondary adverse cardiovascular events176. 
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Figure 1.6 Overview of Atherosclerosis and Peripheral Artery Disease. 
Cardiometabolic imbalances will disrupt endothelial health and permeability, leading to 
subintimal lipid accumulation and monocyte infiltration. Infiltrating monocytes will 
rapidly proliferate and differentiate into lipid-scavenging macrophages. Lipid 
accumulation within macrophages leads to foam cells formation and apoptosis within the 
atherosclerotic plaques. Plaque formation is also mediated by smooth muscle cell 
activation, proliferation, and the deposition of collagen and fibrous cap formation. As 
atherosclerosis progresses, endothelium is compromised, and platelet aggregation will 
occur. Late stages, plaque integrity is comprised and atherothrombosis formation occurs. 
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1.2.7 Strategies to Combat Vascular Disease 
Currently, patient care for the primary treatment of PAD has two main goals; 1) 
management of symptoms to increase quality of life, and 2) mitigate the progression of 
atherosclerosis to prevent heart attack and stroke via pharmaceuticals and/or life-style 
changes177. Depending on the underlying health of an individual, pharmaceuticals 
primarily aim to reduce hyperlipidemia, hyperglycemia, hypertension, or the risk of 
platelet aggregation and clot formation65,93. To mitigate limb amputation for CLI, surgical 
interventions may be performed to increase the luminal diameter of a restricted artery 
(i.e. balloon-catheter angioplasty) or bypass occluded vasculature using autologous or 
synthetic grafts which re-establish blood flow from proximal to distal 
vasculature176,178,179. Unfortunately, a significant proportion of individuals with severe 
PAD are unsuitable surgical candidates due to diffuse microvascular blockage and 
underlying comorbidities. Alternative therapies that re-establish blood flow via the 
restoration of endothelial homeostasis and function have demonstrated preclinical 
potential. The field of regenerative medicine is actively investigating pharmaceutical, and 
gene or cell-based therapies to stimulate revascularization and restore tissue 
homeostasis180,181.  
 
1.3 Regenerative Medicine: A Historical Perspective  
For centuries, scientists and physicians have proposed that the human body possessed 
considerable capacity to heal itself through tissue regeneration. For example, Greek 
mythology describes the story of Prometheus. As a punishment for stealing fire from the 
gods, Prometheus is chained to a rock where his liver is removed daily by an eagle of 
Zeus, only to have his liver grow back by the next day. The Greek physician Hippocrates 
was quoted as saying “Let food be thy medicine and medicine be thy food”. In the 
context of Type 2 diabetes and cardiovascular comorbidities, Hippocrates’ view would 
address a critical need to circumvent these pathologies through individual nutrition and 
lifestyle habits. Hippocrates’ philosophy could also translate to the foundation of current 
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approaches which aim to discover therapeutic strategies that enhance regeneration and re-
establish tissue homeostasis by activation of endogenous signaling networks. Within the 
following section, I will provide a foundational overview on the field regenerative 
medicine; specifically focusing on the applications of post-natal regenerative cell sources 
to develop biotherapeutics for DM and/or comorbid CVD pathologies.  
 
1.3.1 Regenerative Medicine 
Regenerative medicine encompasses a broad spectrum of therapeutic approaches 
and multidisciplinary efforts to restore physiological tissue function in the face of 
disease182. For example, regenerative medicine approaches to treat vascular 
complications of diabetes encompass efforts including: pro-angiogenic gene therapies183, 
pro-vascular stem/progenitor cell transplantation184, pharmaceutical or biological 
activation of pro-angiogenic pathways185, biological and synthetic scaffold 
transplantation186 and related efforts of tissue engineering187. At the core of regenerative 
medicine, is the aim to reverse deficiencies in tissue mass, cell function, and/or 
homeostatic signaling networks which underlie the pathophysiology of a disease. Stem 
cells hold undetermined potential to replace or regenerate damaged tissues; albeit, further 
research is critical to realize this potential. Accordingly, many labs are investigating the 
use of stem cells to treat chronic ailments, such as Type 1 DM and CLI. 
 
1.3.2 Stem Cell Biology 
First discovered by Canadian scientists, James Till and Ernest McCulloch188, stem cells 
are defined by their capacity to undergo symmetric division without differentiation (self-
renewal) while also demonstrating the capacity to differentiate into cells of multiple 
lineages (potency)189. Self-renewal is necessary for the long-term survival of stem cell 
pools throughout the lifetime of an individual so that expendable and functionally mature 
cells can be continuously replaced when damage or senescence occurs. The hierarchy of 
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cell potency apexes with totipotency (the ability to generate cells of the embryo and 
extraembryonic tissue) represented at fertilization and subsequent generation of a zygote. 
As embryogenesis proceeds and the morphogenesis of the blastocysts occurs, and cells of 
the inner cell mass (i.e. embryonic stem cells) are pluripotent (Figure 1.7). Pluripotency 
is the capacity of a cell to differentiate to all 3 germ layers of the embryo proper; i.e., 
ectoderm, mesoderm, endoderm. Embryonic stem cells are the only native tissue that  
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Figure 1.7  Working Model of Pluripotency and Multipotency in Stem Cells 
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demonstrate pluripotency in the human body, as adult stem cells exhibit multipotency 
generating multiple cell types within a specific germ layer. Notably, these barriers in 
potency have been shattered by Yamanaka’s generation of induced-pluripotent stem cells 
from differentiated cells that may represent a potential source of patient specific-stem 
cells190.  
The turnover of cell in the human body requires compartmentalized differentiation of 
lineage-specific stem and progenitor cells that demonstrate multipotency, or the capacity 
to differentiate into multiple lineages of a single germ-layer191,192. For example, 
mesoderm-derived hematopoietic stem cells give rise to multipotent progenitor cells that 
are committed to differentiation of myeloid or lymphoid lineages of the hematopoietic 
system; moreover, these cells do not readily differentiate into related lineages such as 
endothelial or multipotent stromal cells.  These stem and progenitor cells of the 
mesodermal lineage have been targeted in pre-clinical and clinical studies to treat 
diabetes and related cardiovascular complications57,193-197. The phenotypic identity of 
stem cell populations can be differentiated according to surface marker expression, such 
as CD34 expression on hematopoietic stem cells198,199. However, cell surface marker 
expression is dynamic and changes in response to injury or culture in vitro.  
 Molecular functions unique to stem and progenitor that provide protection from 
cytotoxic insults can be used alone or in combination with surface markers to identify 
long-lived stem cell populations in a variety of fetal, postnatal, and adult cancerous 
tissues200. As an example, aldehyde dehydrogenase activity has been used as a conserved 
self-protective enzymatic function that protects against oxidative damage within multiple 
stem and progenitor cells lineages in tissues including blood201, pancreas202, brain, and 
colon203. In general, as cells differentiate toward functional maturity, ALDH-activity is 
reduced. Despite these protective mechanisms, accumulating evidence has demonstrated 
a microenvironment of chronic metabolic disease such as type 2 diabetes can lead to the 
depletion of stem and progenitor numbers, in addition to perturbation of regenerative 
function74. In the context of regenerative medicine, tissue specific stem and progenitor 
cells possess the potential to replace damaged or dysfunctional cells (i.e. β-cells or 
microvessels) through directed differentiation ex vivo204 or through the activation of 
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dormant tissue-resident-progenitor cells via paracrine signaling mechanisms in situ205.  
To exemplify the latter, umbilical cord blood (UCB)-derived hematopoietic progenitor 
cells (HPC) with high aldehyde dehydrogenase activity demonstrate a multifaceted 
secretome that can stimulate β-cell and endothelial cell proliferation in vivo following cell 
transplantation without long-term engraftment or differentiation into damaged cell 
phenotypes58,206.     
 
1.3.3 Aldehyde Dehydrogenase and Retinoic Acid Signaling Pathway 
Aldehyde dehydrogenase (ALDH) plays an essential role in embryogenesis and provides 
post-natal stem and progenitor cell populations long-term protection from cytotoxic 
insults207. The aldehyde dehydrogenase enzyme family contains 19 isoforms, with 
localization to cytosolic or mitochondrial compartments. Previously studies have 
demonstrated that ALDH2 is the main isoform expressed during early embryogenesis, 
whereas ALDH1 and ALDH3 isoforms are primarily expressed throughout post-natal 
tissues. In addition to providing cytosolic protection to reactive aldehyde species, ALDH 
is a rate-limiting step in the metabolism of retinol to retinoic acid (Figure 1.8).  
Retinol (Vitamin A) is a cholesterol derivative taken up from circulation through Retinoic 
Acid 6/STRA6 expression at the plasma membrane of competent cells. Cytosolic retinol 
is metabolized by alcohol dehydrogenase family members (i.e. ADH10/11) to generate 
retinaldehyde (retinal). ALDH1A1 or ALDH1A3 oxidizes retinaldehyde to produce the 
lipophilic morphogen retinoic acid (RA). Following production, RA can be rapidly 
translocated from the cytosol to the nucleus by cellular retinoic acid-binding protein 2 
(CRBP2) and presented to RA-receptor complexes to regulate transcriptional and 
epigenetic events. RA receptors exist as heterodimers consisting of one retinoic acid 
receptor (RARα, RARβ, RARγ) in conjunction with a retinoid X receptor isoform 
(RXRα, RXRβ, RXRγ)208. The binding of RA to the RAR alters the conformation of the 
complex from a transcriptional repressor to a transcriptional activator of numerous targets 
containing retinoic acid receptor elements (RAREs). Furthermore, induction by RA-
signaling pathways regulates the transcription of several important genes that code for 
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proteins involved in RA-signaling including CRBP1/2 (cellular retinol binding protein), 
CRABP1/2 (cellular retinoic acid binding protein), and CYP26 (Cytochrome P450 
family).  
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Figure 1.8 Working Model of Canonical Retinoic Acid Signaling Pathway. Retinol is 
imported through STRA6 (Stimulated by Retinoic Acid Receptor 6) and metabolize by 
ADH (Alcohol Dehydrogenase) to Retinal. Retinal is further metabolized by ALDH 
(Aldehyde Dehydrogenase) into RA (Retinoic Acid). RA is bound by CRABP (Cytosolic 
Retinoic Acid Binding Protein) which will translocate to the nucleus and present RA to 
RAR/RXR (Retinoic Acid Receptor/Retinoid X Receptor) heterodimer complexes bound 
to RARE (Retinoic Acid Response Element) which will regulate the transcription of 
downstream targets. 
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RA signaling was has been shown to function together with several other mitogens for 
the proper development and segmentation of the hindbrain, forebrain, upper limb buds, 
and foregut207. Previous studies have demonstrated that RA forms an opposing 
concentration gradient with CYP26 expression to set developmental boundaries during 
tissue patterning and organogenesis. RA gradients also play a crucial role during foregut 
development, more specifically, the proper development of the insulin-producing 
pancreas. Interestingly, xenopus models have demonstrated retinoic acid signaling to 
induce the endocrine-specification of ventral and dorsal buds209. Collectively, there exists 
a paradoxical and complex balance between the maintenance of high ALDH-activity in 
primitive stem cell populations while preventing differentiation through RA-signaling 
pathways.  
 
1.3.4 Hematopoietic Stem and Progenitor Cells 
Cells of the hematopoietic system serve multifunctional roles to maintain homeostasis in 
the body, overseeing processes such as immunity, tissue remodeling, wound response and 
delivery of oxygen. Therefore, maintenance of hematopoietic stem and progenitor cells is 
crucial and requires an intricate balance between self-renewal and differentiation210. 
Hematopoietic stem cells are originally derived from the blood islands of the yolk sac, 
before repopulating the aorta-gonad mesonephros regions of the developing 
embryo131,210. Subsequently, hematopoiesis takes place in the fetal liver before 
establishing permanent residence within the bone-marrow microenvironment211. 
Hematopoietic stem cells reside within the endosteal niche of the bone marrow that 
allows communication via endothelial and mesenchymal stromal cell populations. 
Accordingly, hematopoietic stem cells will receive signals that influence progenitor cell 
production and commitment towards myeloid or lymphoid lineages.  
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Figure 1.9 Overview of Hierarchy of Hematopoiesis with a specific focus on 
megakaryopoiesis. Working model of human hematopoiesis/megakaryopoiesis beginning 
with quiescent LT-HSC (Long-term Hematopoietic Stem Cell) and transiting to common 
myeloid progenitor cells. Unipotent MEP (Megakaryo-erythocyte progenitors) will give 
rise to CD41+ megakaryoblasts Megakaryopoiesis will continue with the emergence of 
CD41+/CD42+ megakaryocytes capable of platelet generation. 
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Several phenotypic markers have been used to purify hematopoietic stem cells from fetal 
and adult tissues, such as CD34 and CD133198,199.  Similarly, functional characteristics 
such a high ALDH-activity also identifies hematopoietic cells with primitive phenotypic 
and progenitor cell functions. The collective efforts of the Dick laboratory have primarily 
advanced our understanding of human hematopoiesis, including demonstrate single-cell 
HSC transplants can repopulate irradiated murine bone marrow198.  Extending from this 
knowledge, members of the Bonnet laboratory have demonstrated that the apex of adult 
hematopoiesis may be a cell which lacks CD34 and co-expresses a phenotypic profile 
including CD90+/CD49f+/CD45RA-/CD38-199 (Figure 1.9). Nonetheless, FACS 
purification based on CD34 expression and/or high ALDH-activity enriches for primitive 
hematopoietic cells capable of long-term hematopoietic reconstitution in 
immunodeficient mice (i.e. NOD/SCID)212. As hematopoietic stem and progenitor cells 
differentiate towards maturity the loss of CD34 expression occurs, combined with the 
acquisition of mature hematopoietic cell markers such as CD38213. Common myeloid 
progenitor cells will extensively proliferate and give rise to a bipotent progenitor that 
generates cells of the erythroid and megakaryocytic lineages, or a unipotent progenitor 
that generates neutrophils and monocytes. Conversely, select cell types may be derived 
from myeloid and/or lymphoid lineages (i.e. Dendritic cells)214-216, rendering the 
phenotypic identification of intermediate stages of differentiation challenging. Towards 
this end, ALDH-activity is uniformly dampened as differentiation occurs across multiple 
hematopoietic lineages201, suggesting sustained stem cells functions may be more 
indicative of primitive identity compared to the transient nature of cell surface marker 
expression212,217.  
Hematopoietic stem/progenitor cells (HSPC) have been used in a diverse range of clinical 
studies, including bone marrow transplantation for blood disorders218 and 
revascularization strategies for CLI193,194. HSPC are readily isolated from a post-natal 
tissue, such as bone marrow, peripheral blood, and umbilical cord blood219. 
Unfortunately, therapeutic HSPC are rare, thus ex vivo expansion may be required for 
clinical translation for many potential applications. The expansion of HSPC has been met 
with multiple challenges such as tissue source, primitive cell selection, and culture 
conditions. Expansion of HSPC is challenged by the rapid induction of differentiation 
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due to intrinsic signaling networks, such as RA-signaling pathways. Previous studies 
have demonstrated the pharmacological inhibition or activation of select signaling 
pathways can enhance the expansion of therapeutic HSPC220,221. Furthermore, the 
Zandstra lab has demonstrated the dynamic regulation of microenvironmental signaling 
networks can lead to robust expansion of HSPC populations experimentally model in 
silico222-225. Finally, HSPC can be used in alternative therapies for their multifaceted 
therapeutic functions such as the stimulation of islet regeneration57,58 or blood vessel 
formation206,226. Collectively, HSPC harbour multifunctional therapeutic potential that is 
limited by differentiation and loss of regenerative functions during expansion ex vivo. 
Further research is required to identity targetable signaling pathways which may retain or 
expand therapeutic HSPC.  
 
1.3.5 Mesenchymal/Multipotent Stromal Cells 
Since initial clinical use in 1995, multipotent stromal cells (MSC) has been the focus of 
over 200 clinical trials world-wide227-229. MSC, as known as mesenchymal stem cells, 
possess unique characteristics and can be enriched from several tissues according to the 
guidelines established by the International Society of Cellular Therapies (ISCT)230. 
According to these guidelines, MSC must demonstrate 1) plastic adherence 2) 
mesodermal multipotency (into adipose, bone, cartilage lineages), and 3) exhibit a 
distinct surface marker profile (Figure 1.10), which distinguishes it from related 
mesodermal cell contaminants (i.e. hematopoietic and endothelial). Specifically, MSC 
must express surface marker CD90 (Thy-1), CD73 (Ecto-5'-nucleotidase), and CD105 
(Endoglin) after plastic adherent culture; meanwhile, lack the expression of CD45, CD31, 
CD14, HLA-DR, CD19, CD79a and CD34. MSC demonstrate a fibroblast-like 
morphology when cultured ex vivo, which has brought controversy to whether the 
fibroblasts and MSC are interchangeable231-233. Despite several groups reporting that 
select fibroblast lines can satisfy the ISCT guidelines232-234, other studies have reported 
transcriptional and/or functional differences that may distinguish MSC from committed 
fibroblasts231,235,236. For example, MSC are highly proangiogenic and contribute to tissue 
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regeneration and immunomodulation via paracrine signaling networks. Therefore, the 
capacity for MSC to initiate tissue regeneration may be a defining characteristic to 
segregate MSC from fibroblasts235, especially considering the well-established role of 
fibroblast activation during aging and many forms of pathogenesis237,238.  
MSC can be obtained from a variety of adult and fetal tissues, each with a unique 
phenotype and functional characteristics attributed to the tissue of origin239,240. For 
example, MSC classically isolated from BM express higher levels of pericyte marker 
CD146 and alkaline phosphatase compared to placental-derived MSC241; which reflects 
differences in osteogenic potential. Nonetheless, MSC should be considered highly 
heterogeneous and possess distinct subsets with unique surface marker expression 
(CD271, CD56, CD146), enzymatic expression (ALDH) and functional characteristics in 
vitro or in vivo242,243. For example, it has been reported that two distinct populations of 
BM MSC may exist244,245. A CD271+/CD146+ population that regulates the endosteal 
niche and hematopoiesis, while a 271+/CD146- population that serves as a progenitor 
pool to generate osteoblasts of the skeletal bone. We have recently reported that the 
selection of high ALDH-activity ex vivo enriches for a BM-MSC with enhanced pro-
angiogenic secretome243. Collectively, MSC are an attractive cell type with a safe 
therapeutic history and multifaceted regenerative functions, that may be further 
modulated by the selection of tissue-specific MSC and/or MSC subsets within 
heterogeneous expansion cultures. 
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Figure 1.10 Working model of MSC phenotype, multipotency, and pro-regenerative 
secretome. 
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1.3.6 Cellular Therapies for Diabetes 
The clinical demonstration that diabetes could be reversed via the restoration of 
functional β-cell mass103,105, prompted researchers to discover novel methods to either 
replace or regenerate lost β-cell in situ. Currently, the leading approach to restore 
functional β-cell mass is through the transplantation of an exogenous β-cell source246-248. 
Whole pancreas transplantation has reversed diabetes in human patients, however the 
scarcity of donor pancreas tissue and a necessity for HLA-matching and/or 
immunosuppression has limited this approach249. Likewise, islet transplantation can 
reverse diabetes for prolonged periods, however, this approach is met with the same 
limitations as pancreas transplantation. The potential use of pluripotent stem cell (ESC or 
iPSC) technologies has promoted many laboratories to focus their efforts on ex vivo 
generation of an unlimited number of β-cells for transplantation246.  Notably, Kieffer and 
colleagues have demonstrated that transplantation of ESC-derived PDX1+ pancreatic 
progenitors was sufficient to reverse diabetes in rodent models (Ref). Transplanted 
PDX1+ cells differentiated in vivo to generate a mixture of endocrine cell phenotypes, 
with significant representation by insulin-secreting 𝛽-like cells204,250. However, careful 
characterization of cell function revealed insulin secretion from PDX1+ progenitors were 
~10% of native β-cells, which highlights further work is needed to guide β-cell 
maturation either ex vivo or in vivo. In addition, the suppression of the autoimmune 
destruction of the transplanted β-like cells is necessary to sustain euglycemia. In 
pioneering efforts, bioengineering approaches have been tested to encapsulate 
transplanted PDX1+ cells in a device that is permeable to the release of insulin while 
preventing immune cell infiltration248. 
In 2010, the Joslin “Medalist” study demonstrated residual β-cell mass and functional 
insulin secretion within individuals who have lived with Type 1 DM for >50 years251. 
Moreover, histological analysis of post-mortem patients has identified the presence of 
proliferating β-cells coinciding with β-cell apoptosis. Collectively, this study provided 
two foundational concepts; 1) residual β-cell mass is present in individuals with long-
standing Type 1 DM and 2) β-cell proliferation can occur in the face of ongoing 
autoimmunity. Considering the destruction of β-cell mass is heterogeneous across the 
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pancreas and select regions may promote immune cells invasion, these results suggest 
that the stimulation of endogenous β-cell regeneration in situ may be feasible approach in 
T1 DM patients if autoimmunity can be controlled107. Towards this goal, our lab has 
pioneered studies demonstrating the transplantation of blood-derived progenitor cell 
populations can stimulate the regeneration of endogenous islets in murine models of 
DM57,58,195,196,205. Specifically, human HSPC and MSC populations derived from human 
UCB and/or BM can reduce hyperglycemia in NOD/SCID mice subjected to 
streptozotocin-induced β-cell ablation. The Prochymal trial was the first to attempt to 
alleviate early-onset Type 1 DM through the infusion of allogeneic BM-derived MSC 
harvested from a healthy donor252. Despite promising preclinical results, therapeutic 
efficacy observed in this study was transient and modest. Recently, we have 
demonstrated the secretome of expanded human MSC can act as an injectable 
biotherapeutic to potently stimulate islet regeneration205, potentially circumventing the 
limitations encountered by direct cell transplantation, discussed below.   
 
1.3.7 Cellular Therapies for Vascular Disease 
The therapeutic goal for treating ischemic damage induced by vascular disease is to 
promote angiogenesis to revascularize and restore cardiometabolic homeostasis253. Initial 
trials for treating critical limb ischemia with progenitor cell transplantation, have 
primarily entailed the infusion of mononuclear cells derived from autologous 
sources254,255. Collectively, the efficacy of this approaches has been variable, showing 
improvements in ankle brachial index measurements and improved quality of life scores 
(Rutherford index), yet amputation rates were not improved in patients with severe CLI. 
Therefore, refined the cell selection, expansion, or transplantation of therapeutic cell 
populations is currently under intense investigation. Accordingly, Perin et al. recently 
concluded a clinical trial which explored the transplantation of autologous BM-cells 
purified for high ALDH-activity in patients with both critical limb ischemia and 
intermittent claudication193,194. The results of these studies did not show improved clinical 
efficacy over the transplantation of unpurified mononuclear cells. It is becoming evident 
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that the microenvironment of cardiometabolic disorders (i.e. diabetes, obesity, etc.) and 
cardiovascular disease can deplete progenitor cell numbers and diminish regenerative 
functions of pro-angiogenic cell types256-259. Thus, autologous progenitor cell 
transplantation carries severe limitations in the clinical setting.  
Pre-clinical studies have demonstrated the therapeutic potential of progenitor cell 
transplantation for treating vascular disease, yet the translational rate to clinical efficacy 
has been notably underwhelming. In addition to the limitations linked to progenitor cell 
biology, current murine models of CVD and PAD do not accurately reflect 
pathophysiological observations observed in human studies260. Despite mice sharing 
~95% of the protein-coding genome, there exists a measurable distinction between the 
regulatory or non-protein coding regions of the genome. These regions generate nucleic 
acid effectors that provide post-transcriptional/translational regulation of homeostatic and 
inflammatory pathways (i.e. micro-RNAs). As a result, cardiometabolic disorders and 
pathophysiology of vascular disease are not completely recapitulated in current murine 
models261,262. Specifically, transgenic models lack pathological hallmarks of human CVD 
such as lesion development, atherosclerotic plaque complexity, localization to coronary 
arteries, intimal thickening, and thrombotic plaque rupturing observed in human patients. 
Recently, vascular organoids have been generated from both adult263-265 and pluripotent 
stem cell sources266 that organize into a hierarchical arrangement and can be induced to 
exhibit characteristics of human pathology. The Penninger lab recently demonstrated 
organoids derived from human iPSC produced a physiologically-relevant arrangement of 
mesenchymal, endothelial, and hematopoietic cell that could self-assemble, and these 
vessels could mimic diabetic vasculopathy in vitro and in vivo266. From a speculative 
point-of-view, the use of vascular organoids to refine our understanding of vessel 
assembly will lead to development of novel therapies to treat vascular complications of 
diabetes169. 
 
41 
1.3.8 Limitations of Cell Transplantation and the Development of Cell-
free Biotherapeutics 
Limitations of progenitor cell transplantation to treat diabetes and vascular disease 
primarily center around progenitor cell source and extensive expansion required for 
clinical application in humans. We have recently demonstrated additional 3-days of ex 
vivo culture significantly diminished primitive progenitor cell marker expression and 
provascular functions of UCB-derived HPC transplanted into in a murine model of 
hindlimb ischemia226. Our previous studies indicate that the regenerative function of 
transplanted progenitor cells may vary on an individual basis, such as donor health, body 
composition, co-morbidities and/or age267,268.  Accumulating evidence has demonstrated 
the chronic diseases such as diabetes can disrupt progenitor cell homeostasis leading to 
the generation of a pro-inflammatory and pro-fibrotic secretome in mesenchymal cell 
populations269-273. The engraftment of transplanted progenitor cell populations is often 
transient274, thus prolonging engraftment of transplanted cells may enhance therapeutic 
outcomes in vivo. Although, it is difficult to track the biodistribution of transplanted cells 
in human patients275, recent advancements of biomedical imaging is allowing for high-
resolution mapping of transplanted cell populations276. Collectively, current cell 
transplantation strategies are in need of approaches to enhance the expansion of 
therapeutic cell populations ex vivo or prolong engraftment in vivo without the loss of 
regenerative functions. 
We have recently demonstrated that the secretome of BM-MSC can be concentrated to an 
injectable volume and used to stimulate human islet cell proliferation in vitro277 and 
murine islet neogenesis in vivo205. Combining the benefits of protein and cell-based 
approaches are now warranted to: 1) identify therapeutic effectors and their recipient cell 
populations, 2) to determine if therapeutic secretome are progenitor cell-specific, and 3) 
investigate the generation of ‘designer cells’ to tailor the secretome of progenitor cell 
populations toward a treatable disease.  
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1.3.9 Extracellular Vesicles 
The secretome of MSC contains regenerative stimuli secreted in the form of both protein 
and nucleic acids (miRNA and mRNA), which can contribute to pro-regenerative and 
pathological responses in vivo278-282. These regenerative cargoes can be packaged into 
extracellular vesicles (EVs) that signal in an autocrine and paracrine fashion to initiate 
tissue regeneration. EVs are lipid bi-layered vesicles which facilitate intercellular 
communication by protecting and transporting a unique set of cargo distinct from 
traditional cytokine secretion. Specifically, EVs contain protein, nucleic acids, and 
bioactive lipids each with a unique role in cellular communication (Figure 1.11). EVs can 
be subclassified based on their size and cellular-origin into exosomes and microparticles. 
Moreover, EVs are distinct from cell remnants, such as apoptotic bodies. Exosomes 
(30nm-100nm) are the smaller of the two EV sub-classifications and are derived from the 
endosomal pathway. Multivesicular bodies of the endosomal pathways are either shuttled 
to the lysosome for degradation or are repackage with unique cargo and released as 
exosomes via exocytosis283. In contrast, microparticles are larger in size (from 100nm-
1μm) and are generated by blebbing of the cytoplasm and pinching of the cell membrane, 
leading to the direct release of microparticles to the environment surrounding the cell284. 
The generation of exosomes and microparticles is a highly regulated, although the 
mechanism of this organization remains obscure. Nonetheless, EVs contain cargo which 
can activate signaling pathways to significantly alter the physiology of recipient cells285. 
With these properties in mind, the contribution of EVs towards the MSC-generated 
secretome needs to be further investigated to develop novel regenerative therapies. 
43 
 
  
 
 
 
Figure 1.11 Overview of Extracellular Vesicle Secretion, Detection, and Applications 
of Regenerative Medicine 
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1.3.10 Designer Cells and the Future of Regenerative Medicine 
Recent advancement in genetic engineering strategies, such as CRISPR286-288, and in-
depth molecular analyses (i.e. Mass Spectrometry, Single-cell RNAseq) hold the 
potential to be used as vital tools of regenerative medicine. More specifically, global 
transcriptional and translational analyses provide us with a better understanding of the 
molecular characteristics within 1) therapeutic donor cell populations, 2) targeted 
endogenous cell populations for tissue regeneration, 3) dysfunctional/depleted cell 
populations during disease. In return, this insight will permit the directed activation of 
pro-regenerative pathways within therapeutic donor and target cell populations, in an 
attempt to combat disease. As an example of this concept, we have recently demonstrated 
that canonical Wnt-signaling within MSC is dampened as regenerative functions are lost 
during ex vivo culture277. Accordingly, the activation of Wnt-signaling during cell 
propagation enhanced the therapeutic efficacy of the BM-MSC secretome following 
intrapancreatic delivery of this ‘designer’ biotherapeutic. Other examples of current 
designer cell strategies to advance the field of regenerative medicine, include the 
generation of 𝛽-cells from pluripotent stem cell sources246, modelling of human diabetes 
and/or cardiovascular disease within cultured organoid systems266, and T cell289 or NK 
cell290 engineering to target tumor cells. On the horizon of regenerative medicine is the 
advancement of biological scaffold design186,291, 3D tissue engineering292, and in silico 
experimentation with machine learning293.  Therefore, this is an exciting time for 
regenerative medicine approaches yet there currently exists a need to characterize the 
molecular properties of regenerative cell populations with multifaceted therapeutic 
potential. 
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1.4 Thesis Overview and Hypotheses 
Patients with diabetes are burdened with an increased risk of developing life-threating 
cardiovascular comorbidities. Regenerative medicine and cellular therapies possess the 
potential to develop curative therapies for diabetes and/or cardiovascular complications. 
Unfortunately, the depletion and dysfunction of therapeutic cell populations occurs as a 
result of chronic disease, limiting the clinical efficacy of autologous cell transplantation. 
Allogenic sources, such as UCB, offer an alternative source of therapeutic progenitor 
cells that are untouched by chronic inflammation and oxidative stress; but require 
extensive expansion ex vivo to generate clinically relevant cell numbers without the loss 
of regenerative functions. Similarly, MSC represents another therapeutic cell population 
which requires extensive expansion for clinical applications. In addition, the secretome of 
MSC may be used as cell-free biotherapeutic278-282, although further research is necessary 
to refine this approach. During the course of my thesis, I focused on addressed two major 
challenges faced by direct cell transplantation; 1) the limitations of progenitor cell 
expansion ex vivo, and 2) directed delivery of pro-regenerative stimuli to damaged 
tissues. First, I demonstrated that the inhibition of RA-signaling could enhance the 
expansion of UCB-derived HSPC with multifaceted therapeutic potential. Second, I 
demonstrated that MSC derived from human pancreatic tissue generate extracellular 
vesicles with both vascular and islet regenerative stimuli. Throughout these studies, I 
utilized mass spectrometry and multiparametric flow cytometry to identify novel 
proteomic characteristics of both HPC and MSC subsets. Additionally, I performed 
xenotransplantation studies to investigate tissue regeneration induced by human cells 
after femoral artery ligation-induced hindlimb ischemia or streptozotocin-induced 𝛽-cell 
ablation.  
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1.4.1 Chapter 2: Objective & Hypothesis 
1. To characterize proteomic changes during the expansion of UCB ALDHhi cells 
using label-free mass spectrometry and multiparametric flow cytometry.  
2. To assess whether inhibition of ALDH-activity will enhance the expansion of 
UCB ALDHhi cells while retaining primitive surface marker and hematopoietic 
functions in vitro. 
3. To determine whether inhibition of ALDH-activity will expand hematopoietic 
progeny that stimulate vascular regeneration in a murine model of hindlimb 
ischemia. 
In chapter 2, I hypothesized that reversible inhibition of ALDH-activity, using 
diethylaminobenzaldehyde (DEAB), will enhance expansion of UCB-derived 
hematopoietic progenitor cells while retaining primitive surface marker phenotype and 
pro-angiogenic functions in vivo. 
 
1.4.2 Chapter 3: Objective & Hypothesis 
1. To investigate the enrichment of the megakaryocyte-lineage during expansion of 
UCB ALDHhi cells. 
2. To determine whether FACS purification of ALDHhi cells, after ex vivo 
expansion under DEAB-treated conditions, reselects for cells with pro-
angiogenic functions in vitro. 
3. To determine whether FACS purification of ALDHhi cells, under DEAB-treated 
conditions, reselects for cells retaining islet regenerative functions. 
In chapter 3, I hypothesized that reversible inhibition of ALDH-activity, via 
diethylaminobenzaldehyde (DEAB), will enhance the expansion of UCB-derived 
hematopoietic progenitor cells retaining a primitive surface marker phenotype and islet 
regenerative functions in vivo.  
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1.4.3 Chapter 4: Objective & Hypothesis 
1. To determine fibroblast-like cells derived from human islet cultures demonstrate 
MSC-like phenotype and multipotent functions in vitro. 
2. To conduct proteomic comparison of Panc-MSC to BM-MSC using mass 
spectrometry 
3. To determine the competency of Panc-MSC to respond to pro-neural or pro-
adipogenic stimuli 
In chapter 4, I hypothesized that fibroblast-like cells established from human islets will 
demonstrate phenotypic and functional characteristics of MSC with tissue-specific 
functional characteristics.  
 
1.4.4 Chapter 5: Objective & Hypothesis 
1. To characterize the protein content within extracellular vesicle versus the soluble 
fraction generated by Panc-MSC 
2. To determine whether pro-vascular stimuli within extracellular vesicles 
generated by Panc-MSC can improve revascularization after injection into 
ischemic hindlimbs.   
In chapter 5, I hypothesized that extracellular vesicles generated by Panc-MSC would 
contain pro-vascular stimuli capable that accelerate the recovery of hindlimb blood 
perfusion and revascularization in a murine model of hindlimb ischemia. 
 
1.4.5 Chapter 6: Objective & Hypothesis 
3. To characterize the protein content within extracellular vesicle versus the soluble 
fraction generated by Panc-MSC 
48 
4. To determine whether islet regenerative stimuli within extracellular vesicles 
generated by Panc-MSC can improve hyperglycemia after injection into 
pancreas of streptozotocin-treated NOD/SCID mice.   
In chapter 6, I hypothesized that the secretome of Panc-MSC contains islet-regenerative 
stimuli that can reduce hyperglycemia in NOD/SCID subjected to STZ-induced β-cell 
ablation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
49 
1.5 References 
1 Trowell, H. C. Ants distinguish diabetes mellitus from diabetes insipidus. British medical 
journal (Clinical research ed.) 285, 217 (1982). 
2 MacCracken, J., Hoel, D. & Jovanovic, L. From ants to analogues: Puzzles and promises 
in diabetes management. Postgraduate medicine 101, 138-150 (1997). 
3 Robertson, G. L. Diabetes insipidus. Endocrinology and metabolism clinics of North 
America 24, 549-572 (1995). 
4 Bliss, M. The discovery of insulin.  (University of Chicago Press, 2013). 
5 Stern, M. P. Diabetes and cardiovascular disease: the “common soil” hypothesis. 
Diabetes 44, 369-374 (1995). 
6 Kannel, W. B. & McGee, D. L. Diabetes and cardiovascular disease: the Framingham 
study. Jama 241, 2035-2038 (1979). 
7 Sowers, J. R., Epstein, M. & Frohlich, E. D. Diabetes, hypertension, and cardiovascular 
disease: an update. Hypertension 37, 1053-1059 (2001). 
8 Control, D., Interventions, C. T. E. o. D. & Group, C. S. R. Intensive diabetes treatment 
and cardiovascular disease in patients with type 1 diabetes. New England Journal of 
Medicine 353, 2643-2653 (2005). 
9 Gæde, P. et al. Multifactorial intervention and cardiovascular disease in patients with 
type 2 diabetes. New England Journal of Medicine 348, 383-393 (2003). 
10 Group, N. D. D. Classification and diagnosis of diabetes mellitus and other categories of 
glucose intolerance. Diabetes 28, 1039-1057 (1979). 
11 Association, A. D. Diagnosis and classification of diabetes mellitus. Diabetes care 33, 
S62-S69 (2010). 
12 Association, A. D. Gestational diabetes mellitus. Diabetes care 27, s88-s90 (2004). 
13 Atlas, I. D.     1-145 (Brussels, Belgium 2018). 
14 Jennings, R. E. et al. Development of the human pancreas from foregut to endocrine 
commitment. Diabetes 62, 3514-3522 (2013). 
15 Jennings, R. E., Berry, A. A., Strutt, J. P., Gerrard, D. T. & Hanley, N. A. Human 
pancreas development. Development 142, 3126-3137 (2015). 
16 Collombat, P. et al. Opposing actions of Arx and Pax4 in endocrine pancreas 
development. Genes & development 17, 2591-2603 (2003). 
17 Lebenthal, E. & Lee, P. Development of functional response in human exocrine pancreas. 
Pediatrics 66, 556-560 (1980). 
18 Vacca, J. B., Henke, W. J. & Knight, W. A. The exocrine pancreas in diabetes mellitus. 
Annals of internal medicine 61, 242-247 (1964). 
19 Inada, A. et al. Carbonic anhydrase II-positive pancreatic cells are progenitors for both 
endocrine and exocrine pancreas after birth. Proceedings of the National Academy of 
Sciences 105, 19915-19919 (2008). 
20 Furuyama, K. et al. Continuous cell supply from a Sox9-expressing progenitor zone in 
adult liver, exocrine pancreas and intestine. Nature genetics 43, 34 (2011). 
21 Wells, J. M. et al. Wnt/β-catenin signaling is required for development of the exocrine 
pancreas. BMC developmental biology 7, 4 (2007). 
22 Beer, R. L., Parsons, M. J. & Rovira, M. Centroacinar cells: at the center of pancreas 
regeneration. Developmental biology 413, 8-15 (2016). 
23 Zhou, Q. & Melton, D. A. Pancreas regeneration. Nature 557, 351 (2018). 
24 Murtaugh, L. C. & Keefe, M. D. Regeneration and repair of the exocrine pancreas. 
Annual review of physiology 77, 229-249 (2015). 
25 Lehv, M. & Fitzgerald, P. Pancreatic acinar cell regeneration. IV. Regeneration after 
resection. The American journal of pathology 53, 513 (1968). 
50 
26 Zhou, Q., Brown, J., Kanarek, A., Rajagopal, J. & Melton, D. A. In vivo reprogramming 
of adult pancreatic exocrine cells to β-cells. nature 455, 627 (2008). 
27 Muraro, M. J. et al. A single-cell transcriptome atlas of the human pancreas. Cell systems 
3, 385-394. e383 (2016). 
28 Bouwens, L., Lu, W. & De Krijger, R. Proliferation and differentiation in the human fetal 
endocrine pancreas. Diabetologia 40, 398-404 (1997). 
29 Andralojc, K. et al. Ghrelin-producing epsilon cells in the developing and adult human 
pancreas. Diabetologia 52, 486-493 (2009). 
30 Tschöp, M., Smiley, D. L. & Heiman, M. L. Ghrelin induces adiposity in rodents. Nature 
407, 908 (2000). 
31 Richards, O. C., Raines, S. M. & Attie, A. D. The role of blood vessels, endothelial cells, 
and vascular pericytes in insulin secretion and peripheral insulin action. Endocrine 
reviews 31, 343-363 (2010). 
32 Röder, P. V., Wu, B., Liu, Y. & Han, W. Pancreatic regulation of glucose homeostasis. 
Experimental & molecular medicine 48, e219 (2016). 
33 Quesada, I., Tudurí, E., Ripoll, C. & Nadal, A. Physiology of the pancreatic α-cell and 
glucagon secretion: role in glucose homeostasis and diabetes. Journal of Endocrinology 
199, 5-19 (2008). 
34 Drucker, D. J. The role of gut hormones in glucose homeostasis. The Journal of clinical 
investigation 117, 24-32 (2007). 
35 Meyer, C., Dostou, J. M., Welle, S. L. & Gerich, J. E. Role of human liver, kidney, and 
skeletal muscle in postprandial glucose homeostasis. American Journal of Physiology-
Endocrinology And Metabolism 282, E419-E427 (2002). 
36 Collaboration, E. R. F. Diabetes mellitus, fasting glucose, and risk of cause-specific 
death. New England Journal of Medicine 364, 829-841 (2011). 
37 Johnston, N. R. et al. Β cell hubs dictate pancreatic islet responses to glucose. Cell 
metabolism 24, 389-401 (2016). 
38 Thorens, B. GLUT2, glucose sensing and glucose homeostasis. Diabetologia 58, 221-232 
(2015). 
39 Li, J., Shuai, H., Gylfe, E. & Tengholm, A. Oscillations of sub-membrane ATP in 
glucose-stimulated β cells depend on negative feedback from Ca 2+. Diabetologia 56, 
1577-1586 (2013). 
40 Meissner, H. & Schmelz, H. Membrane potential of β-cells in pancreatic islets. Pflügers 
Archiv 351, 195-206 (1974). 
41 Abel, E. D. et al. Adipose-selective targeting of the GLUT4 gene impairs insulin action 
in muscle and liver. Nature 409, 729 (2001). 
42 Leto, D. & Saltiel, A. R. Regulation of glucose transport by insulin: traffic control of 
GLUT4. Nature reviews Molecular cell biology 13, 383 (2012). 
43 Baggio, L. L. & Drucker, D. J. Biology of incretins: GLP-1 and GIP. Gastroenterology 
132, 2131-2157 (2007). 
44 Vilsbøll, T. & Holst, J. J. Incretins, insulin secretion and type 2 diabetes mellitus. 
Diabetologia 47, 357-366 (2004). 
45 Ekblad, E. & Sundler, F. Distribution of pancreatic polypeptide and peptide YY. Peptides 
23, 251-261 (2002). 
46 Strowski, M., Parmar, R., Blake, A. & Schaeffer, J. Somatostatin inhibits insulin and 
glucagon secretion via two receptor subtypes: an in vitro study of pancreatic islets from 
somatostatin receptor 2 knockout mice. Endocrinology 141, 111-117 (2000). 
47 Daneman, D. Type 1 diabetes. The Lancet 367, 847-858 (2006). 
48 Palmer, J. P. & Hirsch, I. B.     (Am Diabetes Assoc, 2003). 
51 
49 Patterson, C. et al. Trends in childhood type 1 diabetes incidence in Europe during 1989–
2008: evidence of non-uniformity over time in rates of increase. Diabetologia 55, 2142-
2147 (2012). 
50 Eisenbarth, G. S. Type I diabetes mellitus. New England journal of medicine 314, 1360-
1368 (1986). 
51 Virtanen, S. M. Dietary factors in the development of type 1 diabetes. Pediatric diabetes 
17, 49-55 (2016). 
52 Stankov, K., Benc, D. & Draskovic, D. Genetic and epigenetic factors in etiology of 
diabetes mellitus type 1. Pediatrics 132, 1112-1122 (2013). 
53 Patel, K. A. et al. Type 1 diabetes genetic risk score: a novel tool to discriminate 
monogenic and type 1 diabetes. Diabetes 65, 2094-2099 (2016). 
54 Van Belle, T. L., Coppieters, K. T. & Von Herrath, M. G. Type 1 diabetes: etiology, 
immunology, and therapeutic strategies. Physiological reviews 91, 79-118 (2011). 
55 Hyöty, H. Viruses in type 1 diabetes. Pediatric diabetes 17, 56-64 (2016). 
56 Rees, D. & Alcolado, J. Animal models of diabetes mellitus. Diabetic medicine 22, 359-
370 (2005). 
57 Seneviratne, A. K. et al. Expanded hematopoietic progenitor cells reselected for high 
aldehyde dehydrogenase activity demonstrate islet regenerative functions. Stem Cells 34, 
873-887 (2016). 
58 Bell, G., Putman, D., Hughes-Large, J. & Hess, D. Intrapancreatic delivery of human 
umbilical cord blood aldehyde dehydrogenase-producing cells promotes islet 
regeneration. Diabetologia 55, 1755-1760 (2012). 
59 DiMeglio, L. A., Evans-Molina, C. & Oram, R. A. Type 1 diabetes. The Lancet 391, 
2449-2462 (2018). 
60 Thompson, P. J. et al. Targeted Elimination of Senescent Β Cells Prevents Type 1 
Diabetes. Cell metabolism (2019). 
61 Eppens, M. C. et al. Prevalence of diabetes complications in adolescents with type 2 
compared with type 1 diabetes. Diabetes care 29, 1300-1306 (2006). 
62 Boulton, A. J. et al. Diabetic neuropathies: a statement by the American Diabetes 
Association. Diabetes care 28, 956-962 (2005). 
63 González‐Clemente, J. et al. Diabetic neuropathy is associated with activation of the 
TNF‐α system in subjects with type 1 diabetes mellitus. Clinical endocrinology 63, 525-
529 (2005). 
64 Shakil, A., Church, R. J. & Rao, S. S. Gastrointestinal complications of diabetes. 
American family physician 77 (2008). 
65 Association, A. D. 7. Obesity management for the treatment of type 2 diabetes. Diabetes 
care 40, S57-S63 (2017). 
66 Hu, F. B. et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. New 
England journal of medicine 345, 790-797 (2001). 
67 Seuring, T., Archangelidi, O. & Suhrcke, M. The economic costs of type 2 diabetes: a 
global systematic review. Pharmacoeconomics 33, 811-831 (2015). 
68 DeFronzo, R. A. Pathogenesis of type 2 diabetes mellitus. Medical Clinics 88, 787-835 
(2004). 
69 Zhu, Y. & Zhang, C. Prevalence of gestational diabetes and risk of progression to type 2 
diabetes: a global perspective. Current diabetes reports 16, 7 (2016). 
70 Chatterjee, S., Khunti, K. & Davies, M. J. Type 2 diabetes. The Lancet 389, 2239-2251 
(2017). 
71 Jaacks, L. M., Siegel, K. R., Gujral, U. P. & Narayan, K. V. Type 2 diabetes: a 21st 
century epidemic. Best Practice & Research Clinical Endocrinology & Metabolism 30, 
331-343 (2016). 
52 
72 van der Berg, J. D. et al. Associations of total amount and patterns of sedentary 
behaviour with type 2 diabetes and the metabolic syndrome: The Maastricht Study. 
Diabetologia 59, 709-718 (2016). 
73 Powers, M. A. et al. Diabetes self-management education and support in type 2 diabetes: 
a joint position statement of the American Diabetes Association, the American 
Association of Diabetes Educators, and the Academy of Nutrition and Dietetics. The 
Diabetes Educator 43, 40-53 (2017). 
74 Hartstra, A. V., Bouter, K. E., Bäckhed, F. & Nieuwdorp, M. Insights into the role of the 
microbiome in obesity and type 2 diabetes. Diabetes care 38, 159-165 (2015). 
75 Tuomilehto, J. et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among 
subjects with impaired glucose tolerance. New England Journal of Medicine 344, 1343-
1350 (2001). 
76 Coppola, A., Sasso, L., Bagnasco, A., Giustina, A. & Gazzaruso, C. The role of patient 
education in the prevention and management of type 2 diabetes: an overview. Endocrine 
53, 18-27 (2016). 
77 Henson, J., Dunstan, D. W., Davies, M. J. & Yates, T. Sedentary behaviour as a new 
behavioural target in the prevention and treatment of type 2 diabetes. 
Diabetes/metabolism research and reviews 32, 213-220 (2016). 
78 Besseling, J., Kastelein, J. J., Defesche, J. C., Hutten, B. A. & Hovingh, G. K. 
Association between familial hypercholesterolemia and prevalence of type 2 diabetes 
mellitus. Jama 313, 1029-1036 (2015). 
79 Li, Y. et al. Exposure to the Chinese famine in early life and the risk of hyperglycemia 
and type 2 diabetes in adulthood. Diabetes 59, 2400-2406 (2010). 
80 de Rooij, S. R., Painter, R. C., Holleman, F., Bossuyt, P. M. & Roseboom, T. J. The 
metabolic syndrome in adults prenatally exposed to the Dutch famine. The American 
journal of clinical nutrition 86, 1219-1224 (2007). 
81 Pessin, J. E. & Saltiel, A. R. Signaling pathways in insulin action: molecular targets of 
insulin resistance. The Journal of clinical investigation 106, 165-169 (2000). 
82 Bollheimer, L. C., Skelly, R. H., Chester, M. W., McGarry, J. D. & Rhodes, C. J. Chronic 
exposure to free fatty acid reduces pancreatic β cell insulin content by increasing basal 
insulin secretion that is not compensated for by a corresponding increase in proinsulin 
biosynthesis translation. The Journal of clinical investigation 101, 1094-1101 (1998). 
83 Cerasi, E., Kaiser, N. & Leibowitz, G. Type 2 diabetes and β cell apoptosis. Diabetes & 
metabolism 26, 13-16 (2000). 
84 Cerf, M. E. Β cell dysfunction and insulin resistance. Frontiers in endocrinology 4, 37 
(2013). 
85 Bonner-Weir, S., Trent, D. & Weir, G. Partial pancreatectomy in the rat and subsequent 
defect in glucose-induced insulin release. The Journal of clinical investigation 71, 1544-
1553 (1983). 
86 Kumar, A. F., Gruessner, R. W. & Seaquist, E. R. Risk of glucose intolerance and 
diabetes in hemipancreatectomized donors selected for normal preoperative glucose 
metabolism. Diabetes Care 31, 1639-1643 (2008). 
87 Kim, A. et al. Islet architecture: a comparative study. Islets 1, 129-136 (2009). 
88 e Drigo, R. A. et al. New insights into the architecture of the islet of Langerhans: a 
focused cross-species assessment. Diabetologia 58, 2218-2228 (2015). 
89 Steiner, D. J., Kim, A., Miller, K. & Hara, M. Pancreatic islet plasticity: interspecies 
comparison of islet architecture and composition. Islets 2, 135-145 (2010). 
90 Sato, T., Herman, L. & Fitzgerald, P. J. The comparative ultrastructure of the pancreatic 
islet of Langerhans. General and Comparative Endocrinology 7, 132-157 (1966). 
91 In’t Veld, P. & Smeets, S. Microscopic anatomy of the human islet of Langerhans. Islets 
of Langerhans, 2. ed., 1-18 (2013). 
53 
92 Bosco, D. et al. Unique arrangement of α-and β-cells in human islets of Langerhans. 
Diabetes 59, 1202-1210 (2010). 
93 Association, A. D. 7. Approaches to glycemic treatment. Diabetes care 39, S52-S59 
(2016). 
94 Mirouze, J., Selam, J., Pham, T. & Cavadore, D. Evaluation of exogenous insulin 
homoeostasis by the artificial pancreas in insulin-dependent diabetes. Diabetologia 13, 
273-278 (1977). 
95 Banting, F. G. & Best, C. H. The internal secretion of the pancreas. Indian Journal of 
Medical Research 125, L251 (2007). 
96 Banting, F. G., Best, C. H., Collip, J. B., Campbell, W. R. & Fletcher, A. A. Pancreatic 
extracts in the treatment of diabetes mellitus. Canadian Medical Association Journal 12, 
141 (1922). 
97 King, K. M. & Rubin, G. A history of diabetes: from antiquity to discovering insulin. 
British journal of nursing 12, 1091-1095 (2003). 
98 Johnson, I. S. Human insulin from recombinant DNA technology. Science 219, 632-637 
(1983). 
99 Walsh, G. Therapeutic insulins and their large-scale manufacture. Applied microbiology 
and biotechnology 67, 151-159 (2005). 
100 Cummins, E. et al. in NIHR Health Technology Assessment programme: Executive 
Summaries     (NIHR Journals Library, 2010). 
101 Association, A. D. Economic costs of diabetes in the US in 2017. Diabetes care 41, 917-
928 (2018). 
102 Shapiro, A. J. et al. Islet transplantation in seven patients with type 1 diabetes mellitus 
using a glucocorticoid-free immunosuppressive regimen. New England Journal of 
Medicine 343, 230-238 (2000). 
103 Ryan, E. A. et al. Clinical outcomes and insulin secretion after islet transplantation with 
the Edmonton protocol. Diabetes 50, 710-719 (2001). 
104 Shapiro, A. J. et al. International trial of the Edmonton protocol for islet transplantation. 
New England Journal of Medicine 355, 1318-1330 (2006). 
105 Brennan, D. C. et al. Long‐term follow‐up of the Edmonton protocol of islet 
transplantation in the United States. American Journal of Transplantation 16, 509-517 
(2016). 
106 Joglekar, M., Parekh, V. & Hardikar, A. Islet-specific microRNAs in pancreas 
development, regeneration and diabetes.  (2011). 
107 Aguayo-Mazzucato, C. & Bonner-Weir, S. Pancreatic β cell regeneration as a possible 
therapy for diabetes. Cell metabolism 27, 57-67 (2018). 
108 QADIR, F. et al.     (Am Diabetes Assoc, 2018). 
109 Ben-Othman, N. et al. Long-term GABA administration induces α cell-mediated β-like 
cell neogenesis. Cell 168, 73-85. e11 (2017). 
110 Druelle, N. et al. Ectopic expression of Pax4 in pancreatic δ cells results in β-like cell 
neogenesis. J Cell Biol 216, 4299-4311 (2017). 
111 Notkins, A. L. & Lernmark, Å. Autoimmune type 1 diabetes: resolved and unresolved 
issues. The Journal of clinical investigation 108, 1247-1252 (2001). 
112 Hu, C.-y. et al. Treatment with CD20-specific antibody prevents and reverses 
autoimmune diabetes in mice. The Journal of clinical investigation 117, 3857-3867 
(2007). 
113 Zhao, Y. Stem cell educator therapy and induction of immune balance. Current diabetes 
reports 12, 517-523 (2012). 
114 Zhao, Y. et al. Targeting insulin resistance in type 2 diabetes via immune modulation of 
cord blood-derived multipotent stem cells (CB-SCs) in stem cell educator therapy: phase 
I/II clinical trial. BMC medicine 11, 160 (2013). 
54 
115 Setter, S. M., Iltz, J. L., Thams, J. & Campbell, R. K. Metformin hydrochloride in the 
treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy. 
Clinical therapeutics 25, 2991-3026 (2003). 
116 Yu, O., Azoulay, L., Yin, H., Filion, K. B. & Suissa, S. Sulfonylureas as initial treatment 
for type 2 diabetes and the risk of severe hypoglycemia. The American journal of 
medicine 131, 317. e311-317. e322 (2018). 
117 Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 
diabetes. New England Journal of Medicine 373, 2117-2128 (2015). 
118 Association, A. D. 4. Foundations of care: education, nutrition, physical activity, smoking 
cessation, psychosocial care, and immunization. Diabetes care 38, S20-S30 (2015). 
119 Eisenberg, D. M. & Burgess, J. D. Nutrition education in an era of global obesity and 
diabetes: thinking outside the box. Academic Medicine 90, 854-860 (2015). 
120 Wang, C. C. L. et al. Cardiovascular and Limb Outcomes in Patients With Diabetes and 
Peripheral Artery Disease: The EUCLID Trial. Journal of the American College of 
Cardiology 72, 3274-3284 (2018). 
121 Pan, H.-z. et al. The oxidative stress status in diabetes mellitus and diabetic nephropathy. 
Acta diabetologica 47, 71-76 (2010). 
122 Peng, L., Liu, W., Zhai, F., He, L. & Wang, H. Microvessel permeability correlates with 
diabetic peripheral neuropathy in early stage of streptozotocin-induced diabetes rats. 
Journal of Diabetes and its Complications 29, 865-871 (2015). 
123 Bosma, E. K., van Noorden, C. J., Klaassen, I. & Schlingemann, R. O. in Diabetic 
Nephropathy     305-321 (Springer, 2019). 
124 Adams, R. H. Molecular control of arterial–venous blood vessel identity. Journal of 
anatomy 202, 105-112 (2003). 
125 Heinke, J., Patterson, C. & Moser, M. Life is a pattern: vascular assembly within the 
embryo. Frontiers in bioscience (Elite edition) 4, 2269 (2012). 
126 Risau, W. & Flamme, I. Vasculogenesis. Annual review of cell and developmental 
biology 11, 73-91 (1995). 
127 Gonzalez‐Crussi, F. Vasculogenesis in the chick embryo. An ultrastructural study. 
American Journal of Anatomy 130, 441-459 (1971). 
128 Matsumoto, K., Yoshitomi, H., Rossant, J. & Zaret, K. S. Liver organogenesis promoted 
by endothelial cells prior to vascular function. Science 294, 559-563 (2001). 
129 Auerbach, R. & Auerbach, W. Profound effects on vascular development caused by 
perturbations during organogenesis. The American journal of pathology 151, 1183 
(1997). 
130 Shalaby, F. et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient 
mice. Nature 376, 62 (1995). 
131 Choi, K., Kennedy, M., Kazarov, A., Papadimitriou, J. C. & Keller, G. A common 
precursor for hematopoietic and endothelial cells. Development 125, 725-732 (1998). 
132 Peters, K. G., De Vries, C. & Williams, L. T. Vascular endothelial growth factor receptor 
expression during embryogenesis and tissue repair suggests a role in endothelial 
differentiation and blood vessel growth. Proceedings of the National Academy of 
Sciences 90, 8915-8919 (1993). 
133 Coultas, L., Chawengsaksophak, K. & Rossant, J. Endothelial cells and VEGF in 
vascular development. Nature 438, 937 (2005). 
134 Thurston, G. et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. 
Nature medicine 6, 460 (2000). 
135 Suri, C. et al. Increased vascularization in mice overexpressing angiopoietin-1. Science 
282, 468-471 (1998). 
136 Suri, C. et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during 
embryonic angiogenesis. Cell 87, 1171-1180 (1996). 
55 
137 Yamamoto, K. et al. Proliferation, differentiation, and tube formation by endothelial 
progenitor cells in response to shear stress. Journal of Applied Physiology 95, 2081-2088 
(2003). 
138 Lehoux, S. & Jones, E. A. Shear stress, arterial identity and atherosclerosis. Thrombosis 
and haemostasis 115, 467-473 (2016). 
139 Crosby, J. R. et al. Endothelial cells of hematopoietic origin make a significant 
contribution to adult blood vessel formation. Circulation research 87, 728-730 (2000). 
140 Frenette, P. S., Subbarao, S., Mazo, I. B., Von Andrian, U. H. & Wagner, D. D. 
Endothelial selectins and vascular cell adhesion molecule-1 promote hematopoietic 
progenitor homing to bone marrow. Proceedings of the National Academy of Sciences 95, 
14423-14428 (1998). 
141 Rhodin, J.     (American Physiological Society, Bethesda, 1980). 
142 Mulvany, M. & Aalkjær, C. Structure and function of small arteries. Physiological 
reviews 70, 921-961 (1990). 
143 Tilton, R. G., Kilo, C. & Williamson, J. R. Pericyte-endothelial relationships in cardiac 
and skeletal muscle capillaries. Microvascular research 18, 325-335 (1979). 
144 Han, S. S. & Avery, J. K. The ultrastructure of capillaries and arterioles of the hamster 
dental pulp. The Anatomical Record 145, 549-571 (1963). 
145 Kumar, S., West, D. C. & Ager, A. Heterogeneity in endothelial cells from large vessels 
and microvessels. Differentiation 36, 57-70 (1987). 
146 Griep, L. et al. BBB on chip: microfluidic platform to mechanically and biochemically 
modulate blood-brain barrier function. Biomedical microdevices 15, 145-150 (2013). 
147 Caggiati, A., Phillips, M., Lametschwandtner, A. & Allegra, C. Valves in small veins and 
venules. European Journal of Vascular and Endovascular Surgery 32, 447-452 (2006). 
148 Cleaver, O. & Melton, D. A. Endothelial signaling during development. Nature medicine 
9, 661 (2003). 
149 Ballian, N. & Brunicardi, F. C. Islet vasculature as a regulator of endocrine pancreas 
function. World journal of surgery 31, 705-714 (2007). 
150 Ruggeri, Z. Von Willebrand factor, platelets and endothelial cell interactions. Journal of 
Thrombosis and Haemostasis 1, 1335-1342 (2003). 
151 Palmer, R. M., Ferrige, A. & Moncada, S. Nitric oxide release accounts for the biological 
activity of endothelium-derived relaxing factor. Nature 327, 524 (1987). 
152 Förstermann, U., Xia, N. & Li, H. Roles of vascular oxidative stress and nitric oxide in 
the pathogenesis of atherosclerosis. Circulation research 120, 713-735 (2017). 
153 Hink, U. et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. 
Circulation research 88, e14-e22 (2001). 
154 Association, A. D. 9. Microvascular complications and foot care. Diabetes care 39, S72-
S80 (2016). 
155 Association, A. D. 10. Microvascular complications and foot care: standards of medical 
care in diabetes—2018. Diabetes Care 41, S105-S118 (2018). 
156 Hinkel, R. et al. Diabetes mellitus–induced microvascular destabilization in the 
myocardium. Journal of the American College of Cardiology 69, 131-143 (2017). 
157 Pyšná, A. et al. Endothelial progenitor cells biology in diabetes mellitus and peripheral 
arterial disease and their therapeutic potential. Stem Cell Reviews and Reports, 1-9 
(2018). 
158 Signorelli, S. S. & Katsiki, N. Oxidative stress and inflammation: Their role in the 
pathogenesis of peripheral artery disease with or without type 2 diabetes mellitus. 
Current vascular pharmacology 16, 547-554 (2018). 
159 Bennett, M. R., Sinha, S. & Owens, G. K. Vascular smooth muscle cells in 
atherosclerosis. Circulation research 118, 692-702 (2016). 
56 
160 Nehls, V., Denzer, K. & Drenckhahn, D. Pericyte involvement in capillary sprouting 
during angiogenesis in situ. Cell and tissue research 270, 469-474 (1992). 
161 Chen, J. et al. CD146 is essential for PDGFRβ-induced pericyte recruitment. Protein & 
cell 9, 743-747 (2018). 
162 da Bandeira, D. S., Casamitjana, J. & Crisan, M. Pericytes, integral components of adult 
hematopoietic stem cell niches. Pharmacology & therapeutics 171, 104-113 (2017). 
163 Crisan, M. et al. A perivascular origin for mesenchymal stem cells in multiple human 
organs. Cell stem cell 3, 301-313 (2008). 
164 Beckman, J. A., Creager, M. A. & Libby, P. Diabetes and atherosclerosis: epidemiology, 
pathophysiology, and management. Jama 287, 2570-2581 (2002). 
165 Libby, P., Ridker, P. M. & Maseri, A. Inflammation and atherosclerosis. Circulation 105, 
1135-1143 (2002). 
166 Wilkins, E. et al. European cardiovascular disease statistics 2017.  (2017). 
167 Mozaffarian, D. et al. Heart disease and stroke statistics-2016 update a report from the 
American Heart Association. Circulation 133, e38-e48 (2016). 
168 Smolderen, K. G. et al. One-year costs associated with cardiovascular disease in Canada: 
insights from the REduction of Atherothrombosis for Continued Health (REACH) 
registry. Canadian Journal of Cardiology 26, e297-e305 (2010). 
169 Cooper, T. T., Hess, D. A. & Verma, S. Vascular Organoids: Are We Entering a New 
Area of Cardiometabolic Research? Cell metabolism 29, 792-794 (2019). 
170 Dunbar, S. B. et al. Projected costs of informal caregiving for cardiovascular disease: 
2015 to 2035: a policy statement from the American Heart Association. Circulation 137, 
e558-e577 (2018). 
171 Association, A. D. Peripheral arterial disease in people with diabetes. Diabetes care 26, 
3333-3341 (2003). 
172 Morley, R. L., Sharma, A., Horsch, A. D. & Hinchliffe, R. J. Peripheral artery disease. 
bmj 360, j5842 (2018). 
173 Thiruvoipati, T., Kielhorn, C. E. & Armstrong, E. J. Peripheral artery disease in patients 
with diabetes: Epidemiology, mechanisms, and outcomes. World journal of diabetes 6, 
961 (2015). 
174 Makowsky, M. et al. Prevalence and treatment patterns of lower extremity peripheral 
arterial disease among patients at risk in ambulatory health settings. Canadian Journal of 
Cardiology 27, 389. e311-389. e318 (2011). 
175 Davies, M. G. Criticial limb ischemia: epidemiology. Methodist DeBakey cardiovascular 
journal 8, 10 (2012). 
176 Varu, V. N., Hogg, M. E. & Kibbe, M. R. Critical limb ischemia. Journal of vascular 
surgery 51, 230-241 (2010). 
177 Hiatt, W. R. Medical treatment of peripheral arterial disease and claudication. New 
England Journal of Medicine 344, 1608-1621 (2001). 
178 Aboyans, V. et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral 
Arterial Diseases, in collaboration with the European Society for Vascular Surgery 
(ESVS) Document covering atherosclerotic disease of extracranial carotid and vertebral, 
mesenteric, renal, upper and lower extremity arteries Endorsed by: the European Stroke 
Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral 
Arterial Diseases of the European Society of Cardiology (ESC) and of the European 
Society for Vascular Surgery (ESVS). European heart journal 39, 763-816 (2017). 
179 Hertzer, N. R. et al. Coronary artery disease in peripheral vascular patients. A 
classification of 1000 coronary angiograms and results of surgical management. Annals 
of surgery 199, 223 (1984). 
180 Gupta, N. K., Armstrong, E. J. & Parikh, S. A. The current state of stem cell therapy for 
peripheral artery disease. Current cardiology reports 16, 447 (2014). 
57 
181 Isner, J. M. et al. Arterial gene therapy for therapeutic angiogenesis in patients with 
peripheral artery disease. Circulation 91, 2687-2692 (1995). 
182 Kemp, P. History of regenerative medicine: looking backwards to move forwards.  
(2006). 
183 Koransky, M. L., Robbins, R. C. & Blau, H. M. VEGF gene delivery for treatment of 
ischemic cardiovascular disease. Trends in cardiovascular medicine 12, 108-114 (2002). 
184 Cooper, T. T. et al. Inhibition of Aldehyde Dehydrogenase‐Activity Expands Multipotent 
Myeloid Progenitor Cells with Vascular Regenerative Function. Stem Cells 36, 723-736 
(2018). 
185 Sutton, J. T., Haworth, K. J., Pyne-Geithman, G. & Holland, C. K. Ultrasound-mediated 
drug delivery for cardiovascular disease. Expert opinion on drug delivery 10, 573-592 
(2013). 
186 Young, S. A. et al. Mechanically resilient injectable scaffolds for intramuscular stem cell 
delivery and cytokine release. Biomaterials 159, 146-160 (2018). 
187 Berthiaume, F., Maguire, T. J. & Yarmush, M. L. Tissue engineering and regenerative 
medicine: history, progress, and challenges. Annual review of chemical and biomolecular 
engineering 2, 403-430 (2011). 
188 Till, J. E. & McCulloch, E. A. A direct measurement of the radiation sensitivity of 
normal mouse bone marrow cells. Radiation research 14, 213-222 (1961). 
189 Reya, T., Morrison, S. J., Clarke, M. F. & Weissman, I. L. Stem cells, cancer, and cancer 
stem cells. nature 414, 105 (2001). 
190 Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by 
defined factors. cell 131, 861-872 (2007). 
191 Conboy, I. M. & Rando, T. A. Aging, stem cells and tissue regeneration: lessons from 
muscle. Cell cycle 4, 407-410 (2005). 
192 Childs, B. G., Durik, M., Baker, D. J. & Van Deursen, J. M. Cellular senescence in aging 
and age-related disease: from mechanisms to therapy. Nature medicine 21, 1424 (2015). 
193 Perin, E. C. et al. Evaluation of cell therapy on exercise performance and limb perfusion 
in peripheral artery disease: the CCTRN PACE trial (patients with intermittent 
claudication injected with ALDH bright cells). Circulation 135, 1417-1428 (2017). 
194 Perin, E. C. et al. Rationale and design for PACE: patients with intermittent claudication 
injected with ALDH bright cells. American heart journal 168, 667-673. e662 (2014). 
195 Hess, D. et al. Bone marrow–derived stem cells initiate pancreatic regeneration. Nature 
biotechnology 21, 763 (2003). 
196 Bell, G. I. et al. Combinatorial human progenitor cell transplantation optimizes islet 
regeneration through secretion of paracrine factors. Stem cells and development 21, 1863-
1876 (2012). 
197 Chhabra, P. & Brayman, K. L. Stem cell therapy to cure type 1 diabetes: from hype to 
hope. Stem cells translational medicine 2, 328-336 (2013). 
198 Notta, F. et al. Isolation of single human hematopoietic stem cells capable of long-term 
multilineage engraftment. Science 333, 218-221 (2011). 
199 Anjos-Afonso, F. et al. CD34− cells at the apex of the human hematopoietic stem cell 
hierarchy have distinctive cellular and molecular signatures. Cell stem cell 13, 161-174 
(2013). 
200 Ma, I. & Allan, A. L. The role of human aldehyde dehydrogenase in normal and cancer 
stem cells. Stem cell reviews and reports 7, 292-306 (2011). 
201 Chanda, B., Ditadi, A., Iscove, N. N. & Keller, G. Retinoic acid signaling is essential for 
embryonic hematopoietic stem cell development. Cell 155, 215-227 (2013). 
202 Liu, Y. et al. Proliferating pancreatic β-cells upregulate ALDH. Histochemistry and cell 
biology 142, 685-691 (2014). 
58 
203 Huang, E. H. et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant 
human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. 
Cancer research 69, 3382-3389 (2009). 
204 Kieffer, T. J., Woltjen, K., Osafune, K., Yabe, D. & Inagaki, N. Β‐cell replacement 
strategies for diabetes. Journal of diabetes investigation 9, 457-463 (2018). 
205 Kuljanin, M. et al. Human multipotent stromal cell secreted effectors accelerate islet 
regeneration. Stem cells 37, 516-528 (2019). 
206 Putman, D. M., Liu, K. Y., Broughton, H. C., Bell, G. I. & Hess, D. A. Umbilical cord 
blood‐derived aldehyde dehydrogenase‐expressing progenitor cells promote recovery 
from acute ischemic injury. Stem cells 30, 2248-2260 (2012). 
207 Rhinn, M. & Dollé, P. Retinoic acid signalling during development. Development 139, 
843-858 (2012). 
208 Mark, M., Ghyselinck, N. B. & Chambon, P. Function of retinoid nuclear receptors: 
lessons from genetic and pharmacological dissections of the retinoic acid signaling 
pathway during mouse embryogenesis. Annu. Rev. Pharmacol. Toxicol. 46, 451-480 
(2006). 
209 Chen, Y. et al. Retinoic acid signaling is essential for pancreas development and 
promotes endocrine at the expense of exocrine cell differentiation in Xenopus. 
Developmental biology 271, 144-160 (2004). 
210 Orkin, S. H. & Zon, L. I. Hematopoiesis: an evolving paradigm for stem cell biology. 
Cell 132, 631-644 (2008). 
211 Moore, K. A. & Lemischka, I. R. Stem cells and their niches. Science 311, 1880-1885 
(2006). 
212 Eaves, C. J. Hematopoietic stem cells: concepts, definitions, and the new reality. Blood 
125, 2605-2613 (2015). 
213 Munshi, C. B., Graeff, R. & Lee, H. C. Evidence for a causal role of CD38 expression in 
granulocytic differentiation of human HL-60 cells. Journal of Biological Chemistry 277, 
49453-49458 (2002). 
214 Steinman, R. M. & Inaba, K. Myeloid dendritic cells. Journal of leukocyte biology 66, 
205-208 (1999). 
215 Guilliams, M. et al. Dendritic cells, monocytes and macrophages: a unified nomenclature 
based on ontogeny. Nature Reviews Immunology 14, 571 (2014). 
216 Geissmann, F. et al. Development of monocytes, macrophages, and dendritic cells. 
Science 327, 656-661 (2010). 
217 Beerman, I. et al. Functionally distinct hematopoietic stem cells modulate hematopoietic 
lineage potential during aging by a mechanism of clonal expansion. Proceedings of the 
National Academy of Sciences 107, 5465-5470 (2010). 
218 Atkinson, K. et al. Clinical bone marrow and blood stem cell transplantation.  
(Cambridge University Press, 2004). 
219 Huss, R. Isolation of primary and immortalized CD34− hematopoietic and mesenchymal 
stem cells from various sources. Stem cells 18, 1-9 (2000). 
220 Sauvageau, G., Iscove, N. N. & Humphries, R. K. In vitro and in vivo expansion of 
hematopoietic stem cells. Oncogene 23, 7223 (2004). 
221 Chute, J. P. et al. Inhibition of aldehyde dehydrogenase and retinoid signaling induces the 
expansion of human hematopoietic stem cells. Proceedings of the National Academy of 
Sciences 103, 11707-11712 (2006). 
222 Madlambayan, G. J. et al. Dynamic changes in cellular and microenvironmental 
composition can be controlled to elicit in vitro human hematopoietic stem cell expansion. 
Experimental hematology 33, 1229-1239 (2005). 
59 
223 Kirouac, D. C. & Zandstra, P. W. Understanding cellular networks to improve 
hematopoietic stem cell expansion cultures. Current Opinion in Biotechnology 17, 538-
547 (2006). 
224 Csaszar, E. et al. Rapid expansion of human hematopoietic stem cells by automated 
control of inhibitory feedback signaling. Cell stem cell 10, 218-229 (2012). 
225 Csaszar, E., Chen, K., Caldwell, J., Chan, W. & Zandstra, P. W. Real‐time monitoring 
and control of soluble signaling factors enables enhanced progenitor cell outputs from 
human cord blood stem cell cultures. Biotechnology and bioengineering 111, 1258-1264 
(2014). 
226 Putman, D. M. et al. Expansion of umbilical cord blood aldehyde dehydrogenase 
expressing cells generates myeloid progenitor cells that stimulate limb revascularization. 
Stem cells translational medicine 6, 1607-1619 (2017). 
227 Squillaro, T., Peluso, G. & Galderisi, U. Clinical trials with mesenchymal stem cells: an 
update. Cell transplantation 25, 829-848 (2016). 
228 Giordano, A., Galderisi, U. & Marino, I. R. From the laboratory bench to the patient's 
bedside: an update on clinical trials with mesenchymal stem cells. Journal of cellular 
physiology 211, 27-35 (2007). 
229 Barry, F. P. & Murphy, J. M. Mesenchymal stem cells: clinical applications and 
biological characterization. The international journal of biochemistry & cell biology 36, 
568-584 (2004). 
230 Dominici, M. et al. Minimal criteria for defining multipotent mesenchymal stromal cells. 
The International Society for Cellular Therapy position statement. Cytotherapy 8, 315-
317 (2006). 
231 Ishii, M. et al. Molecular markers distinguish bone marrow mesenchymal stem cells from 
fibroblasts. Biochemical and biophysical research communications 332, 297-303 (2005). 
232 Haniffa, M. A., Collin, M. P., Buckley, C. D. & Dazzi, F. Mesenchymal stem cells: the 
fibroblasts’ new clothes? haematologica 94, 258-263 (2009). 
233 Cappellesso-Fleury, S. et al. Human fibroblasts share immunosuppressive properties with 
bone marrow mesenchymal stem cells. Journal of clinical immunology 30, 607-619 
(2010). 
234 Yates, C. C. et al. Multipotent stromal cells/mesenchymal stem cells and fibroblasts 
combine to minimize skin hypertrophic scarring. Stem cell research & therapy 8, 193 
(2017). 
235 Blasi, A. et al. Dermal fibroblasts display similar phenotypic and differentiation capacity 
to fat-derived mesenchymal stem cells, but differ in anti-inflammatory and angiogenic 
potential. Vascular cell 3, 5 (2011). 
236 Shumakov, V., Onishchenko, N., Rasulov, M., Krasheninnikov, M. & Zaidenov, V. 
Mesenchymal bone marrow stem cells more effectively stimulate regeneration of deep 
burn wounds than embryonic fibroblasts. Bulletin of experimental biology and medicine 
136, 192-195 (2003). 
237 Diaz-Flores, L. et al. CD34+ stromal cells/fibroblasts/fibrocytes/telocytes as a tissue 
reserve and a principal source of mesenchymal cells. Location, morphology, function and 
role in pathology. Histology and histopathology 29, 831-870 (2014). 
238 Trial, J., Entman, M. L. & Cieslik, K. A. Mesenchymal stem cell-derived inflammatory 
fibroblasts mediate interstitial fibrosis in the aging heart. Journal of molecular and 
cellular cardiology 91, 28-34 (2016). 
239 Bühring, H. J. et al. Phenotypic characterization of distinct human bone marrow–derived 
MSC subsets. Annals of the New York Academy of Sciences 1176, 124-134 (2009). 
240 Hass, R., Kasper, C., Böhm, S. & Jacobs, R. Different populations and sources of human 
mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC. 
Cell Communication and Signaling 9, 12 (2011). 
60 
241 Pilz, G. A. et al. Human term placenta-derived mesenchymal stromal cells are less prone 
to osteogenic differentiation than bone marrow-derived mesenchymal stromal cells. Stem 
cells and development 20, 635-646 (2010). 
242 Crisan, M. et al. Perivascular multipotent progenitor cells in human organs. Annals of the 
New York Academy of Sciences 1176, 118-123 (2009). 
243 Sherman, S. E. et al. High aldehyde dehydrogenase activity identifies a subset of human 
mesenchymal stromal cells with vascular regenerative potential. Stem Cells 35, 1542-
1553 (2017). 
244 Álvarez-Viejo, M., Menéndez-Menéndez, Y. & Otero-Hernández, J. CD271 as a marker 
to identify mesenchymal stem cells from diverse sources before culture. World journal of 
stem cells 7, 470 (2015). 
245 Tormin, A. et al.     (Am Soc Hematology, 2009). 
246 D'amour, K. A., Bang, A. & Baetge, E. E.     (Google Patents, 2012). 
247 Pullen, L. C. Stem Cell–Derived Pancreatic Progenitor Cells Have Now Been 
Transplanted into Patients: Report from IPITA 2018. American Journal of 
Transplantation 18, 1581-1582 (2018). 
248 Agulnick, A. D. et al. Insulin‐producing endocrine cells differentiated in vitro from 
human embryonic stem cells function in macroencapsulation devices in vivo. Stem cells 
translational medicine 4, 1214-1222 (2015). 
249 White, S. A., Shaw, J. A. & Sutherland, D. E. Pancreas transplantation. The Lancet 373, 
1808-1817 (2009). 
250 Ellis, C., Ramzy, A. & Kieffer, T. J. Regenerative medicine and cell-based approaches to 
restore pancreatic function. Nature Reviews Gastroenterology & Hepatology 14, 612 
(2017). 
251 Keenan, H. A. et al. Residual insulin production and pancreatic β-cell turnover after 50 
years of diabetes: Joslin Medalist Study. Diabetes 59, 2846-2853 (2010). 
252 Patel, A. N. & Genovese, J. Potential clinical applications of adult human mesenchymal 
stem cell (Prochymal®) therapy. Stem Cells and Cloning: Advances and Applications 4, 
61 (2011). 
253 Farkouh, M. E. et al. Strategies for multivessel revascularization in patients with 
diabetes. New England journal of medicine 367, 2375-2384 (2012). 
254 Raval, Z. & Losordo, D. W. Cell therapy of peripheral arterial disease: from experimental 
findings to clinical trials. Circulation research 112, 1288-1302 (2013). 
255 Qadura, M., Terenzi, D. C., Verma, S., Al‐Omran, M. & Hess, D. A. Concise review: cell 
therapy for critical limb ischemia: an integrated review of preclinical and clinical studies. 
Stem Cells 36, 161-171 (2018). 
256 Gremmels, H. et al. Exhaustion of the bone marrow progenitor cell reserve is associated 
with major events in severe limb ischemia. Angiogenesis, 1-10 (2019). 
257 Terenzi, D. C. et al. Vascular Regenerative Cell Exhaustion in Diabetes: Translational 
Opportunities to Mitigate Cardiometabolic Risk. Trends in Molecular Medicine (2019). 
258 Pietras, E. M. Inflammation: a key regulator of hematopoietic stem cell fate in health and 
disease. Blood 130, 1693-1698 (2017). 
259 Xing, J. et al. Hypoxia induces senescence of bone marrow mesenchymal stem cells via 
altered gut microbiota. Nature communications 9, 2020 (2018). 
260 von Scheidt, M. et al. Applications and limitations of mouse models for understanding 
human atherosclerosis. Cell metabolism 25, 248-261 (2017). 
261 McNeill, E., Channon, K. & Greaves, D. Inflammatory cell recruitment in cardiovascular 
disease: murine models and potential clinical applications. Clinical science 118, 641-655 
(2010). 
262 Zaragoza, C. et al. Animal models of cardiovascular diseases. BioMed Research 
International 2011 (2011). 
61 
263 Evensen, L. et al. Mural cell associated VEGF is required for organotypic vessel 
formation. PloS one 4, e5798 (2009). 
264 Manikowski, D. et al. Human adipose tissue-derived stromal cells in combination with 
exogenous stimuli facilitate three-dimensional network formation of human endothelial 
cells derived from various sources. Vascular pharmacology 106, 28-36 (2018). 
265 Andrée, B. et al. Formation of three-dimensional tubular endothelial cell networks under 
defined serum-free cell culture conditions in human collagen hydrogels. Scientific reports 
9, 5437 (2019). 
266 Wimmer, R. A. et al. Human blood vessel organoids as a model of diabetic vasculopathy. 
Nature (2019). 
267 Kuljanin, M. et al. Quantitative Proteomics Evaluation of Human Multipotent Stromal 
Cell for β Cell Regeneration. Cell reports 25, 2524-2536. e2524 (2018). 
268 Bell, G. I. et al. Transplanted human bone marrow progenitor subtypes stimulate 
endogenous islet regeneration and revascularization. Stem cells and development 21, 97-
109 (2011). 
269 Yao, B. et al. Age‐associated changes in regenerative capabilities of mesenchymal stem 
cell: impact on chronic wounds repair. International wound journal 13, 1252-1259 
(2016). 
270 Klinkhammer, B. M. et al. Mesenchymal stem cells from rats with chronic kidney disease 
exhibit premature senescence and loss of regenerative potential. PloS one 9, e92115 
(2014). 
271 Jansen, B. J. et al. Functional differences between mesenchymal stem cell populations are 
reflected by their transcriptome. Stem cells and development 19, 481-490 (2010). 
272 Kornicka, K., Houston, J. & Marycz, K. Dysfunction of mesenchymal stem cells isolated 
from metabolic syndrome and type 2 diabetic patients as result of oxidative stress and 
autophagy may limit their potential therapeutic use. Stem Cell Reviews and Reports 14, 
337-345 (2018). 
273 van de Vyver, M. Intrinsic mesenchymal stem cell dysfunction in diabetes mellitus: 
implications for autologous cell therapy. Stem cells and development 26, 1042-1053 
(2017). 
274 Sherman, S. E. The Purification of Human Adult Progenitor Cell Types to Promote 
Angiogenesis.  (2019). 
275 Bulte, J. W. & Daldrup-Link, H. E. Clinical tracking of cell transfer and cell 
transplantation: Trials and tribulations. Radiology 289, 604-615 (2018). 
276 Rosenholm, J. M. et al. Prolonged Dye Release from Mesoporous Silica‐Based Imaging 
Probes Facilitates Long‐Term Optical Tracking of Cell Populations In Vivo. Small 12, 
1578-1592 (2016). 
277 Kuljanin, M., Bell, G. I., Sherman, S. E., Lajoie, G. A. & Hess, D. A. Proteomic 
characterisation reveals active Wnt-signalling by human multipotent stromal cells as a 
key regulator of β cell survival and proliferation. Diabetologia 60, 1987-1998 (2017). 
278 Bollini, S., Gentili, C., Tasso, R. & Cancedda, R. The regenerative role of the fetal and 
adult stem cell secretome. Journal of Clinical Medicine 2, 302-327 (2013). 
279 Bruno, S., Deregibus, M. C. & Camussi, G. The secretome of mesenchymal stromal cells: 
role of extracellular vesicles in immunomodulation. Immunology letters 168, 154-158 
(2015). 
280 Kim, H. O., Choi, S.-M. & Kim, H.-S. Mesenchymal stem cell-derived secretome and 
microvesicles as a cell-free therapeutics for neurodegenerative disorders. Tissue 
Engineering and Regenerative Medicine 10, 93-101 (2013). 
281 Konala, V. B. R. et al. The current landscape of the mesenchymal stromal cell secretome: 
a new paradigm for cell-free regeneration. Cytotherapy 18, 13-24 (2016). 
62 
282 Tran, C. & Damaser, M. S. Stem cells as drug delivery methods: application of stem cell 
secretome for regeneration. Advanced drug delivery reviews 82, 1-11 (2015). 
283 Jeppesen, D. K. et al. Reassessment of exosome composition. Cell 177, 428-445. e418 
(2019). 
284 VanWijk, M. J., VanBavel, E., Sturk, A. & Nieuwland, R. Microparticles in 
cardiovascular diseases. Cardiovascular research 59, 277-287 (2003). 
285 Mulcahy, L. A., Pink, R. C. & Carter, D. R. F. Routes and mechanisms of extracellular 
vesicle uptake. Journal of extracellular vesicles 3, 24641 (2014). 
286 Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 
819-823 (2013). 
287 Hsu, P. D., Lander, E. S. & Zhang, F. Development and applications of CRISPR-Cas9 for 
genome engineering. Cell 157, 1262-1278 (2014). 
288 Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nature protocols 
8, 2281 (2013). 
289 Newick, K., O'Brien, S., Moon, E. & Albelda, S. M. CAR T cell therapy for solid tumors. 
Annual review of medicine 68, 139-152 (2017). 
290 Chen, X. et al. A combinational therapy of EGFR-CAR NK cells and oncolytic herpes 
simplex virus 1 for breast cancer brain metastases. Oncotarget 7, 27764 (2016). 
291 Londono, R. & Badylak, S. F. Biologic scaffolds for regenerative medicine: mechanisms 
of in vivo remodeling. Annals of biomedical engineering 43, 577-592 (2015). 
292 Zhu, W. et al. 3D printing of functional biomaterials for tissue engineering. Current 
opinion in biotechnology 40, 103-112 (2016). 
293 Fan, K. et al. A machine learning assisted, label-free, non-invasive approach for somatic 
reprogramming in induced pluripotent stem cell colony formation detection and 
prediction. Scientific reports 7, 13496 (2017). 
294 Putman, D. M. et al. Expansion of Umbilical Cord Blood Aldehyde Dehydrogenase 
Expressing Cells Generates Myeloid Progenitor Cells that Stimulate Limb 
Revascularization. Stem cells translational medicine (2017). 
295 Caplan, A. I. & Correa, D. The MSC: an injury drugstore. Cell stem cell 9, 11-15 (2011). 
296 Caplan, A. I. MSCs: the sentinel and safe‐guards of injury. Journal of cellular physiology 
231, 1413-1416 (2016). 
297 Leibacher, J. & Henschler, R. Biodistribution, migration and homing of systemically 
applied mesenchymal stem/stromal cells. Stem Cell Research & Therapy 7, 7 (2016). 
298 Kumar, S. & Ponnazhagan, S. Bone homing of mesenchymal stem cells by ectopic α4 
integrin expression. The FASEB Journal 21, 3917-3927 (2007). 
299 Nitzsche, F. et al. Concise review: MSC adhesion cascade—insights into homing and 
transendothelial migration. Stem Cells 35, 1446-1460 (2017). 
300 Rombouts, W. & Ploemacher, R. Primary murine MSC show highly efficient homing to 
the bone marrow but lose homing ability following culture. Leukemia 17, 160 (2003). 
301 Martino, M. M. et al. Inhibition of IL-1R1/MyD88 signalling promotes mesenchymal 
stem cell-driven tissue regeneration. Nature communications 7, 11051 (2016). 
302 Fiore, D. et al. Pharmacological blockage of fibro/adipogenic progenitor expansion and 
suppression of regenerative fibrogenesis is associated with impaired skeletal muscle 
regeneration. Stem cell research 17, 161-169 (2016). 
303 Hoffmann, J. et al. Angiogenic effects despite limited cell survival of bone marrow-
derived mesenchymal stem cells under ischemia. The Thoracic and cardiovascular 
surgeon 58, 136-142 (2010). 
304 Soundararajan, M. & Kannan, S. Fibroblasts and mesenchymal stem cells: Two sides of 
the same coin? Journal of Cellular Physiology (2018). 
305 Kaufman, L. et al. in Plasmonics in Biology and Medicine XVI.  108940B (International 
Society for Optics and Photonics). 
63 
306 Bian, S. et al. Extracellular vesicles derived from human bone marrow mesenchymal 
stem cells promote angiogenesis in a rat myocardial infarction model. Journal of 
molecular medicine 92, 387-397 (2014). 
307 Andaloussi, S. E., Mäger, I., Breakefield, X. O. & Wood, M. J. Extracellular vesicles: 
biology and emerging therapeutic opportunities. Nature reviews Drug discovery 12, 347 
(2013). 
308 Phinney, D. G. et al. Mesenchymal stem cells use extracellular vesicles to outsource 
mitophagy and shuttle microRNAs. Nature communications 6, 8472 (2015). 
309 Raposo, G. & Stoorvogel, W. Extracellular vesicles: exosomes, microvesicles, and 
friends. J Cell Biol 200, 373-383 (2013). 
 
 
64 
Chapter 2  
2 Inhibition of Aldehyde Dehydrogenase‐Activity Expands 
Multipotent Myeloid Progenitor Cells with Vascular 
Regenerative Functioni 
i A version of this chapter has been published: Cooper, T.T., Sherman, S.E., Kuljanin, 
M., Bell, G.I., Lajoie, G.A. and Hess, D.A., 2018. Inhibition of Aldehyde 
Dehydrogenase‐Activity Expands Multipotent Myeloid Progenitor Cells with Vascular 
Regenerative Function. Stem Cells, 36(5), pp.723-736. 
 
 
 
 
 
 
 
 
 
 
 
65 
2.1 Introduction 
Systemic atherosclerosis results in impaired blood vessel architecture and function1, 
leading to peripheral arterial disease (PAD) characterized by obstructed blood flow 
within the peripheral vasculature, limiting delivery of oxygen and nutrients to afflicted 
tissues2. Clinical presentation of PAD ranges from asymptomatic ischemia to exercise-
induced intermittent claudication, which may progress toward critical limb ischemia 
(CLI), the most severe manifestation of PAD. Patients with CLI suffer from pain at rest, 
non-healing tissue ulceration, and life-threatening infections. Current pharmaceutical 
therapies target risk factors to reduce cardiovascular events, whereas endovascular or 
surgical bypass interventions aim to recover perfusion to afflicted tissues. Unfortunately, 
these therapies provide only short-term benefit and are not offered to individuals with 
diffuse CLI3-6. As a result, 25%–30% of CLI patients require limb amputation within the 
first year of diagnosis7, and>60% of CLI patients will succumb to death within 5 years8. 
There is a need to develop effective therapies for the 8–12 million North Americans and 
>200 million individuals worldwide afflicted with advancing PAD7,8. Tissue 
revascularization via “therapeutic angiogenesis” has been proposed as a potential target 
for combating severe PAD. Robust angiogenesis can occur in skeletal muscle following 
ischemic injury; however, this requires activation of several cell types to orchestrate 
vascular remodeling or to activate flow within collateral vessels9,10. Pro-angiogenic 
cytokine/chemokine secretion by hematopoietic progenitor cells (HPCs) direct sprouting 
by vessel-forming endothelial progenitor cells (EPC) and encourage infiltration by vessel 
wrapping pericytes, respectively; two processes essential for stable neovessel 
formation10. Thus, cellular therapies to induce revascularization uses the secretory 
properties of transplanted blood-derived progenitor cells to generate a pro-angiogenic 
microenvironment and restore revascularization within ischemic tissues11. We have 
previously demonstrated the vascular regenerative potential of HPC isolated from healthy 
human bone mar-row (BM) and umbilical cord blood (UCB)12,13. Notably, purification of 
cells with high aldehyde dehydrogenase (ALDH)activity (ALDHhi), a detoxification 
function conserved in pro-genitor cells of multiple lineages, promoted revascularization 
following transplantation into mice with hind-limb ischemia, by stimulating endogenous 
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capillary formation at the site of injury without permanent incorporation into regenerating 
murine neovessels13. Moreover, ALDHhi cells from BM or UCB are also enriched for rare 
non-HPCs (EPC and multipotent stromal cells), with a larger representation of myeloid 
HPC12-15. In 2011, a randomized Phase I clinical trial by Perin et al. demonstrated that 
intramuscular (i.m.) transplantation of autologous BM ALDHhi cells significantly 
improved Rutherford’s Category scores and ankle-brachial index measurements from 
baseline in patients with non-operational CLI but did not improve ischemic ulcer 
healing16. These results provided rationale for a Phase II trial (PACE trial) which aimed 
to stimulate revascularization in patients with intermittent claudication, thereby 
mitigating progression toward end-stage CLI17. This double-blinded multicenter study 
recently reported that transplantation of autologous BM-derived ALDHhi cells was unable 
to effectively improve exercise performance or blood perfusion via collateral vessel 
formation after6 months18. Although the preclinical data used to initiate early clinical 
studies were promising13, several factors may explain why preclinical efficacy in murine 
models does not accurately predict clinical efficacy in humans. The preclinical 
experiments were performed using healthy human BM ALDHhi cells trans-planted into 
immunodeficient mice with surgically induced limb ischemia. Femoral artery ligation 
(FAL) in mice has been the gold-standard preclinical model to assess therapeutic 
angiogenesis elicited by pharmaceuticals or cells; however, the model does possess 
several limitations which need to be addressed to improve clinical translation. 
Specifically, this model mimics an acute ischemic injury occurring in young and healthy 
animals and does not reflect the chronic ischemic microenvironment occurring in human 
patients due to the buildup of atherosclerotic plaques over an extended period of time. In 
addition to physiological differences between species (i.e., heart rate and plasma 
cholesterol), patients with PAD commonly demonstrate other influential factors, chronic 
inflammation, smoking, and sedentary lifestyles, which are difficult to mimic in a murine 
model. Furthermore, emerging preclinical evidence also indicates autologous BM 
mononuclear cells (MNC) harvested from patients with chronic atherosclerosis and 
associated comorbidities exhibit severe functional impairments19,20. Endothelial cells 
derived from healthy animals exhibited vascular regenerative functions in a diabetic 
model of myocardium ischemia, whereas, cells harvested from diabetic animals failed to 
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induce vasculogenesis21. Several studies have aimed to increase clinical efficacy by 
purification of select subpopulations (CD341) derived from autologous BM-MNC 22; 
however, this approach has provided a modest benefit over transplantation of unpurified 
BM-MNC. Alternatively, using healthy allogenic sources may improve the efficacy of 
cell-based therapies, by limiting the exposure of therapeutic cells to the damaging 
microenvironment of chronic disease23,24. ALDH provides protection to long-lived stem 
and progenitor cell populations from cytotoxic insults25. Representing a conserved stem 
cell function and coinciding with primitive surface marker expression (CD341), ALDHhi-
activity rapidly diminishes as multipotent HPC differentiate toward more expendable 
lineage-restricted phenotypes15. ALDH also rep-resents the rate-limiting enzyme in the 
production of retinoic acid (RA), a potent driver of hematopoietic differentiation. RA 
activates the retinoic acid receptor (RAR) - retinoid X receptor (RXR) nuclear receptor 
complex that regulates mRNA transcription and epigenetic modifications26, resulting in 
hematopoietic cell differentiation. For example, activation of RAR/RXR induces the 
expression cyclic-ribose ADP hydrolase (CD38), a membrane-bound enzyme implicated 
with hematopoietic cell differentiation27. Therefore, the ex vivo expansion of UCB 
ALDHhi cells represents a paradoxical challenge to increase primitive and pro-angiogenic 
ALDHhi cell numbers while limiting RA-induced hematopoietic differentiation. We have 
recently shown that UCB ALDHhi cells can be efficiently expanded under serum-free 
conditions to generate hematopoietic progeny retaining vascular regenerative functions in 
vivo28. However, as culture time was increased from 6 to 9 days, expanded progeny failed 
to retain vascular regenerative functions. In addition, reducing RA-production by 
inhibition of ALDH-activity during ex vivo expansion augmented the number of CD34 
HPC with SCID-repopulation capacity29,30. Therefore, we sought to determine whether 
inhibition of ALDH-activity, using diethylaminobenzaldehyde (DEAB) treatment, would 
enhance the expansion of UCB ALDHhi cells without loss of vascular regenerative 
functions assessed after i.m. transplantation into mice with FAL-induced unilateral hind-
limb ischemia 
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2.2 Methods 
2.2.1 Isolation of Human UCB ALDHhi Cells 
Human UCB samples were obtained with informed consent by venipuncture of the 
umbilical vein following Ceasarian section at Victoria Hospital Birthing Centre, London, 
ON, Canada. The Human Studies Research Ethics Board (HSREB) at Western University 
approved all procedures. Within 24 hours of collection, UCB samples were initially 
depleted of mature myeloid, lymphoid and red blood cells (RosetteSep Human Cord 
Blood Progenitor Cell Enrichment Cocktail, Stem Cell Technologies, Vancouver, BC, 
Canada). Lineage-depleted (Lin-) mononuclear cells were isolated by Hypaque Ficoll 
centrifugation and incubated with Aldefluor regent prior to purification by FACS (FACS 
Aria III, BD Biosciences, Mississauga, Ontario, Canada). UCB ALDHhi cells were 
selected based on low side scatter and high ALDH-activity with >98% purity, as 
previously described12,15,28.  
.  
2.2.2 Expansion of UCB ALDHhi Cells in Culture 
UCB ALDHhi cells were plated on fibronectin‐coated flasks and expanded in serum‐free 
X‐vivo 15 (Lonza, Basel, Switzerland) supplemented with 10 ng/ml thrombopoietin 
(TPO), Fms‐like tyrosine kinase 3 ligand (FLT‐3L), and stem cell factor (SCF) for up to 
9 days, herein referred to as Basal conditions. All growth factors were purchased from 
Life Technologies (Carlsbad, CA). To inhibit ALDH‐activity and limit cell 
differentiation, 1.0 × 10−5 mol/l diethylaminobenzaldehyde (DEAB) (Stem Cell 
Technologies, Vancouver, Canada) was added to Basal conditions between days 3 and 6 
of ex vivo expansion, herein referred to as DEAB‐treated conditions. DEAB dose and 
treatment kinetics were optimized based on maximal retention of ALDHhi cells at 
endpoint. Complete media change was performed every 3 days. 
. 
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2.2.3 Generation of HPC‐Conditioned Media and Cell Lysates for 
Proteomic Analyses 
Expanded cells were harvested and washed with phosphate‐buffered saline (PBS) to 
remove residual growth factors and resuspended in fresh RPMI 1640 + 10 ng/ml of SCF, 
TPO, and FLT‐3L for 24 hours to generate conditioned media (CM) in biological 
triplicate. CM was centrifuged to remove cellular debris and concentrated using 3 kDa 
molecular weight cutoff filter units (Millipore, Bedford, MA). Concentrated CM was 
lyophilized overnight and resuspended in 8 mol/l urea, 5.0 × 10−2 mol/l ammonium 
bicarbonate, 1.0 × 10−2 mol/l dithiothreitol, and 2% SDS solution before secreted protein 
quantitation and fractionation. Expanded cell pellets were lysed in 8 M urea buffer, and 
sonicated (20 × 0.5 second pulses; level 1) to shear DNA. Protein concentrations were 
estimated using the Pierce 660 nm protein assay (ThermoFisher Scientific, Waltham, 
MA). 
2.2.4 Chloroform/Methanol Precipitation and Protein Digestion 
Cell lysates or CM were reduced in 1.0 × 10−2 mol/l dithiothreitol for 30 minutes and 
alkylated in 1.0 × 10−1 mol/l iodoacetamide for 30 minutes. Samples were precipitated in 
chloroform/methanol in 1.5 ml microfuge tubes31; 50 μg aliquots of each sample were 
topped up to 150 μl with 5.0 × 10−2 mol/l ammonium bicarbonate, 600 μl of ice-cold 
methanol, followed by 150 μl of chloroform; 450 μl of water was added before vortexing 
and centrifugation at 14,000g for 5 minutes. The upper/aqueous methanol phase was 
removed and 450 μl of ice-cold methanol was added before vortexing and centrifugation. 
Precipitated protein pellet was air dried before protein digestion. For on‐pellet protein 
digestion, 100 μl of 5.0 × 10−2 mol/l ammonium bicarbonate (pH 8.0) trypsin/LysC (1:50 
ratio, enzyme:sample) (Promega, Madison, WI) solution was added before incubation 
overnight at 37°C in water bath shaker. Trypsin (1:100 ratio) was added for 4 hours 
before acidifying with 10% formic acid (pH 3–4). Digests were centrifuged at 16,000g to 
remove insoluble material. Peptide concentrations were estimated using a BCA assay 
(ThermoFisher Scientific). 
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2.2.5 SCX Peptide Fractionation 
Tryptic peptides recovered from chloroform/methanol precipitation of cell lysates or CM 
(50 μg) were fractionated using SCX StageTips32. Peptides were acidified using 1% 
Trifluoroacetic acid and loaded onto a 12‐plug StageTips. Six SCX fractions were 
collected by eluting in 7.5 × 10−2, 1.25 × 10−1, 2.0 × 10−1, 2.50 × 10−1, and 3.0 × 10−1 
mol/l ammonium acetate/20% acetonitrile/0.5% formic acid (FA) solutions followed by 
elution with 5% (w/v) ammonium hydroxide/80% ACN. Fractions were dried in a 
SpeedVac, resuspended in double distilled water and dried again to remove residual 
ammonium acetate. All samples were resuspended in 0.1% FA before liquid 
chromatography–tandem mass spectrometry (LC‐MS)/MS analysis. 
2.2.6 Liquid Chromatography–Tandem Mass Spectrometry 
One microgram of sample was injected into a Waters nanoAcquity HPLC system 
(Waters, Milford, MA) coupled to an ESI Orbitrap mass spectrometer (Orbitrap Elite or 
QExactive, ThermoFisher Scientific). Buffer A consisted of water/0.1% FA and buffer B 
consisted of ACN/0.1% FA. All samples were trapped for 5 minutes at a flow rate of 10 
μl/minute using 99% Buffer A, 1% Buffer B on a Symmetry BEH C18 Trapping Column, 
5 μm, 180 μm × 20 mm (Waters). Peptides were separated using a Peptide BEH C18 
Column, 130Å, 1.7 um, 75 um × 250 mm operating at a flow rate of 300 nl/minute at 
35°C (Waters). Cell lysate samples were separated using a nonlinear gradient consisting 
of 5%–7.5% B over 1 minute, 7.5%–25% B over 180 minutes and 25%–60% B over 240 
minutes before increasing to 98% B and washing. CM samples were separated using a 
nonlinear gradient consisting of 1%–7% B over 3.5 minutes, 7%–19% B over 90 minutes, 
and 19%–30% B over 120 minutes before increasing to 95% B and washing. Settings for 
data acquisition on the Orbitrap Elite and QExactive are provided in Table 2.1. 
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Table 2.1 Overview of parameters used for data acquisition on a Q Exactive and LTQ 
Orbitrap Elite. 
 
. 
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2.2.7 Proteomic Data Analyses 
Data analysis was performed using PEAKS 8.0 software (Bioinformatics Solutions Inc., 
Waterloo, ON, Canada). Raw data files were refined using correct precursor mass and de 
novo sequencing was performed using the following parameters: parent mass tolerance 
20 ppm; fragment ion tolerance 0.80 Da; enzyme was set to trypsin. Data analyses were 
searched against the Uniprot human sequence database (20,178 entries). Quantitative data 
analysis was performed using MaxQuant version 1.5.2.833. Protein and peptide false 
discovery rate were set to 0.01 (1%), while the decoy database was set to revert. All 
parent and fragment tolerances were set as described above. The match between runs was 
enabled and all other parameters left at default. Data were analyzed using label free 
quantitation and intensity‐based absolute quantification as described previously34. 
Bioinformatic analysis was performed using Perseus version 1.5.0.8 and proteins 
identified by site, reverse and contaminants were removed manually. When using the 
match between runs feature, datasets were filtered for proteins containing a minimum of 
one unique peptide in at least two biological replicates. Missing values were replaced 
using data imputation by using a width of 0.3 and a downshift of 1.235. 
2.2.8 Flow Cytometry 
Expanded HPC were harvested following 6- or 9-day expansion and enumerated by trypan blue 
exclusion using hemocytometer counts. Cells were labelled with Aldefluor to assess ALDH-
activity and co-stained with 7-amino-actinomycin D to determine viability. Cells also were 
labeled with anti-human antibodies for CD45 (pan-hematopoietic marker), CD33 (myeloid), 
CD14 (monocytes), CD31 (PECAM), CD41 (ITGA2), and CD42 (megakaryocyte). Cells were 
assessed for the retention of primitive HPC phenotypes using CD34 and differentiation of 
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expanded cells was determined using CD38 (cyclic ADP ribose hydrolase). Cell surface marker 
expression for total cells, as well as ALDHhi versus ALDHlo subsets was determined using an 
LSRII flow cytometer (BD Biosciences) at the London Regional Flow Cytometry Facility. 
Analyses were performed using FlowJo software v8.2.  
2.2.9 Hematopoietic Colony Formation 
To assess the retention of hematopoietic colony forming function following expansion, day 9 
expanded HPC were harvested and seeded in semi-solid methylcellulose media (H4434, Stem 
Cell Technologies) at 500 cells/well in 12-well plates, in duplicate. Hematopoietic colonies were 
enumerated after 12-14 days in vitro and scored based on morphological characteristics. 
2.2.10 qRT-PCR analysis of Retinoic Acid Signaling Pathway 
Total mRNA was extracted from Day 9 Basal or DEAB-expanded HPC using PerfectPure RNA 
Purification kits (5Prime, Beverly, MA). NanodropTM was performed to establish mRNA 
concentration and purifty at the London Regional Genomics Facility prior to production of 500ng 
of cDNA using iScript cDNA conversion kits (Bio-Rad; Hercules, CA), according to 
manufactures protocol. qRT-PCR was performed using the Sofast Evagreen Supermix detection 
system (Bio-Rad) in conjunction with a CFX384 (Bio-Rad, Hercules, CA). Validated primers for 
ALDH1A3 (HQP005252), CYP26A1 (HQP003919), RARA (HQP016114) and RARG 
(HQP016118) were purchased from Genecopoeia (Rockville, MD). Quantification of transcripts 
was assessed using the housekeeping gene GUSB and normalized to Day 9 HPC harvested from 
Basal conditions.  
2.2.11 Femoral Artery Ligation and Transplantation 
Unilateral hind limb ischemia was induced in anesthetised (100mg/kg ketamine/xylazine, 
maintain with 2% isoflurane, 0.8L/min) NOD/SCID mice via surgical ligation and excision of the 
femoral artery and vein (FAL), as previously described206. NOD/SCID mice with unilateral hind-
limb ischemia (perfusion ratio <0.1, 24-hours after surgery (Day 0) were transplanted with a total 
of 5.0x105 expanded cells from Basal or DEAB-treated conditions, or non-cellular vehicle 
control, by intramuscular (i.m) injection (20uL) at three sites between ligation landmarks. To 
serve as a non-cellular vehicle control, mice received i.m.-injections of 60𝜇l of PBS in a similar 
fashion to cell-transplanted mice.  
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2.2.12 Laser Doppler and Catwalk 
Anesthetised NOD/SCID mice were warmed to 37ºC for 5 minutes and hindlimb blood perfusion 
was measured using Laser Doppler perfusion imaging (LDPI). Recovery of blood flow was 
quantified on 3, 7, 14, 21, 28, and 35 days post-transplantation by comparing the perfusion ratio 
(ischemic/non-ischemic) of transplanted mice. Recovery of limb usage in transplanted mice was 
determined by the ratio of paw print area in transplanted limb versus the contralateral control was 
assessed at Day 7 and 35 using the Noldus Catwalk Imaging system, as previously described28.  
2.2.13 Immunofluorescent Microscopy 
Adductor muscle) from both ischemic and non-ischemic thighs were harvested, embedded in 
OCT, and cryosectioned (12𝜇m) to obtain three sections per slide ≥50𝜇m apart. Cryosections 
were fixed in 10% formalin (Sigma) and blocked with 5% serum. Capillary density was 
quantified at 7 and 35-days post-transplantation using rat anti-mouse CD31 (BD Biosciences; 
1:100) detected with fluorescein-labeled rabbit anti-rat secondary antibodies (Vector; 1:200). 
CD31+ cells were enumerated from 4 randomly selected fields of view per section of murine 
thigh muscles, totaling 12 images per limb. EdU+ proliferating cells were detected using the 
Click-iT imaging kit (Alexafluor 594; Life Technologies), co-stained with CD31 to allow 
quantification of proliferating endothelial cells. Functional vessel density was also visualized 
using rabbit anti-mouse von Willebrand factor (1:100) detected with goat anti-rabbit fluorescein-
labeled secondary antibodies (1:200). DAPI was used as counterstain to label nuclei. 
2.2.14 Determination of Human Cell Engraftment into Murine Tissues 
Serial cryosections (25 𝜇m) were obtained across 150𝜇m of ischemic adductor muscles harvested 
7 days post-transplantation (n=4). Cryosections were fixed in 10% formalin and blocked mouse-
on-mouse reagent (Vector Labs, Burlingame, CA, USA). Human cell engraftment was visualized 
by staining muscle sections with mouse anti-human HLA-A,B,C (1:100) detected with horse anti-
mouse fluorescein-labelled secondary antibodies (1:200). DAPI was used as counterstain to label 
nuclei. 
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2.2.15 Statistical Analyses 
A multiple sample t test was performed in Perseus comparing the cell lysates for day 9 
Basal versus DEAB for proteomic analysis; and day 6 Basal versus day 9 Basal for 
secretome analysis. Statistical analysis for flow cytometry, quantitative polymerase chain 
reaction (qPCR), hematopoietic colony forming‐cell analyses was performed using a 
student's t test within each time point. Analysis of significance was performed by one‐
way analysis of variance with Tukey's multiple comparisons tests for all in vivo 
experiments and enumeration of myeloid‐specific colony formation. Outliers were 
identified using Grubb's test; p < .05. 
2.3 Results 
2.3.1 Basal Conditions Promoted Expansion of Cells with 
Megakaryocyte Secretory Profile 
We have recently demonstrated UCB ALDHhi cells expanded under Basal conditions for 
6 but not 9 days, accelerated the recovery of hindlimb perfusion after transplantation28. 
This led us to investigate whether additional culture time (3 days) changed the secretory 
profile of expanded hematopoietic progeny, thereby limiting vascular regenerative 
function in vivo. Mass spectrometry proteomic analysis was used to determine changes in 
the secretome of cells harvested after culture under Basal conditions (N = 3) at day 6 or 
day 9. A total of 5,404 unique proteins were detected, with 3,636 proteins identified in 
CM generated by both day 6 and day 9 expanded cells; 325 proteins or 1443 proteins 
were exclusively contained within CM generated from day 6 or day 9 cells, respectively. 
Major cytokines associated with angiogenesis were present in CM generated from both 
expanded cell populations. Therefore, we focused on the relative quantity of proteins 
commonly secreted. Of the 3,636 common proteins secreted, 144 and 317 proteins were 
significantly increased in day 6 and day 9 CM, respectively. Distinct patterns of 
expression were identified reflecting widespread changes in protein expression as culture 
time was increased (Fig. 2.1A). Although day 6 and day 9 cells demonstrated polarized 
regenerative function in vivo28, the secretion of proangiogenic proteins, such as vascular 
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endothelial growth factor (VEGF)‐A and angiopoietin 1 (ANGPT1), was comparable 
between expanded cell populations. Interestingly, proteins involved in inflammation and 
platelet activation were enriched within CM generated from day 9 cells (Figure 2.1B). 
For example, platelet activation‐associated proteins significantly increased in CM 
generated from day 9 cells included integrin α‐IIb (ITGA2B, CD41), glycoprotein Ib 
(GP1B, CD42), glycoprotein IX (GP9), and platelet endothelial aggregation receptor 1 
(Fig. 2.1C). Flow cytometry was used to validate expression of CD41 and CD42, classic 
markers of megakaryocyte‐lineage differentiation (Fig. 2.1D). These analyses 
demonstrated that expansion of UCB‐derived ALDHhi cells under Basal conditions 
enriched for cells with a committed megakaryocyte (CD41+/CD42+) phenotype as 
culture time progressed from 6 to 9 days (25.76 ± 5.14% vs. 54.7  ± 6.50%; *, p < .05; 
Figure 2.1E). Importantly, this end‐stage megakaryocyte differentiation was also 
associated with the loss of vascular regenerative capacity after transplantation28. 
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Figure 2.1 Umbilical Cord blood ALDHhi cells differentiated toward a 
megakaryocyte phenotype when cultured under Basal conditions. Viable day 6 (N=3) 
or day 9 (N=3) cells expanded under basal conditions were replated in RPMI 1640+ stem 
cell factor, thrombopoietin, Fms-like tyrosine kinase 3 ligand for 24 hours to generate 
conditioned media (CM). (A) Mass Spectomtery analyses of CM revealed distinct 
secretome profiles. (B) Secretory profile of day 9 cells was highly enriched with proteins 
implicated in platelet activation. (C) Day 9 cells significantly upregulated the expression 
of CD41 (ITGA2B) and CD42 (GPIB), compared with day 6 cells. (D, E) Increased 
culture time under Basal conditons enriched for cells with a megakaryocyte phenotype 
(CD41+/CD42+). Data represented as mean + SEM (*, p <.05; N=5-7). Statistical analyses 
were determined by paired Student’s t test.  
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2.3.2 DEAB‐Treatment Augmented ALDHhi Cell Expansion 
ALDHhi cells represented only 2.47  ± 1.33% Lin– cells (Fig. 2.2A) correlating to <0.5% 
of total MNC collected. In addition, UCB ALDHhi cells rapidly reduce ALDH‐activity 
(Fig. 2.2B) during ex vivo expansion 28. Therefore, ALDHhi cells were expanded with or 
without DEAB‐treatment, to inhibit ALDH‐activity and limit RA‐induced differentiation 
during culture (Fig. 2.2B). Exposure of cells to DEAB‐treatment at days 3–6 was selected 
based on the optimal preservation of ALDHhi cells during 6- and 9-days expansion ex 
vivo (Figure 2.3). Temporal DEAB‐treatment from days 3 to 6 increased expanded 
ALDHhi cell frequency at day 6 (40.98  ± 8.43% vs. 13.85  ± 2.38%; **, p < .01) and at 
day 9 (31.04  ± 5.48% vs. 6.58  ±  1.03%; **, p < .01; Fig. 2.2C). Total cell expansion 
kinetics were equivalent over 9 days with or without DEAB‐treatment (82.62 ± 9.51‐fold 
vs. 79.22 ± 16.49‐fold increase; Fig. 2.2D). Taken together, DEAB‐treatment led to a 
25.42  ± 4.35‐fold increase in ALDHhi cell numbers obtained after 9 days; a significant 
increase compared with Basal conditions (5.40  ± 1.27‐fold increase; ***, p < .001; Fig. 
2.2E). Therefore, DEAB‐treatment from days 3 to 6 during a 9‐day expansion protocol 
was selected for further assessment of primitive progenitor cell phenotype and function. 
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Figure 2.2 Diethylaminobenzaldehyde (DEAB)-treatment augmented the expansion 
of early myeloid progenitors with high ALDH-activity. (A) Umbilical cord blood 
ALDHhi cells were isolated by fluorescence-activated cell sorting and expanded with or 
without DEAB-treatment between days 3 and 6. (B) Representative flow cytometry plots 
showing DEAB-treatment enhanced (C) the frequency of ALDHhi cells retained after 9 
days (N=7). (D) Total cell expansion was not affected by DEAB-treatment, whereas (E) 
total ALDHhi cell number was increased ~25-fold under DEAB-treated conditions. (F) 
DEAB-treatment increased hematopoietic colony forming capacity of expanded cells 
seeded in methylcellulose media (N=5). (G) DEAB-treatment enhanced the production of 
colonies with multiple myeloid phenotypes. Data represented as mean + SEM (*, p<.05; 
**p<.01;***p<.001). Statistical analyses were determined by paired Student’s t test.  
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 Figure 2.3 Temporal DEAB-treatment increases the retention of ALDHhi cells 
during ex vivo expansion. (A) UCB ALDHhi cells were cultured under Basal 
conditions (X-vivo 15 + 10ng/mL TPO, SCF, FLT-3L) for 6 days and treated with 
10uM of DEAB between days 0-3, 0-6, or 3-6. (B) DEAB-treatment occurring 
between Days 3-6 increased enrichment of ALDHhi cells. (C-D) Extending on these 
results, DEAB-treatment was either removed (DEAB 3-6) or extended (DEAB 3-9) 
for an additional 3 days of culture. Interestingly, temporal DEAB-treatment (DEAB 
3-6) increased the frequency of ALDHhi cells retained after 9 days of culutre, 
compared to Basal conditions. Data represented as Mean ± SEM (**p<0.01, 
***p<0.001; N=3-13). Statistical analyses were determined by ANOVA with 
Tukey’s multiple comparisons test. 
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2.3.3 RA‐Signaling Was Modified following DEAB‐Treatment 
ALDH‐activity leads to the production of RA, a potent driver of hematopoietic 
differentiation. To validate that DEAB‐treatment modulated RA‐signaling during 
expansion, we first performed reverse transcriptase‐qPCR on transcriptional targets of the 
RAR/RXR complex. Activation of the RAR/RXR complex was expected to increase 
transcription of target genes such as CYP26A1, ALDH1A3 isoform, and RAR25. DEAB‐
treatment significantly reduced transcription of ALDH1A3, CYP26A1, and RAR   
subunit while transcription of RAR   was increased (Figure 2.4). Collectively, this 
suggested RA‐signaling networks were modified following DEAB‐treatment. 
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Figure 2.4 Transcriptional analysis of Day 9 cells cultured under Basal or DEAB-
treated conditions. RT-qPCR was performed on cell lysates (n=3) of UCB ALDHhi cells 
cultured under Basal or DEAB-treated conditions for 9 days. Fold changes are relative to 
Day 9 Basal cells.  DEAB-treated conditions decreased the transcription of (A) Aldehyde 
Dehydrogenase 1A3, (B) Cytochrome P450 Retinoic Acid-Inactivating 1, (C) Retinoic 
Acid Receptor-Alpha, (D) Whereas, DEAB-treated conditions increased the transcription 
of (G) Retinoic Acid Receptor-Gamma. β-glucuronidase (GUSB) was used as a 
housekeeping gene. Data represented as Mean ± SEM.  (*p<0.05, **p<0.01). Statistical 
analyses were determined by Student’s t-test. 
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2.3.4 DEAB‐Treatment Enriched for Cells with Multipotent Myeloid 
Progenitor Function 
To determine whether expanded cells retained hematopoietic colony forming unit (CFU) 
functions in vitro, day 9 cultured cells were seeded in methylcellulose media and 
enumerated for myeloid‐lineage colony formation after 14 days. DEAB‐treated cells 
demonstrated a significantly higher frequency (*, p < .05) of total colony formation (1 
CFU in 7.4 cells) compared with cells expanded under Basal conditions (1 CFU in 13.3 
cells; Fig. 2.2F). DEAB‐treatment enriched specifically for early HPC with myeloid 
multipotency; enumerated by colonies demonstrating multiple myeloid morphologies 
(Fig. 2.2G). Thus, DEAB treatment augmented the expansion of ALDHhi cells that 
retained multipotent hematopoietic CFU capacity in vitro. 
2.3.5 DEAB‐Treatment Enriched for Cells with Primitive Surface 
Marker Expression 
To determine whether DEAB‐treatment also prevented the loss of primitive cell surface 
phenotype (ALDHhi/CD34+/CD38–) during expansion, cells were analyzed using 
multicolor flow cytometry (Table 2.2). At day 9, expanded cells were exclusively 
hematopoietic determined by pan‐leukocyte marker (CD45) expression (>99%), and the 
majority of Basal or DEAB‐treated cells expressed the early myeloid cell surface marker 
CD33 (96.1  ± 0.85 and 94.5  ± 1.53%, Table 2.3). Monocyte‐specific marker (CD14) 
expression was comparable between Basal and DEAB‐treated conditions (2.96  ±1.23 vs. 
4.08  ± 1.64% of total cells). compared with Basal conditions, expression of the 
hematopoietic differentiation marker CD38 was significantly reduced following DEAB‐
treatment (31.06  ± 2.52 vs. 21.16  ± 2.56% of total cells; **, p < .01; Table 1). 
Futhermore, DEAB‐treatment enriched for cells with primitive ALDHhi/CD34+ (2.18  
± 0.42 vs. 6.20  ± 0.73% of total cells; *, p < .05) and ALDHhi/CD34+/CD38– (2.29  ± 
0.35 vs. 5.46 ± 0.59% of total cells; ***, p < .001) phenotypes (Table 2.2). Collectively, 
DEAB‐treatment generated 5‐ and 10‐fold increase in the total number of ALDHhi 
CD34+ or ALDHhi CD34+/CD38– after 9 days, respectively (Table 2.3). In contrast, 
Basal conditions generated a modest 1.7‐ and 4.1‐fold increase in the number of ALDHhi 
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CD34+ or ALDHhi CD34+/CD38–, respectively. Basal conditions highly enriched for 
cells with mature hematopoietic cell (ALDHlo/CD38+) phenotype (24.59  ± 2.70% of 
total cells; ***, p < .001; Table 2.2). Collectively, DEAB‐treatment enhanced the 
expansion of hematopoietic cells retaining ALDHhi‐activity and primitive cell surface 
marker expression patterns. 
 
. 
Table 2.2 DEAB‐treatment enhanced the expansion of cells with a primitive surface 
phenotype 
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Table 2.3 UCB ALDHhi cell expansion under Basal or DEAB-treated conditions generates 
myeloid-specific cell progeny. 
 
  
 
Table 2.4 .  DEAB-treatment enhanced the number of expanded cells with primitive 
surface phenotype 
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2.3.6 DEAB‐Treatment Reduced Megakaryocyte Lineage Maturation 
Basal culture conditions led to UCB ALDHhi cell differentiation toward a megakaryocyte 
phenotype as culture time progressed (Fig. 2.1). Therefore, we sought to determine 
whether DEAB‐treatment delayed differentiation of expanded ALDHhi cells toward the 
megakaryocyte lineage (Fig. 2.5A). Although we did not observe differences in the 
frequency of expanded cells acquiring mature megakaryocyte phenotype (CD41+/CD42+) 
at day 9 (Fig. 2.5B), DEAB‐treatment significantly reduced the frequency of CD41+ cells 
that coexpressed CD38 (17.3 ± 2.7 vs. 26.2 ±  6.4% of CD41+ cells; Fig. 2.5C; *, p < .05, 
and Table 2.5). Furthermore, DEAB‐treatment significantly reduced the expression of 
CD38 on CD41+/CD42+ megakaryocytes, compared with Basal conditions (*, p < .05; 
Fig. 3D). Previous reports have also suggested that expanded CD41+/CD42– 
hematopoietic cells retain myeloid multipotency in vitro and SCID‐repopulating 
capacities in vivo when coexpressing a CD34+/CD38– phenotype36. At day 9, DEAB‐
treatment enriched the CD41+/CD42– megakaryoblast fraction with primitive 
CD34+/CD38– phenotype (13.1  ± 2.4% vs. 8.2 ±  2.0%; *, p < .05; Table 2.5). 
Collectively, these results suggested that DEAB‐treatment delayed the maturation of 
CD41+/CD42– megkaryoblasts by delaying CD38 acquisition and loss of CD34 
expression. 
. 
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Figure 2.5 DEAB-treatment reduced differentiation towards megakaryocyte 
phenotype. Schematic of megakaryopoiesis and acquisition of mature megakaryocyte 
phenotype (CD41+/CD42+/CD38+). (B) DEAB-treatment did not alter CD41 and CD42 
expression patterns at 6 or 9 days. (C) Representative flow cytometry plots showing 
reduced expression of CD38 on CD41+/- cells generated under DEAB-treated conditions. 
(D) CD38 expression was reduced on megakaryocytes (CD41+/CD42+) under DEAB-
treated conditions. Data represented as Mean ±  SEM (*p<0.05; N=5-8). Statistical 
analyses were performed by paired Student’s t-test. 
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Table 2.5 DEAB-treatment retains primitive progenitor cells within CD41+/- 
subpopulations coinciding with reduced CD38 expression. 
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2.3.7 DEAB‐Treated Cells Demonstrated a Pro‐Survival and Pro‐
Angiogenic Proteome 
We used highly sensitive mass spectrometry to compare global proteome changes after 9 
days expansion under either Basal (N = 3) or DEAB‐treated (N = 3) conditions. Expanded 
UCB ALDHhi cells generated a heterogeneous cell population comprised of several 
hematopoietic cell types after 9 days28; therefore, detectable changes in the global 
proteome should reflect changes within influential signaling networks. The proteomic 
profiles of these expanded cell populations were remarkably similar. Of the 6,804 unique 
proteins detected, only 121 proteins were unique to cells harvested from DEAB‐treated 
conditions, and 164 were unique to cells harvested from Basal conditions, (Fig. 2.6A). 
Proteins exclusively expressed under DEAB‐treated conditions were largely associated 
with anti‐apoptotic activity (i.e., NEMO, IKBKG; Caspase Recruitment Domain‐
containing protein 6, CARD6; Table 2.6). Conversely, proteins exclusive to Basal 
conditions included drivers of apoptosis, including Fas cell surface death receptor (FAS) 
(Table 2.7). Several proteins implicated with mature hematopoietic cell functions (i.e., 
plasminogen activator; platelet‐activating factor receptor; dendritic cell‐associated lectin 
2; integrin subunit beta 7) were exclusively produced under Basal conditions. 
 Of the 6,519 proteins common to cells from Basal and DEAB‐treated conditions, only 
117 proteins demonstrated a >1.2‐fold or <1.2‐fold difference comparing DEAB‐treated 
to Basal conditions (Fig. 2.6B, C). Common angiogenic factors (ANGPT1; von 
Willebrand factor, vWF; and transforming growth factor beta 1) were comparable in the 
proteome of Basal and DEAB‐treated cells. Interestingly, DEAB‐treatment primarily 
upregulated intracellular proteins involved in the prevention of apoptosis (i.e., BCL2 
family apoptosis regulator, MCL1), in the preservation of progenitor cell function 
(thrombopoietin receptor, MPL), or with cell motility such as proto‐oncogene C‐Crk 
(CRK) and leucine rich repeat containing 16A. Cells harvested from Basal conditions 
upregulated proteins primarily associated with HPC differentiation; including Fibronectin 
(FN1), Serpin family B member 8 (SERPINB8), lymphocyte antigen 75 (LY75), and 
adenosine deaminase 2 (CECR1). Validating our flow cytometry data, CD38 protein 
levels were decreased 1.68‐fold in cells harvested after DEAB‐treatment compared with 
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Basal conditions. Collectively, these analyses suggest that DEAB‐treatment increased the 
production of pro‐survival proteins and decreased the production of proteins associated 
with hematopoietic differentiation. 
. 
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Figure 2.6 Distinct proteomic 
profiles for DEAB-treated 
versus Basal cells. (A) Mass 
spectrometry identified 6804 
individual proteins across cell 
lysates. Out of 6519 proteins 
were detected in both Basal and 
DEAB-treated cells (N=3), only 
137 proteins were found to be 
(B) differentially expressed (red 
circles, *p<0.05). (C) DEAB-
treatment increased production 
of anti-apoptotic proteins, 
including myeloid cell leukemia-
1 (MCL1) and thrombopoietin 
receptor (MPL). Decreased 
detection of differentiation 
factors including CD38, CECR1, 
SERPINB8, and Fibronectin 
(FN1) was also observed in 
DEAB-treated cells. Statistical 
analyses were performed by 
students t-test. 
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Table 2.6 Proteins exclusively found in the cell lysate of DEAB-treated cells 
 
 
Table 2.7 Proteins exclusively found in the cell lysate of Basal cells 
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2.3.8 Transplantation of DEAB‐Treated Cells Accelerated the Recovery 
of Perfusion 
We have previously shown that extended culture of UCB ALDHhi cells resulted in the 
loss of vascular regenerative functions after transplantation in vivo28. Therefore, we 
sought to determine whether DEAB‐treatment could generate cells that retained vascular 
regenerative function following transplantation into mice with hind‐limb ischemia. After 
unilateral FAL surgery, non‐obese diabetic/severe combined immunodeficient 
(NOD/SCID) mice with hind‐limb ischemia (Perfusion Ratio, PR; PR < 0.1) received i.m. 
injection of UCB ALDHhi cells expanded for 9 days under Basal or DEAB‐treated culture 
conditions. Transplantation of 5.0 × 105 cells generated under Basal conditions failed to 
improve limb perfusion from baseline recovery observed with PBS‐injected controls 
(PR = 0.58 ±  0.04 vs. 0.49 ±  0.05 at day 35, respectively; Fig. 2.7A, B). However, i.m.‐
transplantation with 5.0 × 105 cells generated under DEAB‐treated conditions 
significantly increased limb perfusion as early as day 21, compared with PBS controls 
(0.70 ±  0.04 vs. 0.43 ±  0.03; **, p < .01), and improved limb perfusion persisted until 
day 35 post‐transplantation (0.76 ±  0.06; **, p < .01). Limb usage assessed by Catwalk 
paw print area measurements for all groups were equivalent at day 35. However, at 7 
days post‐transplantation mice that received DEAB‐treated cells showed modestly 
improved limb usage compared with PBS‐controls (p = .17) (Figure 2.7C). 
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Figure 2.7 DEAB-treated cells accelerated the recovery of limb perfusion after 
transplantation. (A) Representative LDPI following FAL and intramuscular 
transplantation of PBS (n=7), 5x105 Basal cells (n=11), or 5x105 DEAB-treated cells 
(n=11). Perfusion ratio (PR) in the ischemic (orange box) versus non-ischemic (yellow 
box) limbs are shown in white text. (B) NOD/SCID mice i.m.-injected with Basal cells 
showed similar recovery of perfusion compared to PBS controls (Day 35 PR=0.58±0.04 
vs. 0.49±0.06; respectively). Transplantation of DEAB-treated cells enhanced the 
recovery of limb perfusion compared to PBS vehicle controls or Basal cells at days 21-
35. (C) Paw area ratio of ischemic vs. non-ischemic limb measure at 7- and 35-days post-
transplantation (n=5-7). DEAB-treated cells modestly increased limb usage at 7 days 
post-transplantation, albeit limb usage was equal across transplantation conditions at day 
35 post-transplantation. Data represented as Mean ± SEM (*p<0.05, **p<0.01). 
Statistical analyses were performed by ANOVA with Tukey’s multiple comparisons test 
relative to PBS-injected mice. 
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2.3.9 Transplantation of DEAB‐Treated Cells Stimulated Endothelial 
Cell Proliferation and Increased Capillary Density within Ischemic 
Limbs 
To investigate potential mechanisms by which DEAB‐treated cells accelerated the 
recovery of limb perfusion, vascular density was assessed alongside human cell 
engraftment kinetics at day 7 and day 35 post‐transplantation in ischemic thigh muscle 
tissue sections. Human cell engraftment was detected within ischemic thigh muscles at 7‐
days post‐transplantation with either Basal or DEAB‐treated cells (Figure 2.8). Compared 
with Basal cells, DEAB‐treated cells demonstrated a trend toward increased engraftment 
within the ischemia thigh muscle (1.25 ± 0.21 vs. 0.83 ± 0.11 HLA+ cells/mm2, n = 4, 
p = .13). Moreover, transplanted cells were not detected after 35‐days post‐
transplantation. Mice were injected with EdU 24 hours before euthanasia to allow 
quantification of proliferating CD31+ endothelial cells. At day 7 post‐transplantation, 
mice transplanted with DEAB‐treated cells showed an increased number of EdU+/CD31+ 
cells/mm2 within ischemic thigh muscle, compared with mice injected with cells 
generated under Basal conditions (3.06  ± 1.08 vs. 0.67  ± 0.27, *, p < .05) or PBS (0.11 
± 0.11, **, p < .01; Fig. 2.9A, B). Augmented endothelial cell proliferation corresponded 
to increased CD31+ capillary density at day 35 with DEAB‐treated cells (*, p < .05; Fig. 
2.9C). In addition, mice transplanted with DEAB‐treated cells increased the number of 
larger vessels expressing vWF at day 35 (Figure 2.10), compared with PBS‐injected 
controls. Collectively, DEAB‐treated cells survived for at least 7 days post‐
transplantation and stimulated endothelial cell proliferation leading to increased vascular 
density in the ischemic limb 
. 
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Figure 2.8 Human cell engraftment detected in the ischemic thigh muscle 7 days post-
transplantation. Representative confocal photomicrograph (20x) of a thigh muscle cryosections 
stained for HLA-A, B,C, detecting human cells 7 days after the intramuscular transplantation of 
(A) Day 9 Basal cells or (B) Day 9 DEAB-treated cells. Arrows indicate location of detected 
human cells. Scale bar = 50𝝁m 
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Figure 2.9 Transplantation of DEAB-treated cells increased capillary density via 
increasing murine endothelial cell proliferation. NOD/SCID mice transplanted with either PBS 
(n=5), Basal cells (n=6), or DEAB-treated cells (n=6) were injected with EdU 24-hrs prior to 
euthanasia at 7 days post-transplantation. (A) Representative confocal images (10x) of 
cryosectioned thigh muscles stained for endothelial cell marker (CD31) and EdU-incorporation 
(Alexafluor 594). (B) Representative confocal image (40x) of endothelial cell proliferation 
(EdU+/CD31+) in the ischemic limb of mice transplanted with DEAB-treated cells. (C) Mice 
transplanted with DEAB-treated cells had a significantly increased number of proliferating 
endothelial cells within the ischemic limb, compared to PBS-injected or Basal cell transplanted 
mice. (D) Intramuscular transplantation of DEAB-treated cells increased CD31+ capillary density 
in ischemic limbs of mice sacrificed at day 35 (n=7-11). Data represented as Mean 
±  SEM.(*p<0.05, **p<0.01). Statistical analyses were performed by ANOVA with Tukey’s 
multiple comparisons test. Scale bar = 150μm. 
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Figure 2.10 Intramuscular transplantation of DEAB-treated cells prevented the loss of von 
Willebrand factor-positive blood vessel networks after femoral artery ligation-induced CLI. 
(A) Representative immunofluorescent images (20x) of cyrosectioned thigh muscles harvested 7-
days post-transplantation and stained for von Willebrand factor (vWF). (B) DEAB-treated and 
Basal cells increased the number of vWF+ vessels 35 days post-transplantation, compared to PBS 
control. Data represented as Mean ± SEM (*p<0.05; n=5-7). Statistical analyses were determined 
by ANOVA with Tukey’s multiple comparisons relative to PBS-injected mice. Scale bar = 50𝝁m 
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2.4 Discussion 
Blood‐derived progenitor cells with ALDHhi‐activity demonstrate multifaceted 
regenerative functions in preclinical studies12, 15. However, it is becoming well accepted 
in preclinical studies that harvesting autologous cells from the BM of individuals with 
diffuse atherosclerosis19 and associated comorbidities such as obesity and type 2 
diabetes20, 37, results in the accrual of progenitor cells with depleted numbers and 
dysfunctional vascular regenerative capacity. The use of allogenic UCB cells with limited 
exposure to damaging metabolic by‐products of chronic disease24 may mitigate 
progenitor cell exhaustion and facilitate the development of cellular therapies with 
improved efficacy. UCB represents a readily accessible source of regenerative cells, 
usually considered discarded material, and is easily harvested with no risk to either the 
newborn or mother. Recent establishment of national cord blood banking programs 
generates a renewable multi-donor pool with increased diversity for HLA‐matching and 
subsequent use in allogeneic therapeutic applications. A phase I clinical trial 
(NCT01019681) was recently initiated to determine the safety and efficacy of UCB‐
MNC; however, these results have yet to be reported. We have previously demonstrated 
enhanced vascular regenerative functions of UCB‐derived ALDHhi cells compared with 
unpurified UCB‐MNC12. However, ALDHhi cells only represent <0.5% of total UCB‐
MNC and require ex vivo expansion to increase the number of progenitor cells needed to 
support early preclinical studies. Herein, we demonstrate an expansion strategy and early 
preclinical evidence which indicates expanded allogeneic UCB ALDHhi cells could be 
used for treating severe ischemic disease16. 
 
UCB ALDHhi cells are primarily comprised of early myeloid HPC12 that can be 
efficiently expanded in short‐term culture under serum‐free conditions28. Unfortunately, 
when culture time was extended from 6 to 9 days, the vascular regenerative function of 
expanded progeny was diminished after i.m.‐transplantation into NOD/SCID mice with 
hind‐limb ischemia23. This led us to speculate that prolonged culture time under serum‐
free (Basal) conditions reduced pro‐angiogenic growth factor production and/or secretion, 
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such as VEGF‐A, from expanded progeny. Despite robust differentiation toward the 
megakaryocyte lineage between days 6 and 9, we did not observe significant decrease in 
secreted levels of common pro‐angiogenic growth factors (VEGF‐A, ANGPT1, CCL5). 
In contrast, we observed an increased expression of megakaryocyte lineage‐specific 
proteins, including CD41 (ITGA2B) and CD42 (GPIB). Specifically, flow cytometry 
analyses demonstrated a reduction of primitive surface marker (CD34) expression 
alongside diminished ALDH‐activity, which coincided with the acquisition of a mature 
megakaryocyte phenotype (CD41+/CD42+/CD38+). 
 
Megakaryocytes represent large hematopoietic cells (50–100 𝜇m) which release platelets 
into systemic circulation through the fragmentation of proplatelet extensions that protrude 
into vascular sinuses of the BM niche. The turnover of circulating platelets is frequent 
(<9 days); therefore, the consistent production of platelets is necessary to ensure vessel 
hemostasis and injury repair38,39. Platelet‐derived CD42 binds to vWF on exposed 
subendothelium collagen during vascular injury, the subsequent activation of platelets 
will stimulate soluble protein and extracellular vesicle secretion into the local 
microenvironment and systemic circulation. These stimuli recruit and activate biological 
processes within endothelial or hematopoietic cells38, 40,41. Specifically, platelet‐derived 
stimuli (i.e., VEGF‐A) influence both angiogenic and inflammatory pathways during 
wound healing and vascular regeneration in vitro and in vivo39, 40,42. To our knowledge, 
this is the first study to characterize and investigate the vascular regenerative potential of 
a culture‐expanded, megakaryocyte‐enriched cell population for treating ischemic 
disease. Indeed, the acquisition of a mature megakaryocyte phenotype 
(CD41+/CD42+/CD38+) and concomitant loss of ALDHhi‐activity under Basal conditions 
diminished the vascular regenerative capacity of UCB‐derived ALDHhi cells. 
 
Chute et al. were the first to show that DEAB‐treatment enhanced the expansion of UCB‐
derived CD34+ CD38– cells with SCID repopulating capacity. Specifically, DEAB‐
treated cultures were enriched 11.6‐fold with cells retaining primitive CD34+/CD38– 
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phenotype after 7 days. The benefit of DEAB‐treatment was reversed after RA‐
supplementation, suggesting that inhibition of ALDH‐activity promoted HSC self‐
renewal via reduced RA‐production. Our study extends these findings to show that 
inhibition of ALDH‐activity and RAR/RXR complex activation could modify the 
transcription of downstream targets (i.e., CYP26A1)29. Despite equal expansion of 
CD34+ cells compared with Basal conditions, DEAB‐treated progeny better retained a 
primitive phenotype, with a 15‐fold expansion in CD34+ CD38– cells and an 11‐fold 
expansion of the most primitive ALDHhi/CD34+/CD38– cells. Importantly, DEAB‐
treatment significantly increased multipotent myeloid colony formation in vitro, 
suggesting that ALDHhi activity can segregate multipotent CD34+ cells from committed, 
unipotent ALDHlo CD34+ cells43. 
 
Under Basal conditions, rapid loss of ALDHhi‐activity coincided with the acquisition of 
mature hematopoietic surface marker, CD38. In contrast, DEAB‐treatment enhanced 
retention of ALDHhi phenotype and reduced CD38 expression. CD38 (Cyclic Ribose 
ADP Hydrolase) is a multifunctional enzyme implicated with intracellular Ca+ signaling, 
platelet aggregation, and adhesion of leukocytes to CD31+ endothelial cells44,45. CD38 is 
also a direct target of RA‐signaling27, suggesting that DEAB‐treatment limited CD38 
expression by modifying RA‐signaling networks. Furthermore, DEAB‐treated cell lysates 
exhibited increased levels of MCL1 and MPL, cellular proteins implicated with 
progenitor cell maintenance46,47. Conversely, Basal conditions, increased the expression 
of proteins implicated with hematopoietic differentiation (i.e., CECR1, FN1, SERPINB8, 
and LY75). Collectively, flow cytometry and proteomic data confirmed DEAB‐treatment 
enhanced the expansion of multipotent HPC by limiting RA‐induced differentiation. 
 
We next investigated whether differentiation toward the megakaryocyte lineage was 
delayed by the inhibition of RA‐production. Commitment to the megakaryocyte lineage 
is marked by the acquisition of CD41 (ITGA2B), whereas CD42 (GP1B) expression 
occurs later in megakaryopoiesis48. However, acquisition of CD41 and CD42 expression 
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was not altered by DEAB‐treatment. This was not a surprise considering treatment with 
TPO and FLT‐3L is known to drive early megakaryopoiesis and increase CD41 
expression during ex vivo expansion49. Several reports have suggested that cells with the 
immature megakaryoblast phenotype (CD34+/CD38–/CD41+/CD42–) retain multipotency 
in vitro and in vivo 36, 50,51.DEAB‐treatment increased the accumulation of CD34+/CD38– 
progenitor cells and delayed the acquisition of CD38 within the megakaryoblast lineage 
(CD41+/CD42–). DEAB‐treatment also limited the production of mature megakaryocytes 
(CD41+/CD42+/CD38+); suggesting that inhibition of RA‐production delayed 
differentiation at multiple stages of megakaryopoeisis. 
 
Although the secretome and proteome of day 9 Basal cells showed similar expression of 
pro‐angiogenic stimuli (i.e., VEGF‐A), day 9 Basal cells did not support the recovery of 
perfusion after i.m. transplantation into the ischemic limb of NOD/SCID mice. In 
contrast, DEAB‐treated cells accelerated the recovery of blood perfusion by increasing 
endothelial cell proliferation in ischemic muscle tissue. Both Basal and DEAB‐treated 
cells were detected 7‐days post‐transplantation but were absent at day 35. DEAB‐treated 
cells demonstrated a trend toward increased engraftment and were found to be closely 
associated with proliferating endothelial cells, however, did not engraft into murine 
vasculature. Thus, we predict that survival and/or migration to a regenerative niche is 
compromised in day 9 Basal cells following i.m.‐transplantation. In support of this 
interpretation, day 9 Basal cells exclusively expressed proteins implicated with the 
induction of apoptosis, including FAS52. In contrast, DEAB‐treated cells exclusively 
expressed several pro‐survival molecules (i.e., CARD6, MCL1, KRT18, etc.), in addition 
to retaining the cytoprotective functions of ALDHhi‐activity. Further studies are 
warranted to determine the role of apoptotic and pro‐survival pathways identified in this 
study. Several studies have demonstrated increased regenerative cell function by pre‐
treating cells with small molecules to enhance survival following transplantation53,54. Our 
data suggest DEAB‐treatment generated heterogeneous myeloid cell progeny with pro‐
angiogenic secretory capacity that were more likely to survive i.m.‐transplantation into a 
harsh ischemic microenvironment. Furthermore, our data suggest ALDHhi ‐activity and 
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reduced CD38 expression may be a characteristic of vascular regenerative hematopoietic 
cells. Especially considering day 9 DEAB‐treated, day 6 Basal, and fresh UCB ALDHhi 
cells 12 share these characteristics (ALDHhi/CD38lo), in contrast to day 9 Basal cells with 
diminished vascular regenerative functions (ALDHlo/CD38hi). 
 
Both Basal and DEAB‐treated cells were identified by proteomics to equally express 
integrin complexes including CD41, CD61, CD18, and CD29 after culture on fibronectin. 
Activation of integrin signaling is expected to increase transplanted cells survival and/or 
migration. In contrast, detachment induced apoptosis could negatively impact 
transplanted cell engraftment. In addition, UCB ALDHhi cells cultured under Basal 
conditions for 9 days increased the production of extracellular matrix (ECM) molecules 
(fibronectin and collagen), compared with DEAB‐treated cells. The increased production 
of ECM molecules is characteristic of cells within the megakaryocyte lineage that could 
potentially limit bio‐distribution throughout the ischemic muscle. Additional studies are 
needed to specifically address whether pre‐exposure to a matrix influences the 
engraftment and bio‐distribution of transplanted progenitor cells. Interestingly, Whiteley 
et al. demonstrated UCB‐derived CD34+/CD45+ cells cultured for 8 days, engrafted 
ischemic murine muscle tissue at a higher rate than uncultured CD34+ cells or MNC, 
suggesting that ex vivo culture may benefit cellular therapies for PAD55. Several early 
trials have reported modest clinical benefits following the i.m. transplantation of 
expanded progenitor cells from autologous BM or peripheral blood56,57; however, these 
trials were unable to improve limb amputation rates. 
 
In summary, our previous studies established that UCB ALDHhi cells and day 6 expanded 
progeny temporally engraft ischemic muscle tissues and induce neovascularization in 
NOD/SCID mice with hind‐limb ischemia28. Unfortunately, the low number of 
transplantable cells would limit or impede a controlled clinical study to effectively 
investigate currently unestablished parameters of expandable UCB‐cells, such as clinical 
efficacy and cell dose. This study demonstrates limiting RA‐induced differentiation 
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during UCB‐cell expansion can expand total cell number by ∼80‐fold, and total ALDHhi 
cells by ∼25‐fold, without a significant loss of vascular regenerative function. Therefore, 
we consider these results early preclinical evidence that reasonable cell numbers can be 
generated from a single UCB sample to assess currently undetermined parameters leading 
to improved efficacy, such as cell dose, phenotype (ALDH, CD34, CD38, etc.), or 
therapeutic cell source (BM vs. UCB). Collectively, (a) advanced understanding of 
signaling pathways which drive progenitor cell differentiation, (b) identification of 
vascular regenerative cell subpopulations, and (c) improving culture conditions to 
facilitate cell type specific expansion is warranted for the development of effective 
vascular regenerative therapies. 
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Chapter 3  
3 Inhibition of retinoic acid production expands a 
megakaryocyte-enriched subpopulation with islet 
regenerative functionii 
ii A version of this chapter has been published: Cooper, T.T., Bell, G.I. and Hess, D.A., 
2018. Inhibition of retinoic acid production expands a megakaryocyte-enriched 
subpopulation with islet regenerative function. Stem cells and development, 27 (20), 
pp.1449-1461. 
 
3.1 Introduction 
The current ‘‘epidemic’’ status of diabetes mellitus (DM) is expected to increase from 
425 million individuals in 2017 to >625 million individuals by 2045, amplifying the 
surging financial burden on the healthcare system1. Two classifications of DM exist, each 
with a distinct etiology and pathology2,3. Type 1 DM represents *10% of reported cases 
and is associated with the autoimmune destruction of insulin-secreting β-cell s. Type II 
DM accounts for *90% of reported cases and is associated with insulin resistance in 
peripheral tissues. In both Type I or long-standing Type II DM, exogenous insulin is used 
for treatment of unregulated glycemic control. Unfortunately, current treatments do not 
mimic homeostatic insulin secretion, which leads to extreme fluctuations of blood 
glycemic levels. As a result, >80% of individuals with DM will develop life-threatening 
cardiovascular complications3. There is accumulating evidence that demonstrates human 
pancreas contains resident stem/progenitor cell populations4-6 and DM may be effectively 
treated by the restoration of physiologically functional β-cell  mass6,7. As a result, cell-
based therapies have become a focus of translational research aiming to restore depleted 
β-cell mass be either replacement or regeneration strategies8,9. Recent phase I/II clinical 
investigations to replace (NCT02239354) or regenerate (NCT00690066) β-cell mass are 
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currently underway or have reported early results. In 2010, the Joslin Medalist study 
reported measurable C-peptides levels and actively proliferating β-cell mass in the 
pancreata of individuals with Type I DM for >50 years10. 
This encouraged the idea that transplantation of appropriate cell types and/or stimuli may 
boost endogenous β-cell  regeneration in the islets of a diabetic individual5. We initially 
demonstrated human bone marrow (BM) and umbilical cord blood (UCB)-derived 
progenitor cells selected for high aldehyde dehydrogenase (ALDH) activity could 
stimulate endogenous β-cell  regeneration and reduce hyperglycemia in streptozotocin 
(STZ)-treated NOD/ SCID mice11,12. We have recently demonstrated the secretome of 
blood-derived progenitor cells such as multipotent stromal cells or hematopoietic 
progenitor cells (HPC) can stimulate human β-cell  proliferation in vitro13,14. It has also 
been demonstrated that mature hematopoietic cells, such as platelets, may have β-cell 
supportive functions during the clinical treatment of Type 1 DM autoimmunity15. 
Collectively, identifying phenotypic characteristics islet-regenerative cell populations and 
the effectors used to orchestrate robust islet regeneration is crucial to effective treating or 
reversing DM. UCB represents an accessible source of hematopoietic, endothelial, and 
mesenchymal progenitor cells and collection imposes no risk to either the newborn or 
mother. The worldwide establishment of public and private cord blood banking registries 
has generated a renewable pool with increased diversity for human leukocyte antigen 
(HLA)-matching for use in therapeutic applications. We view UCB as a favorable source 
of progenitor cells compared to autologous bone marrow, as accumulating evidence 
demonstrates loss of progenitor cell number and function when cells are harvested from 
the microenvironment of chronic diseases16-19. Cells harvested from healthy allogenic 
sources (i.e., UCB) are untouched by damaging metabolites that circulate throughout the 
body of diabetic individuals18. Further research is warranted to determine the full 
potential of UCB cell progeny for therapeutic strategies to treat DM and common 
cardiovascular comorbidities. The selection of UCB ALDHhi cells isolates an HPC-
enriched cell population with multifaceted regenerative functions11,20. Unfortunately, 
UCB ALDHhi cells represent a rare subpopulation (70-fold after 9 days; >1.0 · 107 viable 
cells); however, a primitive cell phenotype and regenerative function are rapidly lost21-23. 
We have recently identified that UCB ALDHhi cells preferably differentiate toward the 
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megakaryocyte lineage as culture time was increased22. Specifically, we detected 
increased expression of megakaryocyte-specific lineage markers, including CD41 
(ITGA2) and CD42 (GP1B), by global proteomic analyses and validated by 
multiparametric flow cytometry. UCB ALDHhi cells became enriched for a 
megakaryoblast phenotype (CD41+/CD42-) during ex vivo expansion and subsequently 
acquired a committed megakaryocyte phenotype (CD41+/CD42+); coinciding with loss of 
high ALDH-activity (UCB hematopoietic progeny capable of robustly stimulating islet 
regeneration. ALDH is rate limiting enzyme in the production of retinoic acid (RA), a 
potent driver of HPC differentiation via the activation of the RAR/RXR nuclear receptor 
complex (RAR/ RXR)24. Activation of the RAR/RXR complex will increase the 
production of downstream products that initiate hematopoietic differentiation and/or cell 
proliferation25-27. This imposes a paradoxical challenge to efficiently expand ALDHhi 
HPC while limiting the intrinsic propensity for hematopoietic differentiation in vitro. 
Reversible inhibition of ALDH1A-activity, using diethylaminobenzaldehyde (DEAB) 
supplementation, limited HPC differentiation during 9-day culture and generated an 
ALDHhi cell-enriched population (>20% of day 9 progeny; >20-fold increase of ALDHhi 
cells) that retained vascular regenerative function in vivo22. Herein, we investigated the 
islet regenerative capacity of expanded UCB ALDHhi cells reselected for high versus low 
ALDH-activity following 9 days culture under previously described DEAB-treated 
culture conditions. We hypothesized expanded ALDHhi cells reselected from DEAB-
treated conditions would demonstrate islet regenerative function following 
intrapancreatic transplantation into STZ-induced hyperglycemic NOD/SCID mice. 
Surprisingly, this study identified that only a CD41+ megakaryocyte-lineage enriched 
ALDHlo cell population harvested from DEAB-treated conditions supported islet 
regeneration, albeit modestly. Collectively, this study provides evidence that the retention 
of high ALDH-activity, via DEAB-treated conditions, does not coincide with islet 
regenerative function. 
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3.2 Methods 
3.2.1 UCB ALDHhi cell isolation and expansion 
3.2.2 Human UCB samples were obtained with informed consent by venipuncture of 
the umbilical vein following Caesarian section at Victoria Hospital Birthing 
Centre, London, ON, Canada (REB No. 12934). The Human Studies Research 
Ethics Board (HSREB) at Western University approved all procedures. Within 
24 h of collection, UCB samples were initially depleted of mature myeloid, 
lymphoid and red blood cells using RosetteSep Human Cord Blood Progenitor 
Cell Enrichment Cocktail (Stem Cell Technologies, Vancouver, BC, Canada). 
Lineage-depleted (Lin-) mononuclear cells were isolated by Hypaque Ficoll 
centrifugation and incubated with Aldefluor regent before purification by FACS 
(FACS Aria III; BD Biosciences, Mississauga, ON, Canada). UCB ALDHhi cells 
were selected based on low side scatter and high ALDH-activity with >98% 
purity (n = 5). Purified UCB ALDHhi cells were cultured on fibronectin-coated 
plates for 9 days under untreated (X-vivo 15 + 10 ng/mL SCF, TPO, FLT-3L) or 
DEAB-treated (Untreated+10 mM DEAB on days 3–6), as previously described 
(Figure 3.1A)22. 
3.2.3 Flow cytometry 
UCB ALDHhi cells expanded under untreated or DEAB-treated conditions were 
harvested at day 9 and enumerated by trypan blue exclusion using hemocytometer counts. 
Cells were labeled with Aldefluor to assess ALDH-activity. and co-stained with 7-amino-
actinomycin D to determine viability. Fresh UCB Lin- MNC and expanded UCB ALDHhi 
cell progeny were co-labeled with anti-human antibodies for CD41 (ITGA2), and CD42 
(GP1B; megakaryocyte). Expanded cells were assessed for a primitive HPC phenotype 
using anti-human CD34 and hematopoietic lineage differentiation was determined using 
anti-human CD38 (cyclic ADP ribose hydrolase). Cell surface marker expression for 
fresh cells, and expanded ALDHhi versus ALDHlo subsets was determined using an 
114 
LSRII flow cytometer (BD Biosciences) at the London Regional Flow Cytometry 
Facility. All analyses were performed using FlowJo software v8.2. 
3.2.4 Hematopoietic colony formation 
Day 9 expanded cells were harvested from untreated or DEAB-treated conditions and 
reselected for high or low ALDH-activity before being seeded in semi-solid 
methylcellulose media (H4434; Stem Cell Technologies) at 500 cells/mL in 12-well 
plates, performed in duplicate (Figure 3.2C). Hematopoietic colonies were enumerated 
after 12–14 days in vitro and scored based on morphological characteristics of burst 
forming unit erythrocyte (BFU-E), colony forming unit granulocyte (CFU-G), colony 
forming unit macrophage (CFU-M), colony forming unit granulocyte/macrophage (CFU-
GM), or colony forming unit mixed (CFU-Mixed)20. CFU/100 cells were calculated by 
number of colonies formed per 100 cells seeded in the assay. Furthermore, the frequency 
of lineage-specific colony formation was calculated by dividing the number of a lineage-
specific colony (i.e., BFU-E) by the total number of colonies enumerated. 
3.2.5 Transplantation of expanded ALDHlo and ALDHhi cells 
Pancreatic β-cell ablation was induced in NOD/SCID mice aged 8- to 10-weeks ( Jackson 
Laboratories, Bar Harbor, ME; www.jax.org) by intraperitoneal injection of STZ (35 
mg/kg/ day) for 5 consecutive days11 (Figure 3.3A). All animal procedures were 
approved by the Animal Care Committee at Western University Canada (AUP 2015-
033). On day 10, hyperglycemic (15–25 mM) mice were sublethally irradiated (300 cGy) 
and transplanted in a blinded fashion by intrapancreatic injection of phosphate-buffered 
saline (PBS), or 105 expanded (bulk) cells, 2.0 x 105 ALDHlo cells, or 2.0 x 105 ALDHhi 
cells harvested from untreated or DEAB-treated conditions. Systemic blood glycemic 
levels were monitored weekly in a blinded fashion for 42 days. Twenty-four hours before 
sacrifice, mice were i.p.- injected with 200 µg 5-ethynyl-20-deoxyuridine (EdU; 
Invitrogen) to label proliferating cells in situ. In addition, glucose tolerance tests were 
performed over 120 min after i.p.-injection of 2 g/kg glucose bolus at day 41, as 
previously described (Figure 3.4A)23. 
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3.2.6 Immunohistochemistry and immunofluorescent analyses 
Pancreata were harvested, embedded in OCT, and cryosectioned (12 µm) to obtain three 
sections per slide ± 200 µm apart. Cryosections were fixed in 10% formalin (Sigma) and 
blocked with 5% serum before immunohistochemical staining for insulin to determine 
islet number, size, and β-cell area as previously described23. Additionally, 
immunofluorescent co-staining for insulin with EdU, CD31, Nkx6.1, and/or HLA-A,B,C 
was performed. EdU+ proliferating cells were detected using the Click-iT imaging kit 
(Alexafluor 488; Life Technologies). Intra-islet capillary density was enumerated post-
transplantation using rat anti-mouse CD31 (1:100; BD Biosciences) detected with FITC-
labeled rabbit anti-rat secondary antibodies (1:200; Vector). Nxk6.1+ cell nuclei were 
enumerated using anti-rabbit (1:2000; AbCam) and detected using goat anti-rabbit FITC-
labeled secondary antibodies (1:200; Vector). Human cell engraftment was enumerated 
by staining pancreas sections with mouse anti-human HLA A,B,C (1:100; AbCam) 
detected with horse anti-mouse FITC-labeled secondary antibodies (1:200; Vector). 
DAPI was used as counterstain to label nuclei. Quantification and analyses were 
performed using Fiji (Image J v2.0). 
3.2.7 Quantification of islet number, size, and β-cell mass 
Islet number was quantified across four random images per tissue section (12 images per 
mouse) by enumerating the presence of insulin+ islet structures containing more than 20 
nuclei. Islet size was determined by measuring the circumference of each islet identified 
in the previous quantification using Fiji (Image J v2.0). Lastly, β-cell mass of each mouse 
was calculated:  
𝑃𝑎𝑛𝑐𝑟𝑒𝑎𝑠 𝑊𝑒𝑖𝑔ℎ𝑡 (𝑚𝑔) 𝑥 (
𝐼𝑠𝑙𝑒𝑡 𝐴𝑟𝑒𝑎 (𝐼𝑛𝑠𝑢𝑙𝑖𝑛 +)
𝑁𝑜𝑛 − 𝑖𝑠𝑙𝑒𝑡 𝐴𝑟𝑒𝑎
) = 𝛽 − 𝑐𝑒𝑙𝑙 𝑚𝑎𝑠𝑠 
3.2.8 Statistical analyses 
Statistical analysis for flow cytometry and colony analyses was performed by one-way 
ANOVA with Tukey’s multiple comparisons tests. Analysis of significance was 
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performed by one-way ANOVA with Tukey’s multiple comparisons tests for all in vivo 
experiments and enumeration of histological analyses. Outliers were identified using 
Grubb’s test; P < 0.05. 
3.3 Results 
3.3.1 High ALDH-activity does not select for the megakaryocyte lineage 
in fresh UCB cells 
We have previously demonstrated that purified UCB Lin− ALDHhi cells represent a 
heterogeneous progenitor cell population with multifaceted regenerative functions11,20. 
However, the robust expansion of UCB Lin− ALDHhi cells (>70-fold) under serum-free 
conditions containing SCF, Flt-3L, and TPO generated a megakaryocyte-enriched 
population with diminished ALDH-activity and progenitor cell surface marker 
expression22. To understand the propensity of UCB Lin− ALDHhi cells to differentiate 
toward the megakaryocyte lineage, we sought to determine whether the initial selection 
of primitive cells based on high ALDH-activity also enriched for committed precursors 
within the megakaryocyte lineage. Therefore, we first compared fresh UCB Lin− MNC, 
or FACS-purified ALDHhi and ALDHlo cells for megakaryoblast (CD41+/CD42−) and 
megakaryocyte (CD41+/CD42+) cell surface marker expression (Figure 3.11A). The 
frequency of cells with CD41+/CD42− megakaryoblast phenotype was equivalent 
between freshly isolated UCB Lin− MNC (28.8% ± 6.12%), or purified ALDHhi 
(26.9% ± 2.1%) versus ALDHlo cell subpopulations (29.1% ± 6.4%; Figure 3.1B). 
Moreover, the frequency of committed CD41+/CD42+ megakaryocytes was also 
equivalent within the fresh UCB Lin− cell subsets (Figure 3.1C). Thus, selection of UCB 
Lin− cells based on high ALDH-activity did not enrich for cells of the megakaryocyte 
lineage; although ∼60% of UCB ALDHhi cells expressed early megakaryocyte marker 
CD41. 
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Figure 3.1 Expansion of UCB ALDHhi cells generated cells of the megakaryocyte 
lineage in vitro. (A) Schematic for the initial FACS-purification of cells with low side-
scatter (SSC-A) and high aldehyde dehydrogenase (ALDH) activity from lineage-
depleted (Lin-) human umbilical cord blood (UCB) and subsequent expansion under 
serum-free conditions with or without DEAB-treatment. The frequency of (B) 
CD41+/CD42- megakaryoblasts, and (C) CD41+/CD42+ megakaryocytes was equivalent 
within fresh UCB Lin- mononuclear cells, and purified ALDHhi or ALDHlo cell subsets. 
Following expansion of UCB ALDHhi cells for 9 days with or without DEAB-treatment, 
(D) expanded cells re-selected for high ALDH-activity were enriched for CD41+/CD42- 
megakaryoblasts compared to the ALDHlo cell subset. Conversely, (E) expanded cells re-
selected for low ALDH-activity were enriched for CD41+/CD42+ megakaryocytes, 
compared to the ALDHhi cell subset. Data represented as Mean ± SEM (*p<0.05, N=3-
5). Statistical analyses were determined by one-way ANOVA with Tukey’s post-hoc test. 
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3.3.2 The expanded ALDHhi cell subpopulation was enriched for a 
megakaryoblast phenotype and the ALDHlo cell subpopulation was 
enriched for a megakaryocyte phenotype 
The ex vivo expansion of UCB Lin− ALDHhi cells under DEAB-treated culture 
conditions robustly increased the total number of viable ALDHhi cells for preclinical 
studies (>20-fold)22. Despite the retainment of ALDHhi cells under DEAB-treated 
conditions, the frequency of CD41+/CD42+ megakaryocytes in the total cell population 
was comparable to untreated conditions. It is currently unreported whether ALDHhi cells 
reselected from DEAB-treated conditions are enriched for specific subpopulations of the 
megakaryocyte lineage, compared to untreated conditions. Following ex vivo expansion 
of UCB Lin− ALDHhi cells under untreated or DEAB-supplemented conditions, cell 
progeny that retained high ALDH-activity was enriched (*p< 0.05) for early 
megakaryoblast (CD41+/CD42−) phenotype, compared to the ALDHlo cell subpopulation 
(Figure 3.1D) from either condition. Conversely, the ALDHlo cell subpopulation 
generated under untreated and DEAB-treated conditions was significantly enriched 
(**P < 0.01) for a committed CD41+/CD42+ megakaryocyte phenotype, compared to the 
ALDHhi cell subpopulation (Figure 3.1E). Collectively, DEAB-treated conditions 
generated CD41+/CD42− megakaryoblasts that retained ALDHhi progenitor cell 
characteristics and reduced the commitment of UCB Lin− ALDHhi cells toward an 
ALDHlo CD41+/CD42+ megakaryocyte phenotype. 
3.3.3 Reselection of ALDHhi cells enriched for primitive phenotypes and 
increased multipotent hematopoietic colony formation in vitro 
 
Multipotent HPC with colony formation function in vitro and SCID-repopulating 
capacity in vivo can be enriched from fresh UCB samples by the selection of 
CD34+/CD38− or ALDHhi cells28,29. To determine whether multipotent HPC remained 
after 9-days culture, we assessed expanded UCB Lin− ALDHhi cells for a primitive 
progenitor cell phenotype and for clonal colony formation in vitro. Following ex vivo 
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expansion of UCB Lin− ALDHhi cells under untreated or DEAB-supplemented 
conditions, reselected ALDHhi cells were significantly enriched (**p < 0.01) for primitive 
CD34+/CD38- cell surface marker expression (20.8% ± 7.3% or 15.1% ± 3.9%), 
compared to the ALDHlo cell subpopulation (1.7% ± 0.7% or 1.7% ± 0.5%; Figure 2A). 
The frequency of CD34+/CD38- cells in the ALDHhi subset was comparable between 
culture conditions (Figure 2A). Regardless, we have previously reported that the 
enrichment of ALDHhi cells under DEAB-treated conditions induced a more than twofold 
increase in the number of ALDHhi/CD34+/CD38- cells, compared to untreated 
conditions22. Importantly, DEAB-treated conditions induced a significant decrease in 
frequency of ALDHhi or ALDHlo cells with CD38+ expression (Figure 3.2B), a marker of 
hematopoietic maturation27. To determine hematopoietic colony forming capacity in 
vitro, ALDHhi and ALDHlo cells were reselected after expansion under untreated and 
DEAB-treated conditions and seeded in methylcellulose media. Hematopoietic colony 
formation was manually enumerated after 14 days (Figure 3.2C). Notably, ALDHhi cells 
from either untreated or DEAB-treated conditions were significantly enriched for colony 
forming cells compared to ALDHlo cells (Figure 3.2D). ALDHhi cells from DEAB-treated 
cultures also demonstrated a higher frequency (*p < 0.05) of colony formation (1 CFU in 
10.5 cells, *p < 0.05) compared to ALDHhi cells expanded under untreated conditions (1 
CFU in 30.0 cells). The frequency of myeloid colonies formed was found to be similar to 
cells expanded under untreated or DEAB-treated conditions (Figure 2E). Within the 
ALDHhi or ALDHlo subsets only ALDHhi cells demonstrated myeloid multipotency by 
the formation of CFU-mixed colonies, whereas ALDHlo cells largely contained 
progenitors restricted to the macrophage (CFU-M) or granulocyte (CFU-G) lineages 
(Figure 2E). Collectively, these results demonstrate DEAB-treated conditions reduced the 
acquisition of mature marker CD38 and augmented the expansion of ALDHhi cells that 
retained multipotent hematopoietic colony forming capacity in vitro. 
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Figure 3.2 Re-selection of expanded cells with high ALDH-activity enriched for cells 
retaining primitive (CD34+/CD38-) phenotype and multipotent colony forming 
capacity in vitro. (A) Following expansion for 9 days with or without DEAB-treatment, 
primitive (CD34+/CD38-) cell phenotype was enriched within the expanded ALDHhi cell 
subset compared to the ALDHlo cell subset. (B) CD38 expression was significantly 
decreased following DEAB-treatment. Specifically, CD34-/CD38+ cell frequency was 
reduced in both the ALDHhi and ALDHlo cell subpopulation of cells harvested from 
DEAB-treated conditions. (C) Following expansion for 9 days with or without DEAB-
treatment, expanded cells re-purified for low or high ALDH-activity were seeded in 
methylcellulose media and colony formation was enumerated after 14 days. (D) Total 
hematopoietic colony formation was increased within expanded cells re-selected for high 
ALDH-activity and was also increased for re-selected ALDHhi cells generated under 
DEAB-treated conditions compared to re-selected ALDHhi cells generated untreated 
conditions. (E) Only ALDHhi cells from either Untreated or DEAB-treated conditions 
demonstrated full myeloid-specific multipotency, compared to re-selected ALDHlo cells 
that did not form mixed colonies. Data represented as Mean ± SEM (*p<0.05, **p<0.01, 
***p<0.001; N=3-5). Statistical analyses were determined by one-way ANOVA with 
Tukey’s post-hoc test. 
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3.3.4 Intrapancreatic transplantation of ALDHlo cells from DEAB-
treated conditions reduced hyperglycemia in STZ-treated 
NOD/SCID mice 
We have shown that ex vivo expansion of UCB Lin− ALDHhi cells rapidly diminishes 
islet regenerative function as culture time was increased13. Therefore, we sought to utilize 
previously reported culture conditions that increase the number (two-fold) of ALDHhi 
cells following 9-day expansion, compared to untreated conditions22. On day 10, STZ-
treated, hyperglycemic (>15 mM) NOD/SCID mice received intrapancreatic 
transplantation (Figure 3.3A) of PBS or 5.0 × 105 bulk cells harvested from either 
untreated or DEAB-treated conditions. Similar to PBS-injected controls, mice 
transplanted with untreated bulk cells remained hyperglycemic up to 42 days (Figure 
3.3B, C). Compared to PBS-injected controls, transplantation of DEAB-treated bulk cells 
reduced hyperglycemia on day 17 (*p < 0.05); however, a sustained reduction of 
hyperglycemia was not observed at later time points out to day 42 (*p = 0.17; Figure 
3.3B, C). In a recent publication, we also demonstrated that sustained reduction in 
hyperglycemia was only achieved when 6-day expanded cells were reselected for high 
ALDH-activity before intravenous transplantation23. Therefore, we reselected our 
expanded cell populations for high versus low ALDH-activity before direct 
intrapancreatic transplantation. Hyperglycemic mice received an intrapancreatic 
transplantation of 2.0 × 105 ALDHhi or ALDHlo cells harvested from either untreated or 
DEAB-treated conditions. ALDHhi cells harvested from either untreated or DEAB-treated 
conditions at 9 days were unable to reduce hyperglycemia, compared to PBS-injected 
controls (Figure 3D, E). Interestingly, the ALDHlo cell subset from DEAB-treated 
conditions significantly reduced hyperglycemia at days 14, 17, and 28 (*p < 0.05; Figure 
3.3D). More importantly, hyperglycemia was significantly reduced by measurement of 
area under the curve (*p < 0.05; Figure 3.3E), compared to PBS-injected controls. After 
performing glucose tolerance tests 24-h before euthanasia, mice transplanted with bulk, 
ALDHhi, or ALDHlo cells from either untreated or DEAB-treated conditions did not 
demonstrate an improved physiological response to i.p. injection of a glucose bolus 
(Figure 3.4). Thus, DEAB-treated conditions generated ALDHlo cells that modestly 
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reduced resting glycemia levels in STZ-treated NOD/SCID mice following 
intrapancreatic transplantation. However, the reduction in hyperglycemia was modest, 
transient, and mice were unable to respond to glucose bolus in a physiological manner at 
a later time point. 
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Figure 3.3 Intrapancreatic transplantation of re-selected ALDHlo cells from DEAB-
treated conditions reduced hyperglycemia in STZ-treated NOD/SCID mice. (A) 
Hyperglycemia was induced in NOD/SCID mice by serial injections of STZ 
(35mg/kg/day) between days 0-4. Hyperglycemic mice (>15.0 mmol/L at day 10) were 
sublethally irradiated (300 cGy) on Day 10 and received intrapancreatic transplantation 
of 5.0x105 bulk cells, 2.0x105 ALDHhi cells or 2.0x105 ALDHlo cells harvested after 9 
days expansion using either Untreated or DEAB-treated conditions. To serve as a vehicle 
control (PBS), mice received an intrapancreatic injection of phosphate buffered saline at 
an equivalent volume (20µl). (B) Resting blood glucose levels of mice transplanted with 
vehicle control (PBS), or bulk cells expanded under untreated or DEAB-treated 
conditions. (C) Mice transplanted with untreated (n=10) or DEAB-treated (n=11) 
expanded cells did not show reduced glycemia area under the curve (AUC), compared to 
PBS-injected (n=8) controls. (D) Mice transplanted with ALDHlo cells from DEAB-
treated conditions (n=7) showed reduced resting blood glucose levels (Day 14, 17 and 28) 
compared to PBS-injected controls (n=10). (E) Mice transplanted with ALDHlo cells 
from DEAB-treated conditions (n=7) showed reduced glycemia area under the curve 
(AUC), compared to PBS-injected (n=8) controls. Data represented as Mean ± SEM 
(*p<0.05, n=6-11 mice per group). Statistical analyses were determined by one-way 
ANOVA with Tukey’s post-hoc test compared to PBS control. 
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Figure 3.4 Mice transplanted with expanded cells do not respond to intraperitoneal 
injection of glucose. (A) On Day 41, transplanted mice were fasted (4h) and received 
intraperitoneal injection of 2.0mg/kg dextrose followed by serial serum glucose 
measurements up to 120 min. (B, C) Mice transplanted with expanded cells from 
untreated or DEAB-treated conditions did not demonstrate a physiological response to 
glucose bolus. (D, E) Similarily, mice transplanted with expanded cells from untreated or 
DEAB-treated conditions reselected for low or high ALDH-activity did not demonstrate a 
physiological response to glucose bolus. Data represented as mean + SEM (n= 3-8). 
Statistical analyses were determined by one-way ANOVA with post-hoc Tukey’s t-test.  
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3.3.5 Intrapancreatic transplantation of expanded ALDHlo cells from 
DEAB-treated conditions increased islet number 
To investigate the mechanisms by which expanded ALDHlo cells generated from DEAB-
treated conditions modestly reduced hyperglycemia in NOD/SCID mice, pancreas 
sections were analyzed for islet size, number, and total β-cell mass (Figure 3.5A–D). 
Histological analysis revealed a significant increase in the number of insulin+ islets in 
mice receiving intrapancreatic transplantation of DEAB-treated ALDHlo cells, compared 
to PBS-injected mice (*p < 0.05; Figure 3.5B). In contrast, islet circumference remained 
comparable between all transplantation conditions (Figure 3.5C). Ultimately, mice 
transplanted with DEAB-treated ALDHlo cells demonstrated an increased trend in total β 
cell mass, compared to PBS-injected controls (p = 0.14; Figure 3.5D). Thus, expanded 
DEAB-treated ALDHlo cells did not robustly increase β cell mass and transplanted mice 
demonstrated a failed physiological response to a glucose challenge, despite modestly 
improved resting glycemic levels 
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Figure 3.4 Mice transplanted with ALDHlo cells from DEAB-treated conditions 
showed modestly increased islet number and beta-cell mass. (A) Representative 
photomicrographs of islets stained for insulin (brown) at day 42 in STZ-treated 
NOD/SCID mice transplanted with vehicle control or ALDHlo cells harvested from 
Untreated or DEAB-treated conditions. Compared to vehicle control, mice transplanted 
with DEAB-treated ALDHlo cells demonstrated (B) increased islet number without (C) 
measurable changes in islet size. (D) Mice transplanted with ALDHlo cells from DEAB-
treated conditions did not show significantly (p=0.14) increased β-cell mass, compared 
to mice injected with vehicle control. Data represented as Mean ± SEM (n=6-10). 
Statistical analyses were determined by one-way ANOVA with Tukey’s post-hoc test 
compared to PBS control. Scale bar = 100µm. 
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3.3.6 Expanded ALDHlo cells increased intra-islet cell proliferation but 
did not increase intra-islet vascularity or Nxk6.1+ expression 
To better understand regenerative processes induced by intrapancreatic ALDHlo cell 
xenotransplantation, we assessed intra-islet cell proliferation in mice pulsed with EdU for 
24 h before sacrifice at day 42. Pancreata transplanted with ALDHlo cells harvested from 
DEAB-treated conditions demonstrated an increase in the number of proliferating (EdU+) 
cells within islets at day 42 (Figure 3.6A). Although increased proliferation was 
observed, intra-islet vascular density (CD31+ cells/Islet Area; Figure 3.6B) and β cell 
identity marker expression (Nkx6.1; Figure 3.6C) were equivalent to PBS-injected mice. 
Thus, indicating proliferating cells were likely not of an endothelial or β cell phenotype. 
HLA-A,B,C+ human cells were not detected in the pancreas of transplanted mice at day 
42, despite detectable engraftment at day 14 (Figure 3.7). Collectively, ALDHlo cells 
from DEAB-treated conditions transiently engrafted the murine pancreas and modestly 
increased islet cell proliferation without significantly increasing islet-vascularity or 
functional β cell mass. 
. 
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Figure 3.5  Intrapancreatic transplantation of ALDHlo cells from DEAB-treated 
conditions increased intra-islet cell proliferation. (A) Representative photomicrograph of 
EdU+ cells within insulin-expressing islets at day 42 in an STZ-treated mouse transplanted 
with DEAB-treated ALDHlo cells. Compared to PBS-injected control mice (n=9), mice 
transplanted with DEAB-treated ALDHlo cells (n=7) showed an increased number of 
proliferating cells (EdU+) within islets. (B) Representative photomicrograph of murine 
CD31+ cells within insulin-expressing islets at Day 42 in an STZ-treated mouse transplanted 
with DEAB-treated ALDHlo cells. Intra-islet vascularization (CD31+) was equivalent for all 
transplanted groups. (C) Representative photomicrograph of murine Nkx6.1+ nuclei with 
insulin-expressing islets at day 42 in a STZ-treated mouse transplanted with DEAB-treated 
ALDHlo cells. Intra-islet Nkx6.1+ cells per islet area was equivalent for all transplanted 
groups. Data represented as Mean ± SEM (*p<0.05; n=6-10). Statistical analyses were 
determined by one-way ANOVA with post-hoc Tukey’s post-hoc test compared to PBS 
control. Scale bar = 100µm. 
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Figure 3.6 Mice transplanted with expanded cells re-selected for low ALDH-activity 
showed human cell engraftment at 4-days post-transplantation. (A) Representative 
photomicrographs of human cell engraftment in the pancreas of mice transplanted with 
expanded cells re-selected for low ALDH-activity at 4 days post-transplantation. HLA-A, 
B, C-expressing cells were detected in mice transplanted with ALDHlo cells generated 
under untreated (n=2) and DEAB-treated conditions (n=2).  Scale bar = 100µm. 
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3.4 Discussion 
Restoration of β cell mass for the treatment of diabetes has recently become an intense 
focus of translational research, yet many of the mechanisms facilitating the regeneration 
of endogenous β cell mass remain elusive. For example, identifying hematopoietic cell 
subtypes that stimulate islet regenerative mechanisms has largely been unexplored. We 
have demonstrated selection of UCB Lin− ALDHhi cells enriched for a HPC population 
capable of reducing hyperglycemia in STZ-injected NOD/SCID mice11. Unfortunately, 
UCB ALDHhi cells are rare and expansion will be required to collect enough cells to 
potentially treat human subjects. Our recent work and this study demonstrate the 
challenge in expanding these cells with concurrent retention of islet regenerative 
capacity13. The selection of UCB Lin− ALDHhi cells biases HPC differentiation by active 
RA-induced differentiation under serum-free conditions that promoted the acquisition of 
a megakaryocyte phenotype (CD41+/CD42+) and loss of regenerative function (Figure 6). 
On the other hand, we have recently reported that DEAB-induced inhibition of RA-
production enhanced the expansion of HPC that retained vascular regenerative paracrine 
functions in vivo22. With these properties in mind, we initially hypothesized that 
reversible inhibition of ALDH-activity could enhance the expansion of UCB-derived 
hematopoietic progeny with islet regenerative function by preventing differentiation from 
an ALDHhi cell phenotype. Herein, we show the robust islet regenerative function of 
UCB Lin− ALDHhi cells is lost during ex vivo culture; however, beneficial functions 
were partially retained by inhibiting RA-induced differentiation and paradoxically 
reselecting for CD41+ enriched ALDHlo cells. 
The islet regenerative function of uncultured UCB Lin− ALDHhi cells was rapidly lost 
under clinically applicable, hematopoietic selective serum-free culture conditions. With 
this in mind, we first sought to determine whether the megakaryocyte content of 
uncultured UCB Lin− ALDHhi cells could provide help elucidate the phenotype of an 
islet regenerative cell population, as expanded cells are largely committed to the 
megakaryocyte lineage. CD41+/CD42+ cell content was equivalent between uncultured 
UCB Lin− cells, or Lin− ALDHhi or Lin− ALDHlo cell subsets. These results provided 
indirect evidence that CD41+/CD42+ megakaryocyte content likely played a minimal role 
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in the islet regenerative function of transplanted uncultured UCB Lin− ALDHhi cells and 
the enrichment of a megakaryocyte phenotype is a result of subsequent culture 
conditions. Interestingly, Gentry et al. previously reported that the selection of ALDHhi 
cells enriched for megakaryocyte progenitors by >2000-fold, compared to the ALDHlo 
subpopulation30. We attributed our conflicting results observed in this study to our use of 
a lineage-depletion cocktail, which does not deplete cells of the megakaryocyte lineage 
from UCB MNC. Furthermore, megakaryoblast and megakaryocyte phenotype in UCB 
cells was assessed by flow cytometry in our study, as opposed to the use of a clonogenic 
assay that would assess the megakaryocyte potential of selected subpopulations. 
Nonetheless, our results corroborate the findings by Gentry et al., such that UCB ALDHhi 
cells robustly generated cells of the megakaryocyte lineage in vitro. 
 
Megakaryocytes are large cells (>50 𝜇m) that primarily reside within the bone marrow31 
or lungs32 and are derived from a common megakaryocyte/erythroid myeloid progenitor 
cell33. Considering our culture conditions are supplemented with TPO, a known driver of 
megakaryopoiesis and paradoxically required for effective progenitor cell expansion, it is 
likely that the expansion of CD41+/CD42+ cells from ALDHhi cells can be attributed to 
active TPO-signaling. Future research would need to determine the role exogenous TPO 
and/or extracellular matrix molecules have on UCB ALDHhi cell differentiation toward a 
CD41+/CD42+ phenotype, an area that has been extensively studied with other HPC 
subpopulations34-36. Moreover, TPO produced by cells of the megakaryocyte lineage 
could signal in an autocrine fashion to stimulate the expression of CD41 and CD4236. 
Considering that >60% of freshly isolated UCB Lin− ALDHhi cells express CD41, we 
propose that UCB Lin− ALDHhi cells are primed to respond to drivers of differentiation, 
including the RA- and TPO-signaling pathways. Collectively, the expansion of ALDHhi 
cells and modulation of megakaryopoiesis in vitro is complex and future studies would 
need to consider several parameters including (1) progenitor cell purification, (2) culture 
conditions, and (3) culture duration. 
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For nearly 2 decades, high ALDH-activity has served as an enzymatic marker to identify 
and enrich for hematopoietic progenitor subtypes in fetal and adult tissue37-39. Our recent 
publication demonstrated DEAB supplementation and subsequent inhibition of RA-
production enriched for ALDHhi cells progeny (>2-fold) during UCB HPC expansion24, 
leading to a >20-fold increase in viable ALDHhi cell number. Supporting our previous 
studies, we report that CD34+/CD38− cell surface expression was enriched within the 
ALDHhi cell subset following expansion23; moreover, reselected ALDHhi cells 
demonstrated enhanced multipotent hematopoietic colony formation, compared to 
ALDHlo cells23. Importantly, ALDHhi cells reselected from DEAB-treated conditions 
showed enhanced hematopoietic colony formation, compared to untreated conditions. 
Considering CD34+/CD38− enrichment within the ALDHhi subset was comparable 
between untreated and DEAB-treated conditions, our results support previous reports that 
high ALDH-activity further enriches for multipotent HPC from the CD34+/CD38− 
subpopulation29. These results indicate that the loss of high ALDH-activity coincides 
with the loss of multipotent progenitor capacity and hematopoietic colony formation can 
be retained by temporarily inhibiting RA-production in vitro. The loss of ALDH-activity 
has been associated with HPC differentiation and here we add that the ALDHlo cell 
subsets were enriched for a CD41+/CD42+ megakaryocyte phenotype (>50%) following 
ex vivo expansion. On the other hand, ALDHhi cells were enriched for CD41+/CD42− 
megakaryoblasts compared to ALDHlo cells. Therefore, we propose a model where high 
ALDH-activity is gradually diminished during culture as uncommitted multipotent 
myeloid progenitors lose a primitive CD34+/CD38− phenotype and transition toward a 
CD41+/CD42− megakaryoblast phenotype, before commitment toward a CD41+/CD42+ 
megakaryocyte phenotype and acquisition of CD38 expression (Figure 6). 
 
In the current study, we observed a modest improvement of glycemia levels in STZ-
treated NOD/SCID mice receiving intrapancreatic transplantation of expanded cells 
harvested from DEAB-treated conditions. However, our histological analysis revealed 
minimal regeneration of β cell mass had occurred following direct transplantation of bulk 
expanded cells. These results lead us to predict the reselection of cells based on high 
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versus low ALDH-activity would be required to purify regenerative cells with enhanced 
engraftment and/or migration. Intrapancreatic transplantation of expanded cells reselected 
for high versus low-activity surprisingly revealed that only ALDHlo cells harvested from 
DEAB-treated conditions (DEAB ALDHlo) reduced hyperglycemia. The capacity of 
ALDHlo cells harvested from DEAB-treated conditions to reduce hyperglycemia and 
improve islet function after intrapancreatic transplantation was highly variable, with 3 of 
7 mice showing notable recovery. Although we observed increased islet number within 
the pancreas of mice transplanted with DEAB ALDHlo cells, the size of murine islets and 
total β cell mass were comparable between all conditions. Our previous reports 
demonstrated that transplanted fresh UCB ALDHhi cells transiently engrafted the 
pancreas yet demonstrated sustained regeneration of β cell mass12. Similarly, we detected 
engraftment of transplanted expanded cell progeny at day 14 but not day 42; suggesting 
that expanded ALDHlo cell engraftment is also transient while islet regenerative function 
is modest. Nonetheless, DEAB-treated ALDHlo cells modestly reduced hyperglycemia, 
by increasing islet number through unidentified mechanisms. The results of this study 
contrast our previous HPC transplantation studies that reported increased β cell mass as a 
result of increased islet size not islet number23. We observed an increased rate of 
proliferating cells within murine islets at day 42 following direct transplantation of 
DEAB ALDHlo cells, however, it was concluded that EdU+ cells were not of an 
endothelial (CD31) or β cell (Nkx6.1) phenotype. Collectively, we provided preliminary 
evidence that transplanted DEAB ALDHlo cells temporarily engraft the pancreas to 
support β cell function via unidentified and likely multifactorial mechanisms. 
 
Highly vascularized networks within islets of Langerhans facilitate the release and 
transport of blood glucose regulating hormones, including insulin and glucagon, through 
systemic circulation40. Seneviratne et al. demonstrated increased intra-islet vascularity 
islet size and β cell mass after intravenous transplantation of 6-day expanded ALDHhi 
HPC23. Considering DEAB-treated cells robustly stimulate angiogenesis in the ischemic 
hindlimb, we investigated whether islet vascularity was increased following 
intrapancreatic transplantation; in return increasing the efficiency of systemic insulin 
137 
delivery. Immunofluorescent analysis revealed intra-islet vascularity was equivalent 
between all transplantation conditions. This was anticipated, considering islet size was 
not increased following DEAB-treated ALDHlo cell transplantation. These collective 
results suggest that intra-islet vascularity may increase only when robust recovery β cell 
mass occurs. Previous studies have demonstrated a “symbiotic” relationship between 
endothelial cells and pancreatic β-cells41,42. Specifically, the proliferation and survival of 
β-cells was dependent on paracrine signaling from the neighboring vascular network. In 
this study, DEAB ALDHlo cell transplantation increased islet number and not size. 
Therefore, we suggest the modest reduction of hyperglycemia was likely a result of 
increasing the number of endogenous islets capable of releasing insulin into systemic 
circulation. We propose that DEAB ALDHlo cells likely provided unidentified supportive 
stimuli to surviving islets following STZ-induced β-cell ablation. Nonetheless, 
identification of these stimuli will require future proteomic studies using cell populations 
with more robust and consistent islet regenerative function in vivo. 
 
In summary, we provide preliminary evidence that expanding ALDHhi cells while 
retaining islet regenerative function is complex and the loss of islet regenerative function 
is likely multifactorial. Specifically, we have identified several important findings that 
may benefit future research aiming to expand HPC ex vivo for therapeutic applications. 
These include results such as the following: (1) FACS purification of UCB Lin− MNC 
based on ALDH-activity does not enrich for megakaryocytes, (2) inhibition of RA-
production generates multipotent ALDHhi cells in vitro, and (3) retainment of a primitive 
ALDHhi phenotype does not coincide with islet regenerative function following 
intrapancreatic transplantation. Collectively, these results indicate that cellular therapies 
using expanded HPC to accelerate endogenous islet regeneration require further studies 
to prevent the loss of islet proliferative and vascularizing function. 
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Figure 3.7 UCB Lin-  ALDHhi cells acquire megakaryocyte phenotype during 
expansion that coincide with reduced islet regenerative function. UCB ALDHhi 
cells efficiently expand under serum-free conditions; however, UCB ALDHhi cells will 
rapidly lose an ALDHhi phenotype and acquire a committed megakaryocyte phenotype. 
The differentiation of UCB ALDHhi cells coincides with the loss of islet regenerative 
function. 
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Chapter 4  
4 The Proteome of Human Pancreas-derived Multipotent 
Stromal Cells Restricts Adipogenesis, Drives Cell Division 
and Defines a Unique Surface Marker Profile 
4.1 Introduction  
Since initial clinical use for cellular therapy in 1995, human multipotent stromal 
cells (MSC) has been used in over 400 clinical trials reported by the US National 
Institutes of Health (http://www.clinicaltrial.gov/), a reflection of the diverse therapeutic 
potential of MSC 1. Specifically, MSC have demonstrated beneficial therapeutic 
characteristics including proangiogenic, immunomodulatory, and tissue-regenerative 
functions after transplantation in an diverse array of pre-clinical studies and clinical 
applications. Unfortunately, MSC possess phenotypic and functional characteristics 
modified by selective culture conditions in vitro. The absence of a unique molecular 
fingerprint has led to establishment of heterogenous MSC populations as a result of 
different tissue sources, isolation protocols, and culture techniques 2-4.  
In a collective effort to unify the field, the International Society of Cellular 
Therapies (ISCT) established a set of minimal criteria that MSC must demonstrate: 1) 
growth after plastic adherence, 2) a surface marker profile during culture that 
distinguishes MSC from related mesodermal cell lineages (i.e. hematopoietic and 
endothelial), and (3) mesodermal multipotency into bone, cartilage and adipose tissue in 
vitro 5. Specifically, MSC must express stromal cell markers CD90 (Thy-1), CD73 (Ecto-
5'-nucleotidase), and CD105 (Endoglin) during culture; and lack the expression of CD45, 
CD31, CD14, HLA-DR, CD19, CD79a and CD34. However, several studies have 
reported conflicting heterogeneity regarding proposed surface markers expression 6.  
Cultured MSC are dynamically heterogenous and can be segregated into distinct 
subsets based on surface marker expression 7,8, enzymatic activity 9 and/or multipotency 
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in vitro 10. The use of various adult and fetal sources has amplified the complexity of a 
standardized MSC-identity generating tissue-specific MSC populations with unique 
phenotypic, molecular, and functional characteristics in vitro. For example, MSC isolated 
from bone-marrow (BM) express higher levels of CD146 and alkaline phosphatase 
compared to placental-derived MSC; which reflected inherent transcriptional and 
epigenetic differences resulting in enhanced osteogenic potential of BM-MSC in vitro 10. 
Intracellular markers such as vimentin have been utilized to identify MSC populations in 
vitro and in vivo 11, however comparative levels of vimentin and surface marker 
expression between MSC and progeny prevent culture-independent isolation of pure 
MSC populations. Considering MSC are the precursors to ECM-modeling fibroblasts and 
vessel stabilizing pericytes in vivo, a hierarchy of MSC identity an function, akin to the 
hematopoietic system, likely exists in vitro.  
Bone marrow-derived MSC (BM-MSC) is arguably the most widely utilized MSC 
populations in vitro and in vivo, however a limited number of in-depth proteomic and 
functional comparisons between MSC populations from distinct tissue 
microenvironments have been reported. This has limited our understanding of molecular 
and functional diversity across MSC derived from various tissue sources. Therefore, 
insightful experimentation, such as global proteomic characterization, are warranted to 
obtain a foundation of knowledge to support the identification of MSC with robust 
scalability, reduced heterogeneity, and biotherapeutic potential. Herein, we consider BM-
MSC the “gold-standard” of therapeutic MSC populations and utilize the phenotypic and 
molecular fingerprint of BM-MSC to characterize a previously understudied human 
pancreas-derived MSC population 12-14. To our knowledge, this is the first in-depth 
proteomic characterization of human (Pancreas-derived) Panc-MSC combined with 
multiparametric flow cytometry and functional testing in comparison to BM-MSC. 
Specifically, we revealed unique phenotypic, molecular, and functional characteristics of 
Panc-MSC, such as accelerated growth kinetics and restricted adipogenic potential. 
Overall, this study provides novel insights into MSC population that has been previously 
understudied for applications of stem cell biology and regenerative medicine. 
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4.2  Methods 
4.2.1 MSC Culture, Expansion and Growth Dynamics 
BM-MSC Establishment: 
Human BM aspirates were obtained from healthy donors with informed consent from the 
London Health Sciences Centre (London, ON). BM-MSC were established as previously 
described 9. 
 
Panc-MSC Establishment: 
Ricordi-chamber isolated human islets were obtained through the Integrated Islet 
Distribution Program (IIDP, USA). 200 islet equivalents were plated in RPMI 1640 + 
10% FBS for up to 7 days. Between days 5-7, adherent fibroblast-like cells were 
separated from non-adherent islets by media aspiration followed by trypzination and 
filtration using a 40𝜇m cell strainer. Single cell suspensions were subsequently reseeded 
on tissue culture plastic at 4,000 cells/cm2 and expanded in Amniomax-C100TM with 
AmniomaxTM E100 Supplement (Life Technologies). 
 
MSC Culture and Growth Dynamics: 
Panc-MSC and BM-MSC were utilized for experimentation between passage 2-4. In 
order to investigate the growth dynamics of Panc-MSC and BM-MSC, manual 
hemocytometer counts were performed every 24 hours over a 96-hour period. 
Microenvironmental Stiffness: 
To determine how microenvironmental stiffness (kPa) affects the phenotype or 
adipogenic potential of MSC, 24-well silicone-based soft substrate plates coated with 
fibronectin were used to culture MSC under growth or adipogenic conditions (see below). 
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Specifically, MSC were seeded on substrates at 2, 10, 30, 100 kPA stiffness (ExCellness, 
Switzerland).  
4.2.2 Flow Cytometry  
Panc-MSC and BM-MSC were stained with anti-human antibodies for MSC markers 
(CD73, CD105, CD90; BD Biosciences), hematopoietic markers (CD34, CD14, CD45, 
CD133; BD Biosciences), endothelial marker CD31 (BD Biosciences), and the pericyte 
marker CD146 (BD Biosciences). MSC were also co-stained with AldeflourTM (Stem 
Cell Technologies) reagent to determine ALDH-activity and cell viability was assessed 
by co-staining with 7-amino-actinomycin D (7AAD; 5μl; BD Biosciences). Additionally, 
MSC were stained using antibodies for α-SMA, vimentin, adiponectin, STRO-1, and 
HLA-DR (BD Biosciences). Adiponectin and α-SMA (AbCam) were detected using anti-
mouse or anti-rabbit Cy5 secondary antibody (BD Biosciences), respectively. Neural 
lineage markers TUBB3, MBP, and GFAP (AbCam) were also measured on cultured 
MSC and detected using an anti-mouse FITC secondary antibody (Vector). Data was 
acquired using a LSRII flow cytometer at the London Regional Flow Cytometry Facility. 
All data was analyzed using FloJo software (v8.2). 
4.2.3 Immunohistochemistry and Immunofluorescent Analyses 
MSC were cultured on glass coverslips until 60% confluency was achieved. MSC were 
washed twice with PBS prior to fixation with 10% formalin and permeabilization with 
0.1% Triton X-100. Coverslips were stained with hematoxylin and eosin, rinsed with 
deionized water and embedded in an aqueous mounting media. Additional coverslips 
were co-stained with PE-conjugated anti-human CD146 (BD Biosciences) and primary 
rabbit anti-human ALDH1A1 (1:500, AbCam) detected by a goat anti-rabbit FITC 
secondary antibody (1:200, Vector). Additional coverslips were co-stained with APC-
conjugated anti-human STRO-1, PE-conjugated anti-human vimentin (BD-Biosciences) 
and BV421-conjugated anti-human HLA-DR antibodies. Immunofluorescent images 
were counterstained with DAPI (1:1000) or DRAQ5. Colorimetric images were acquired 
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at 40x using an Olympus (BX50) and confocal images were acquired under oil-
immersion at 40x and 63x using a Leica TCS SP8.  
4.2.4 Determination of Mesodermal Multipotency 
Adipogenesis Differentiation Assay:  
MSC were seeded at a density of 1 x 104 cells/cm2 in supplemented Amniomax C100 for 
24 hours. Media was replaced with Complete Adipogenesis Differentiation Medium with 
Adipogenesis Supplement (Life Technologies). Complete media changes occurred every 
3 days. After 10 days, MSC were stained for lipid accumulation using Oil Red O 
(Sigma).  
 
Osteogenesis Differentiation Assay: 
MSC were seeded at a density of 5 x 103 cells/cm2 in Amniomax C100 + supplement for 
24 hours. Media was replaced with Complete Osteogenesis Differentiation Medium with 
Osteogenesis Supplement (Life Technologies). Media was changed every 3 days. After 
21 days, MSC were stained for calcium deposits using Alzarian Red (VWR). 
 
Chondrogenesis Differentiation Assay Protocol:  
MSC were seeded as 5𝜇l micro-masses at a density of 2 x 104 cells/𝜇l in Amniomax 
C100 + supplement for 2 hours. Media was replaced with Complete Chondrogenesis 
Differentiation Medium with Chondrogenesis Supplement (Life Technologies). Media 
was changed every 3 days. After 21 days, chondrocyte pellets were embedded and OCT 
and cryosectioned prior to staining glycosaminoglycans using Alcian Blue (Sigma).  
147 
4.2.5 Label-free Mass Spectrometry 
Lysate protein was subjected to 1D SDS-PAGE fractionation using 12% gels. All MS 
data was collected using a Q Exactive Plus Orbitrap (ThermoFisher Scientific, Waltham, 
MA, USA), as previously described15. Full MS parameters are outlined in the 
Supplementary Table 1. Data analysis was performed using PeaksStudio 7.5 and 
MaxQuant 1.5.2.8. 
4.2.6 RT-qPCR Analysis 
RNA was collected using RNAeasy purification kit (Qiagen) and quantified using the 
Nanodrop ND-100 Spectrophotometer at the London Regional Genomics Center at 
Robarts Research Institute. RNA was converted to 1µg of cDNA per sample using the 
iScriptTM cDNA Synthesis Kit (Bio-Rad, London, Canada) on the Eppendorf Master 
Cycler (Thermo Fisher). cDNA was stored at -80⁰C.  RT-qPCR was performed using the 
SSofast kit (Bio-rad) along with primers ALDH1A1 (Cat#HQP005075), ALDH1A3 
(Cat#HQP005252), MCAM (Cat#HQP011099) and housekeeping gene, GUSB 
(Cat#HQP008583) from GeneCopoeia. Information regarding, PPARG, CEBPA, LPL 
primers used for adipogenesis studies are listed in Table 4. 1.  The relative quantification 
of mRNA was acquired using the CFX96 Real-Time PCR Detection System. 
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Table 4.1 Primer for Adipogenesis RT-qPCR Analyses 
 
 
4.2.7 Statistical Analyses 
The majority of statistical analyses were performed by unpaired student’s t-test between 
BM- and Panc-MSC. Phenotypic analyses during culture on soft substrates were analyzed 
using repeated measures one-way ANOVA with post-hoc Tukey’s t-test. Outliers were 
identified using Grubb’s test; p<0.05. 
 
 
 
Full Name/ Gene Name Primer Sequences 
Peroxisome Proliferator-activated 
Receptor Gamma/PPARG 
FWD: TTCAGAAATGCCTTGCAGTG 
REV: CCAACAGCTTCTCCTTCTCG 
CCAAT/enhancer-binding Protein 
Alpha/CEBPA 
FWD: CAGAGGGACCGGAGTTATGA 
REV: TTCACATTGCACAAGGCACT 
Lipoprotein Lipase/LPL 
FWD: GTCCGTGGCTACCTGTCATT  
REV:TGGCACCCAACTCTCATACA 
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4.3 Results 
4.3.1 Panc-MSC robustly expand ex vivo and express a classical MSC-
like phenotype. 
We have recently reported that the secretome of human BM-MSC stimulated human β-
cell proliferation in vitro 15. During these studies we observed emergence of fibroblast-
like cells that formed colonies adherent to plastic from islets cultured with media 
supplemented with FBS or MSC-generated CM. Fibroblast-like cells were subcultured 
into supplemented AmnioMax C-100 media and compared to BM-MSC for phenotypic, 
functional, and molecular characteristics. Herein, we refer to this cell population as 
pancreatic-MSC (Panc-MSC). 
After colony establishment, Panc-MSC were adherent to tissue culture plastic 
(TCP) and demonstrated spindle-like morphology (Supplemental Figure 1A), albeit the 
size (forward-scatter area) of Panc-MSC was smaller than BM-MSC (Supplemental 
Figure 1B). Panc-MSC underwent robust expansion across several passages under typical 
BM-MSC growth conditions in AmnioMax C-100. Notably, when each MSC subtype 
were seeded at an equal density between passages 2-4, Panc-MSC demonstrated a 2-fold 
increase (*p<0.05) in cell growth kinetics over 4 days compared to BM-MSC, (Figure 
1A). Panc-MSC also expressed classical MSC surface markers, including CD73, CD105, 
and CD90 (Figure 1B-C). Importantly, Panc-MSC did not express surface markers of the 
endothelial (CD31, or PECAM-1) or hematopoietic (CD45, pan-leukocyte) lineages 
(Figure 1D-E). Overall, Panc-MSC demonstrated a classical MSC phenotype and robust 
growth kinetics in plastic adherent culture. 
4.3.2 The multipotency of Panc-MSC is skewed away from 
adipogenesis. 
BM-MSC harbor tri-lineage differentiation potential under pro-differentiation culture 
conditions in vitro 5. Panc-MSC were found to efficiently undergo chondrogenesis and 
osteogenesis marked by the positive identification of glycoprotein (Alcian Blue) and 
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calcium deposition (Alazarian Red), respectively (Figure 1F). Compared to BM-MSC, 
the capacity of Panc-MSC to make adipocytes was restricted, albeit lipid droplet 
formation was consistently detected across all Panc-MSC cell lines. We performed 
transcriptional analysis of adipogenesis-associated mRNA transcripts Peroxisome 
Proliferator-activated Receptor Gamma (PPAR𝛾; PPARG), CCAAT/enhancer-binding 
protein α (CEBP𝛼; CEBPA), and Lipoprotein Lipase (LPL) 10 days after induction in 
differentiative adipogenic media (Figure 1G) and compared to mRNA expression levels 
to MSC harvested before induction. Interestingly, BM-MSC robustly increased 
transcription of PPAR𝛾, CEBP∝, and LPL mRNA (15.8±6.52, 172.6±142.1, 
4549.0±3072.0 fold-increase, respectively); whereas transcriptional adipogenic induction 
was significantly lower in Panc-MSC (1.27±0.29, 0.71±0.33, 2.30±1.44 fold-increase, 
respectively; *p<0.05). Furthermore, the frequency of adiponectin+ cells, detected by 
flow cytometry, generated from Panc-MSC was significantly reduced compared to BM-
MSC (4.40±1.43 versus 22.47±5.02 % of MSC, *p<0.05; Figure 1H). Thus, Panc-MSC 
demonstrated mesodermal multipotency with robust osteogenic and chondrogenic 
potential; however, adipogenesis was transcriptionally and functionally restricted in 
response to pro-adipogenic stimuli. 
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Figure 4.1 Panc-MSC demonstrate spindle-like morphology and decreased forward 
scatter area compared to BM-MSC. (A) Representative photomicrographs of BM-MSC 
and Panc-MSC stained with hematoxylin and eosin. (B) Panc-MSC are significantly 
smaller than BM-MSC under MSC-growth conditions or under adipogenic conditions as 
microenvironmental stiffness is decreased, measured by forward scatter area. Data 
represented as Mean ± SEM (*p<0.05; N=3). Statistical analyses were determined by 
Student’s t-test. 
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Figure 4.2 Panc-MSC demonstrated robust growth kinetics, classical MSC surface 
marker expression and restricted adipogenic potential. (A). Panc-MSC demonstrated 
robust cell expansion kinetics in vitro and generated increased cell number after 96 hours 
in vitro, compared to BM-MSC. (B-C) Representative flow cytometry plots showing 
comparable expression (>95%) of CD73, CD90, and CD105 in BM-MSC and Panc-
MSC. (D) Panc-MSC did not express endothelial or endothelial (CD31) or hematopoietic 
(CD45) lineage markers, respectively. (E) Panc-MSC demonstrated osteogenic and 
chondrogenic differentiation in vitro; however, adipogenic differentiation was 
qualitatively less pronounced than observed in BM-MSC. (F) BM-MSC robustly 
increased transcription of PPARG, CEBPA, and LPL following adipogenic induction for 
14 days. In contrast, Panc-MSC demonstrated a minimal increase of adipogenesis-related 
transcriptional targets after adipogenic induction. β-glucuronidase (GUSB) was used as a 
housekeeping gene. (G) The frequency of Panc-MSC acquiring adiponectin expression 
after adipogenic induction was ~5-fold less than BM-MSC. Data represented as Mean ± 
SEM (*p<0.05; n=3-5). Statistical analyses were determined by unpaired Student’s t-test. 
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Figure 4.3 Panc-MSC exhibit comparable STRO-1 membrane-surface expression 
compared to BM-MSC. (A) Representative confocal images of vimentin and STRO-1 
expression by BM-MSC and Panc-MSC. (B) Representative flow cytometry plots (insert) 
demonstrated comparable expression of STRO-1 between Panc-MSC and BM-MSC, 
measured by MFI.  Data represented as Mean ± SEM (*p<0.05; N=3). Statistical analyses 
were determined by Student’s t-test. 
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4.3.3 Selection of 500 highest expressed proteins generates a unique 
fingerprint for Panc-MSC. 
Proteomic technologies provide a unique opportunity to characterize global 
protein content between related cell types. Using label-free mass spectrometry, we 
identified >7500 unique proteins in the proteome of both BM-MSC or Panc-MSC (Figure 
2A). Principle component analyses of the entire dataset generated a unique signature that 
tightly clustered BM-MSC samples distinct from Panc-MSC samples (Figure 2B). We 
focused our initial analyses on the top 500 (T-500) identified proteins based on 
expression intensity (LFQ). Vimentin was the most abundant protein detected in both 
MSC subtypes and was expressed at comparable levels (BM/Panc; Log10 p=1.14, Figure 
2C). We additionally detected STRO-1 expression on both BM-MSC and Panc-MSC at 
comparable expression levels (Supplemental Figure 2A-B). Furthermore, Panther 
pathway enrichment analysis of the T-500 proteome identified that both MSC-types 
robustly expressed components of integrin signaling (P00034), including ITGB1 and 
ITGA1 (Figure 2D-E). Moreover, both MSC-types produced several secreted ECM 
molecules at comparable levels, although fibronectin-1 (FN1) expression was 
significantly increased in BM-MSC (**p>0.01; Figure 2F). Human Gene Atlas 
enrichment analysis suggested the T-500 proteome of both MSC sub-type was 
statistically comparable to smooth muscle cells, reflected by high expression of α-SMA 
(Figure 2G). On the other hand, BM-MSC were determined to harbor a T-500 proteome 
that was statistically more comparable to adipocytes (*p<0.05), suggesting a distinct 
propensity of BM-MSC to generate cells of the adipocyte lineage compared to Panc-
MSC.  
 Next, we identified differential expressed proteins in the T-500 proteome 
comparing BM and Panc-MSC (Figure 2H). As previously mentioned, expression 
proteins associated with lipid metabolism such as Acetyl-CoA Acyltransferase 2 
(ACAA2), Aldo-Keto Reductase Family 1 Member C2 (ARK1C1), or Hydroxysteroid 
17-Β Dehydrogenase 4 (HSD17B4) were significantly increased in BM-MSC compared 
to Panc-MSC. Conversely, Panc-MSC showed increased expression of the proliferation 
marker Ki67 (MKI67), progenitor cell marker nestin (NES) and intermediate filament 
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keratin 18 (KRT18). Collectively, these proteomic fingerprints established a unique 
protein expression signature distinguishing each MSC sub-types that correlated with key 
functional distinctions including growth kinetics and adipogenic potential.  
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Figure 4.4 Label-free mass spectrometry reveals unique proteomic signatures 
comparing Panc-MSC and BM-MSC. (A) >7500 unique proteins were identified in the 
proteome of MSC subtypes. (B) PCA analysis demonstrated the unique proteomes of 
BM-MSC and Panc-MSC. (C) Top 500 proteins based on LFQ intensities identified 
vimentin as the most highly expressed protein in both MSC populations. (D) Top 500 
proteins were matched to Panther Pathway enrichment annotations and revealed a 
significant enrichment of integrin signaling components (P00034), (E) including the 
expression of ITGB1 and ITGA2 in both MSC sub-types. (F) Extracellular matrix proteins 
were comparably expressed between MSC subtypes, with the exception of FN1 with 
increased expression in BM-MSC. (G) Human Gene Atlas enrichment analyses 
determined the BM-MSC proteome was comparable to adipocytes, whereas both MSC 
populations showed similarities to smooth muscle cells with comparable expression of 
alpha-SMA. Representative confocal photomicrographs of alpha-SMA expression in BM- 
and Panc-MSC.  (H) Out of the top 500 proteins, 8 proteins were upregulated in Panc-
MSC, including Nestin (NES), Ki67 (MKI67) and cytokeratin 18 (CK18).  Selected 
enrichment annotations contained >3 protein hits with p-value cutoff of p<0.01 and 
minimal overlap of 1.5-fold. Data represented as Mean ± SEM (N=3). 
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4.3.4 Panc-MSC demonstrate accelerated competency to pro-neurogenic 
stimuli. 
To further investigate the relevance of elevated Nestin expression in Panc-MSC, we 
determined whether additional neural-lineage markers were detected by mass 
spectrometry that fell below our initial T-500 cut-off. Surprisingly, we identified 15 
additional proteins, expressed in Panc-MSC, associated with the neural lineage (Figure 
3A). This included markers of neurons (Tubulin 3, TUBB3), oligodendrocytes (Myelin 
Binding Protein, MBP) and astrocytes (Glial Fibrillary Acidic Protein, GFAP). GFAP 
and MBP were detected at comparable levels within both MSC-types, however detection 
of TUBB3 was increased 2-fold in BM-MSC. Flow cytometry validated the expression of 
TUBB3, MBP, and GFAP in both MSC subtypes cultured under MSC-expansion 
conditions (Figure 3B).  
To assess the competency of Panc-MSC to respond to pro-neurogenic stimuli in 
vitro, MSC were cultured in Neurocult media for up to 10 days. Compared to 
maintenance in AmnioMax C-100 media, both MSC populations significantly increased 
expression of TUBB3, MBP, and GFAP after 10 days of culture in Neurocult media, 
measured by flow cytometry. Interestingly, Panc-MSC showed significantly elevated 
TUBB3 and GFAP expression within 4-days culture in Neurocult (Figure 3C-E). 
However, the frequency of cells expressing TUBB3 or GFAP remained high when BM or 
Panc-MSC were cultured in either MSC-growth media (AmnioMax C-100) or Neurocult 
(Figure 3F). In contrast, the frequency of MBP+ MSC was significantly increased when 
ether MSC subtype was cultured in pro-neurogenic media (**p<0.01). Collectively, these 
results confirmed both MSC populations expressed neural-lineage markers; albeit, Panc-
MSC were initially more competent to pro-neural stimuli compared to BM-MSC. 
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Figure 4.5 Panc-MSC express neural-lineage markers and respond to neurogenic 
stimuli.  (A) Volcano plot of neural lineage-associated proteins expressed within Panc- 
and BM-MSC. (B) Representative flow cytometry plots validate the expression of neural-
lineage markers Tubulin-3/TUBB3 (neuron), Myelin Binding Protein/MBP 
(oligodendrocyte) and Glial Fibrillary Acidic Protein/ GFAP (astrocyte) during culture in 
Aminomax C-100. After culture in Neurocult, Panc-MSC increased expression of (C) 
TUBB3, (D) MBP and (E) GFAP between 4 – 10 days post-induction. (F) Representative 
confocal photomicrographs of TUBB3, MBP, and GFAP expression in BM- and Panc- 
MSC cultured in Aminomax or Neurocult at 10 days. Bar graphs demonstrate the 
frequency of cells positive for TUBB3, MBP, or GFAP under each condition. Expression 
was measured by geometrical mean fluorescence intensity (MFI) and normalized to 
expression levels of MSC cultured in Aminomax C-100. Data represented as Mean ± 
SEM (n=3). Statistical analyses were determined by unpaired Student’s t-test. 
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4.3.5 Panc-MSC upregulate cell-cycle proteins driving cellular division 
while BM-MSC upregulated proteins associated with lipid 
metabolism. 
Differential protein expression between MSC populations may translate to functional 
characteristics 10. Accordingly, Panc-MSC demonstrated unique functional characteristics 
compared to BM-MSC, including increased growth kinetics and restricted adipogenic 
competency. Our mass spectrometry analyses identified 483 and 383 significantly 
upregulated in BM-MSC and Panc-MSC, respectively (Figure 4A).  Pathway enrichment 
analysis on differentially expressed proteins was performed using Gene Ontology (GO) 
pathway, and Reactome (R-HSA) annotations, uncovered distinguishable molecular 
signatures when comparing the BM- and Panc-MSC populations (Figure 4B). Notably, 
BM-MSC upregulated proteins involved in the metabolism of lipids (R-HSA-556833, 
Figure 4C), whereas Panc-MSC upregulated proteins involved in the control of cell cycle 
and mitosis (R-HSA-1640170, Figure 4D). More specifically, BM-MSC also upregulated 
proteins with small molecule biosynthetic functions, including members of retinoic-acid 
signaling pathways such as ALDH1A3, ALDH2, and STRA6 (Figure 4E). On the other 
hand, Panc-MSC upregulated proteins associated with cell cycle complexes; including 
origin of replication components such as ORC2/6, MCM2/5, GMNN, CCNB1 (Figure 
4F).  Collectively, Panc-MSC and BM-MSC demonstrated protein expression signatures 
that drive distinctive cellular functions such as cell division and lipid metabolism, 
respectively. 
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Figure 4.6 Panc-MSC proteome was enriched for cell cycle proteins and BM-MSC 
proteome was enriched for proteins involved with lipid metabolism.  (A) Volcano plot 
of 418 and 383 proteins significantly increased in the proteome of Panc-MSC (purple dots) 
and BM-MSC (red dots), respectively.  Upregulated proteins from BM-MSC and Panc-
MSC were matched to GO- pathway, Reactome, and BioCarta enrichment annotations. (B) 
10 annotations with smallest adjusted p-values from each cell-type were plotted against the 
number of unique proteins identified within each annotation. (C) Proteins upregulated in 
BM-MSC were strongly associated with the metabolism of lipids annotation (R-HSA-
556833), which included small molecule biosynthetic pathways (i.e. retinoic acid 
production, ALDH1A3). In contrast, (D) Panc-MSC upregulated proteins associated with 
cell cycle annotation (R-HSA-1640170), specifically with (F) mitotic function.  Selected 
enrichment annotations contained >3 protein hits with p-value cutoff of 0.01 and minimal 
overlap of 1.5-fold. N=3, p<0.05. 
165 
4.3.6 Panc-MSC and BM-MSC share common phenotypic proteins, 
however each harbour distinct expression levels and unique surface 
protein expression. 
It is well established that cultured human MSC classically express surface markers 
including CD73, CD105, CD90, however, cell surface marker expression selective for 
tissue specific MSC subtypes is much less well established. We directly compared 
surface marker expression of both Panc-MSC and BM-MSC using mass spectrometry. In 
addition to classical MSC surface marker expression, we identified an additional 64 CD 
surface markers with similar expression levels in both MSC populations, validated by 
flow cytometry (i.e. CD109) using both MSC subtypes (Figure 5A). 15 CD-markers were 
differentially expressed (Figure 5B). Specifically, Panc-MSC showed upregulated 
expression of 7 surface markers, including CD142, CD9, CD168, CD55, CD166, CD97, 
and CD49d (Figure 5B). In contrast, BM-MSC showed upregulated expression of 8 
surface markers including CD63, CD74, CD146, CD318, CD297, CD230, CD304, and 
CD276 (Figure 5B). Interestingly, our mass spectrometry and flow cytometry analyses 
identified the expression of CD14 and HLA-DR (Figure 5C), previously reported to be 
absent from plasma membrane of MSC. Specifically, 6 isoforms of HLA-DR were 
upregulated in the proteome of BM-MSC (Figure 5D-E), albeit only HLA-DRA was 
significantly elevated compared to Panc-MSC. Collectively, these results validated that 
Panc-MSC possessed a unique surface marker profile compared to BM-MSC. 
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Figure 4.7 Panc-MSC demonstrate a unique CD marker expression profile 
compared to BM-MSC. (A) 67 CD markers were detected by label-free mass 
spectrometry that showed comparable expression levels on both Panc- and BM-MSC. 
Validated detected of CD109 using flow cytometry. (B) Volcano plot of CD markers 
significantly upregulated in Panc-MSC (i.e. CD9) and BM-MSC (i.e. CD146). (C) 
Expression of CD14 and HLA-DR surface expression was validated by flow cytometry 
compared to isotype control (green line). (D-E) Several isoforms of HLA-DR were 
upregulated by BM-MSC, compared to Panc-MSC. Horizontal dashed line is 
representative of p<0.05.  N=3 
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4.3.7 Panc-MSC exhibit dampened CD146 expression and retinoic acid-
signaling. 
We sought to further investigate the phenotypic profile of Panc-MSC compared to BM-
MSC generated using label-free mass spectrometry. We determined pericyte marker 
(CD146) expression was reduced at the level of protein translation (25.60±11.19 versus 
76.25±4.02 % of MSC, *p<0.05; Figure 5A-B) and mRNA transcription (0.53±0.05 fold-
increase, *p<0.05; Figure 5C) in Panc-MSC compared to BM-MSC, respectively. 
Furthermore, Panc-MSC expressed dampened levels of ALDH-activity (7.58±2.54 versus 
54.2±9.51 % of MSC, *p<0.05; Figure 6A,6D), measured by cytoplasmic Aldefluor 
accumulation. Aldefluor is reduced to a cell-impermeable product primarily by several 
ALDH family members, which was confirmed at both the level of ALDH1A3 mRNA 
transcription (0.34±0.15 fold-increase, *p<0.05; Figure 6C) and ALDH1A3 protein 
expression (Figure 4E) in Panc-MSC. Interestingly, Panc-MSC had elevated ALDH1A1 
mRNA transcription (59.54±37.13 fold-increase, *p<0.05; Figure 5C) that was detected 
in the proteome (Figure 6E). Furthermore, mass spectrometry detected differential 
expression of several components and/or targets of the retinoic acid signaling pathway 
(Figure 6F-G). In addition to increased ALDH-activity, we identified an increased 
detection of increased detection of retinol transporter (STRA6), alcohol dehydrogenase 
(RDH11), and regulators of retinoic signaling (i.e. DGAT1, DHRS3) in BM-MSC. 
Collectively, a mosaic of phenotype differences, such as dampened CD146 expression 
and retinoic acid-signaling pathways, can distinguish Panc-MSC from BM-MSC in vitro. 
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Figure 4.8 Panc-MSC exhibit reduced expression of pericyte marker CD146 and 
reduced aldehyde dehydrogenase-activity. (A) Representative flow cytometry plots for 
BM-MSC (red) or Panc-MSC (purple) co-stained for pericyte marker CD146 and 
cytosolic ALDH-activity. (B) Compared to BM-MSC, Panc-MSC demonstrated reduced 
expression of pericyte marker CD146, and (C) reduced MSAM (CD146) mRNA 
expression. Panc-MSC also demonstrated increased expression of ALDH1A1 mRNA, 
however ALDH1A3 mRNA expression was reduced compared to BM-MSC. β-
glucuronidase (GUSB) was used as a housekeeping gene. (D) Panc-MSC demonstrated 
(D) reduced ALDH-activity by flow cytometry. (E) CD146 and ALDH1A protein 
expression was confirmed in BM- and Panc-MSC by confocal microscopy. 
Immunofluorescent images were acquired under 40x oil-immersion, scale bar = 20𝝁m. 
(F) Schematic highlighting retinoic acid signaling pathway components with (G) 
differential expression in BM-MSC. Data represented as Mean ± SEM (*p<0.05; N=3-5). 
Statistical analyses were determined by Student’s t-test. 
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4.3.8 Adipogenic potential of Panc- and BM-MSC is independent of 
microenvironment stiffness.   
We sought to further investigate functionally relevant phenotypic differences between 
Panc-MSC compared to BM-MSC generated using label-free mass spectrometry. Pericyte 
marker (CD146) expression was reduced at the level of protein translation (25.60±11.1 
versus 76.25±4.02 % in Panc- versus BM-MSC, *p<0.05; Figure 6A-B) and mRNA 
expression (0.53±0.05 fold difference in Panc- versus BM-MSC, *p<0.05; Figure 6C) . 
Panc-MSC also demonstrated a reduced frequency of cells with high ALDH-activity 
(7.58±2.54 versus 54.2±9.51 % of cells, *p<0.05; Figure 6A,6D), measured by flow 
cytometric assessment of AldefluorTM accumulation. AldefluorTM reagent is reduced to a 
cell-impermeable product primarily by several cytosolic ALDH isoforms, primarily 
ALDH1A family members. ALDH1A3 mRNA expression (0.34±0.15 fold difference in 
Panc- versus BM-MSC, *p<0.05; Figure 6C) and ALDH1A protein expression (Figure 
6E) was decreased in Panc-MSC. Interestingly, Panc-MSC demonstrated elevated 
ALDH1A1 mRNA expression (59.54±37.13 fold-increase, *p<0.05; Figure 6C). Indeed, 
our mass spectrometry data confirmed differential expression of several components of 
the retinoic acid signaling pathway (Figure 6F-G). In addition to increased ALDH1A3 
expression in BM-MSC, we identified an increased expression of retinol transporter 
(STRA6), retinol dehydrogenase 11 (RDH11), alcohol dehydrogenase 2 (ADH2), cellular 
retinoic acid binding protein 2 (CRABP2), and other regulators of retinoic signaling (i.e. 
DGAT1, DHRS3) in BM-MSC. Collectively, a mosaic of phenotype differences, such as 
reduced pericyte marker CD146 expression and retinoic acid-signaling, can distinguish 
Panc-MSC from BM-MSC in vitro.  
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Figure 4.9 Soft culture stiffness increased growth kinetics but did not enhance 
adipogenic differentiation in BM- or Panc-MSC.  (A) A schematic briefly describing 
MSC culture on substrates with a range of Young’s Modulus (2-100kpa) in MSC-growth 
(solid line) or pro-adipogenic media (dashed line). (B) Both MSC subtypes generated 
greater cell numbers after 5 days expansion culture on soft substrate compared to TCP.  
(C) CD105 or (D) CD146 or (E) vimentin expression was not altered when MSC were 
cultured on softer substrates compared to TCP. Similarly, (F) the frequency of cells with 
high ALDH-activity was not changed when MSC were cultured on softer substrates, 
compared to TCP. (G) ∝-SMA expression was not altered by expansion of either MSC 
subtype on soft substrates. (H-J) In response to adipogenic stimuli, Panc-MSC cultured 
on softer substrates reduced (H) ∝-SMA expression compared to TCP, whereas (I) 
vimentin expression was increased in Panc-MSC cultured on 10kPa or 100kPa. Although 
BM-MSC were capable of robust adipocyte formation quantified by adiponectin 
expression (MFI), Panc-MSC cultured on soft substrates remained resistant to adipogenic 
differentiation in vitro. Horizontal dashed lines represent MFI of adiponectin in BM-
MSC or Panc-MSC cultured under expansion conditions in AmniomaxTM media.  Data 
represented as Mean ± SEM (*p<0.05; N=3-5). Statistical analyses were determined by 
repeated measures one-way Anova with post-Hoc Tukey’s t-test, comparing MSC 
subtypes across varying substrate stiffness. 
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4.4 Discussion 
This study employed label-free mass spectrometry and multiparametric flow cytometry to 
determine the proteomic and phenotypic profile of human Panc-MSC, a MSC subtype 
that can be readily isolated from cultured human pancreatic tissue. Using BM-derived 
MSC as the ‘gold standard’ for therapeutic MSC, this study provides novel evidence that 
distinguished Panc-MSC as a tissue-specific MSC population with unique phenotypic, 
molecular, and functional characteristics in vitro. Specifically, Panc-MSC harbour a 
proteome that drives robust expansion kinetics, defines a surface marker profile with 
reduced CD146 and ALDH1A3 expression, and increases competency towards pro-
neurogenic stimuli. Additionally, Panc-MSC were resistant to adipogenic differentiation, 
a feature independent of vimentin expression, or decreased ∝-SMA expression in 
response to decreased microenvironmental stiffness. Collectively, we provide 
foundational proteomic, phenotypic and functional characterizations in vitro, towards a 
tissue-specific MSC whose therapeutic potential has yet to be determined. 
 The prospective purification of MSC from human tissues has been complicated by 
the lack of a selective cell surface marker expression 4 that permits efficient purification 
of MSC. As a result, MSC cultures are highly heterogeneous due to dependence on 
clonogenic expansion using selective media(s) and autonomous adherence to TCP 
dependent on adhesion protein expression and ECM deposition 17. Accordingly, Panc-
MSC readily adhered to TCP and our proteomic analyses demonstrated diverse integrin 
expression accompanied by robust ECM production. Integrins detected on Panc-MSC 
were expressed at comparable levels to BM-MSC, albeit integrin 𝛼-4 (CD49d) was 
upregulated in Panc-MSC. Integrins heterodimers play a vital role in cell migration, 
survival, and proliferation through the prorogation of intracellular signaling networks 17-
19. We did not directly assess the functional relevance of integrin expression in this study.  
Regardless, Panc-MSC exhibited accelerated growth kinetics in vitro compared to BM-
MSC. Further studies are warranted to elucidate the functional roles of integrin 
expression and ECM molecule deposition in the coordination of pro-mitotic signaling in 
Panc-MSC. 
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  To elucidate phenotypic characteristics that distinguish MSC subtypes from 
different tissue sources, we investigated differential CD-marker expression between 
Panc-MSC and BM-MSC. Both MSC subtypes highly expressed cell surface markers 
CD73, CD90, and CD105; and were devoid of CD45 and CD31 expression. These 
characteristics satisfy the minimal criteria to identify MSC colony formation adherent to 
plastic, however our proteomic detection of cell surface marker expression conflicted 
with the current ISCT guidelines 5, which suggest that MSC should be devoid of CD14 
and HLA-DR expression. Here, we validated expression of CD14 on both MSC subtypes 
and elevated HLA-DR expression on BM-MSC. These results and previous reports 6,20,21, 
demonstrate highly sensitive proteomic approaches are required to establish surface 
marker expression within heterogeneous MSC populations. Nonetheless, Panc-MSC and 
BM-MSC demonstrated mesodermal multipotency, vimentin and α-SMA expression, and 
STRO-1 surface marker expression 22,23. Additionally, 64 CD-markers were detected at 
comparable levels between Panc-MSC and BM-MSC, suggesting that a uniform 
phenotype between tissue-specific MSC likely exists.  Conversely, we demonstrated 
differential expression of 15 CD-markers, whose functional roles on MSC remain 
undetermined. For example, CD9 is a multifunctional tetraspanin family member that is 
upregulated in Panc-MSC. Halfon et al. previously reported CD9 was enriched on the 
surface of fibroblasts compared to BM-MSC and was upregulated on BM-MSC with 
extended culture 24.  On the other hand, we observed increased expression of the pericyte 
marker CD146 on BM-MSC. Nestin+/CD146+ MSC have been shown to maintain 
hematopoietic stem cell pools in the perivascular niche of bone marrow 25 and 
purification of CD146+ cells from several human tissue sources can enrich for MSC 
colony forming cells 26.  However, the functional relevance of CD146 expression on 
MSC in vitro remains undetermined. Collectively, we have reported a unique surface 
“fingerprint” for Panc-MSC that reflects a different tissue source of origin. Thus, future 
studies are warranted to elucidate the functional roles of CD-markers identified in this 
study.  
Directed differentiation of MSC in vitro is currently the standard assay for 
assessing progenitor cell multipotency, yet these assays remain primarily reliant on 
qualitative histology. Accordingly, Panc-MSC demonstrated robust osteogenic and 
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chondrogenic potential in vitro, however adipogenic potential was notably restricted with 
Panc-MSC showing small lipid-droplet formation and infrequent Oil Red O staining. We 
build upon these qualitative observations to demonstrate adipogenesis was quantitatively 
restricted in Panc-MSC at the transcriptional and translational level. Proteomic analysis 
revealed BM-MSC demonstrated protein expression patterns similar to adipocytes with 
functions involved in lipid metabolism. Notably, we also detected expression of 
progenitor cell marker Nestin, in Panc-MSC alongside accelerated response to pro-
neurogenic stimuli compared to BM-MSC. It has been proposed that some MSC may 
arise from non-mesodermal tissues, such as the neural crest 27. In addition, it has been 
previously suggested that pancreas-derived MSC may be generated from a ductal 
epithelial-to-mesenchymal transition initiated by culture in vitro 12. Our proteomic 
findings support both these hypotheses, as Panc-MSC also highly expressed epithelial 
cell markers such at KRT18. Conversely, Kubo et al. found that KRT18 was transcribed 
>30-fold higher in BM-MSC 28 compared to fibroblasts, osteoblasts or adipocytes, 
suggesting a better understanding of the functional relevance in Panc-MSC is warranted.  
These observations amongst other studies suggest the multipotency of MSC may be 
tissue-specific and likely entails epigenetic, transcriptional, and translation regulation 
tightly controlled alongside extrinsic microenvironmental cues. Ultimately, the 
development of in vivo functional testing will be required to further understand the true 
multipotent potential of MSC.   
Pathways activated by lipid metabolites drive cellular functions including tissue 
patterning, cell division, cell survival, and differentiation 29.  We identified that BM-MSC 
up-regulated several members of the RA-signaling pathway, including ALDH1A3, 
ALDH2, STRA6 and RDH10. ALDH-activity has been reported to be differentially 
expressed by cells with high proliferative capacity, engraftment, and/or multipotency in 
tissues such as blood, pancreas, or cancer 30,31. We have previously demonstrated 
selection of high ALDH-activity can isolate hematopoietic progenitors with multifaceted 
regenerative functions in vivo 30,32; in addition to enhanced multipotency and growth 
kinetics in vitro. Conversely, BM-MSC with high ALDH-activity did not demonstrate 
enhanced multipotency but instead generated a pro-angiogenic secretome with pro-
vascular functions in vivo 9. Here we report Panc-MSC, with dampened ALDH-activity, 
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demonstrated accelerated growth kinetics in addition to reduced adipogenic potential. 
Thus, the functional role of ALDH-activity in Panc-MSC in vitro remains elusive and the 
pro-angiogenic potential of Panc-MSC in vivo is currently undetermined. 
 It is well established that microenvironmental properties in vitro can affect MSC 
functional characteristics; including, lineage-differentiation and surface marker 
expression 4,16. Talele et al. demonstrated ∝-SMA expression could be linked to 
microenvironmental stiffness and was upregulated in BM-MSC with reduced adipogenic 
capacity. In our studies, we observed comparable ∝-SMA expression between BM- and 
Panc-MSC subtypes with restricted adipogenesis and reduced cell size in Panc-MSC. 
Similar to Talele we observed reducing ∝-SMA expression when Panc-MSC were 
cultured on a softer substrate, however adipogenesis was not recovered by Panc-MSC 
cultured on a microenvironmental stiffness <100kPa. Notably, microenvironmental 
stiffness appeared to have a minimal impact on CD105, CD146, vimentin expression or 
ALDH-activity in both BM or Panc-MSC, suggesting alternate control mechanisms may 
govern the multipotent capacity of MSC in vitro. 
In summary, we employed label-free mass spectrometry and multiparametric flow 
cytometry to characterize the proliferative and multipotent functions of Panc-MSC in 
vitro. The foundational knowledge acquired in this study will support our future 
investigations comparing the regenerative potential of distinct MSC subtypes in vivo, a 
characteristic considered exclusive to MSC populations 33,34. Moreover, proteomic and 
functional differences observed in this study would benefit from complementary 
epigenetic and transcriptional profiling, with specific-focus on RA-signaling pathways, 
adipogenesis, and the functional role(s) of surface marker expression.   
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Chapter 5  
5 Human Pancreas-derived Multipotent Stromal Cells Secrete 
Extracellular Vesicles that Stimulate Microvessel Formation 
5.1 Introduction 
Human multipotent stromal cells (MSC) have been described as regenerative 
‘biofactories’ or ‘sentinals’ of the regenerative response 1,2. However, clinical translation 
of promising preclinical studies utilizing MSC has not fulfilled expectations 3, due to the 
transfer of heterogeneous cells showing transient engraftment 4, poor survival and 
biodistribution 5-7, and/or the loss of pro-regenerative functions after exposure to a 
diseased or inflamed microenvironment 8-11. We recently demonstrated bone marrow 
(BM) MSC may be employed as ‘biofactories’ in vitro to generate a serum-free and cell-
free mixture of effectors that stimulate islet regeneration in hyperglycemic mice 
following intrapancreatic delivery 12,13. Moreover, pharmaceutical manipulation of BM-
MSC in vitro successfully tailored a secretome enriched for pro-regenerative stimuli that 
improved islet regenerative capacity in vivo. Collectively, development of cell-free 
biotherapeutic approaches for regenerative medicine mitigates many of the translational 
barriers associated with allogeneic MSC transplantation, yet in-depth investigation of the 
biotherapeutic products secreted by various MSC subtypes are required to better 
understand and stimulate the regenerative response.  
 We recently conducted an in-depth proteomic and phenotypic characterization of 
MSC derived from human pancreatic islet preparations (Panc-MSC) that shared classical 
MSC characteristics with BM-MSC. Panc-MSC demonstrated reduced aldehyde 
dehydrogenase (ALDH)-activity and CD146 pericyte marker expression, compared to 
BM-MSC, suggesting functional differences may exist between tissue specific human 
MSC subtypes that can be exploited for therapeutic gain. Although identification of a 
selective cell surface or functional phenotype to distinguish MSC from differentiated 
progeny has been met with limited success 14; the capacity for MSC isolated from 
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different tissues to coordinate complex regenerative processes, such as angiogenesis, may 
arguably segregate therapeutic MSC from non-therapeutic sources 15. Because Panc-MSC 
are derived from healthy islets containing an intricate microvascular network 16, we 
hypothesized Panc-MSC would possess a vascular supportive or pro-angiogenic 
secretome. 
The secretome generated by MSC contains a complex mixture of regenerative 
stimuli, in the form of protein, bioactive lipids and nucleic acids that contribute to tissue 
regeneration in vivo 17,18. Notably, extracellular vesicles (EVs) secreted into the 
peripheral microenvironment or circulation facilitate the transportation of regenerative 
stimuli from tissue-specific MSC subtypes to target cells 19-21. EVs can be subclassified 
based on their size and cellular-origin; moreover, MSC-derived EVs are phenotypically 
distinct from apoptotic bodies 22. Small extracellular vesicles or exosomes (30nm-100nm) 
are generated through the endosomal pathway and are actively released through 
exocytosis. In contrast, larger EVs referred to as microparticles (100nm-1µm) are 
generated by blebbing of the cytoplasm and localized ‘pinching’ of the plasma 
membrane, leading to the direct release of microparticles to the surrounding 
microenvironment or systemic circulation. Despite containing the parent cell cytoplasmic 
components, EVs are packaged with a unique set of cargo (bioactive proteins, lipids and 
RNA moieties) within an intact a bilayer membrane. Although generation of both 
exosomes and microparticles represents a highly regulated cellular process, 
understanding of the mechanisms by which MSC organize the generation and delivery of 
EVs to areas of tissue damage is warranted for regenerative medicine applications. We 
have recently demonstrated EVs-derived from Panc-MSC contain a diversity of cargo 
including proteins, lipids, and nucleic acids using surface-enhanced Ramen spectroscopy 
18, although the functional significance of this cargo remains to be determined. 
Collectively, the contribution of EVs to the regenerative functions of MSC 
requires further investigation to: 1) better understand cellular communication 
mechanisms driving tissue regeneration 2) to identify vascular regenerative stimuli that 
may improve therapeutic applications in regenerative medicine. Herein, we demonstrate 
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that Panc-MSC generate a unique pro-angiogenic secretome that promoted endothelial 
cell recruitment, proliferation and microvessel formation in vitro and in vivo. Notably, 
these functions were transmitted primarily within Panc-MSC EV-enriched subfraction 
which accelerated the recovery of blood perfusion in mice with femoral artery ligation-
induced unilateral hindlimb ischemia. 
5.2 Methods 
5.2.1 BM-MSC and Panc-MSC Isolation and Culture 
BM-MSC: 
Human BM aspirates were obtained from healthy donors with informed consent from the London 
Health Sciences Centre (London, ON). BM-MSC were established and cultured in Amniomax-
C100TM media + AmnioMax C100 (Life Technologies) supplement as previously described 23. 
 
Panc-MSC: 
Ricordi-chamber isolated human islets were obtained through the Integrated Islet Distribution 
Program (IIDP) funded by the National Institute of Diabetes and Digestive and Kidney Diseases 
(NIDDK). Panc-MSC were established by plastic adherence during islet suspension cultures and 
expanded as previously described37.  
5.2.2 Enrichment of EVs from MSC Conditioned Media 
Conditioned media (CM) was generated by culturing BM-MSC and Panc-MSC to ~80% 
confluency, rinsed twice with pre-warmed PBS, switched to basal Aminomax C100 
media without supplement and media was collected after 24-hours culture. CM was 
subsequently processed in one of three ways (Supplemental Figure 2). 1) Cell-free CM 
was concentrated (~20-fold by volume) by centrifugation in 3kDa centrifuge filter unit 
for 45 minutes at 2800g. This fraction contained both EVs and soluble proteins >3kDa 
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and is referred to as bulk CM. 2) Cell-free CM was concentrated in 100kDa centrifuge 
filter units for 20 minutes at 2800g. This fraction (EV+) was enriched with EVs and 
proteins complexes larger than 100kDa This fraction was referred to as EV+ CM or EV-
enriched CM. 3) CM which passed through the 100kDA filter was centrifuged in 3kDA 
centrifuge filter units for 40 minutes at 2800g to concentrate soluble proteins between 
>3kDa and <100kDA size. This fraction was referred to as EV- CM or EV-depleted CM.  
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Figure 5.1 Concentration of MSC CM and segregation of EV+ versus EV- CM 
subfractions.  
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5.2.3 Pierce 660nm protein quantification 
CM fractions BM- and Panc-MSC subtypes were analyzed for total protein content using 
the detergent compatible reagent to measure 660nm absorbance using a micro-plate 
reader. The membranes of EVs were dissociated using a urea-based lysis buffer 
containing ammonium bicarbonate, DTT, and 20% SDS. Lysed CM was then diluted 
200-fold with an ionic detergent compatibility reagent (Thermo Fisher) incubated for 5 
minutes at room temperature. 
5.2.4 Mass Spectrometry 
Methodological details of protein precipitation, digestion, SFX peptide fractionation, 
liquid chromatography-tandem mass spectrometry, and proteomic data base analysis are 
described thoroughly in Supplemental Methods and previous studies 13,38. 
5.2.5 Directed in vivo Angiogenesis Assay (DIVAA) 
The directed in vivo angiogenesis assay (DIVAA) was performed as per manufacturer’s 
instructions (Trevigen, Gaithersburg, MD, www.trevigen.com). DIVAA angioreactors 
were loaded with 2.0x105 Panc-MSC, 2.0x105 BM-MSC, or with 10𝜇g of BM-MSC or 
Panc-MSC bulk CM suspended in 20𝜇l basement membrane extract. Angioreactors were 
incubated at 37⁰C ex vivo for 10 days prior to subcutaneous implantation into the upper 
dorsal flank of 10-12-week-old nonobese diabetic/severe combined immunodeficiency 
(NOD/SCID) mice. After 10 days, the recruitment of murine endothelial cells into 
implanted angioreactors was quantified by lectin-uptake, detected with a SpectraMax 
plate reader (MolecularDevices, Sunnyvale, CA, www.moleculardevices.com). 
5.2.6 Assessment of HMVEC Survival and Proliferation 
Human Microvascular Endothelial Cells (HMVEC) were seeded at 104 cells/cm2 in 
complete endothelial growth media, EGM-2 (EBM-2 + 5%FBS, IGF, bFGF, EGF, and 
VEGF) for 24 hours. HMVEC were washed twice with pre-warmed PBS and switched to 
serum/growth factor-deprived EBM-2 for up to 48 hours. 40µg total protein of BM-MSC 
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or Panc-MSC CM was supplemented into EBM-2 without serum or growth factors (<5% 
of total culture volume), and 750nM of EdU was added 24 prior to harvest to label 
proliferating cells. HMVEC were harvested at 48-hours and enumerated using automated 
hematocytometer counts (Life Technologies). Harvested HMVEC were divided in half 
prior for detecting EdU incorporation in fixed (10% Formalin) and permeabilized (1x 
Saponin Buffer) cells using the Click-It system with Alexfluor 594 (Life Technologies), 
according to manufacturer’s instructions. Nonpermeabilized HMVEC were co-stained 
with BV421- Annexin V and 7-AAD to assess early apoptosis or cell death, respectively. 
man Microvascular Endothelial Cells (HMVEC) were seeded at 104 cells/cm2 in 
complete endothelial growth media, EGM-2 (EBM-2 + 5%FBS, IGF, bFGF, EGF, and 
VEGF) for 24 hours. HMVEC were washed twice with pre-warmed PBS and switched to 
serum/growth factor-deprived EBM-2 for up to 48 hours. 40µg total protein of BM-MSC 
or Panc-MSC CM was supplemented into EBM-2 without serum or growth factors (<5% 
of total culture volume), and 750nM of EdU was added 24 prior to harvest to label 
proliferating cells. HMVEC were harvested at 48-hours and enumerated using automated 
hematocytometer counts (Life Technologies). Harvested HMVEC were divided in half 
prior for detecting EdU incorporation in fixed (10% Formalin) and permeabilized (1x 
Saponin Buffer) cells using the Click-It system with Alexfluor 594 (Life Technologies), 
according to manufacturer’s instructions. Nonpermeabilized HMVEC were co-stained 
with BV421- Annexin V and 7-AAD to assess early apoptosis or cell death, respectively. 
5.2.7 Nanoscale Flow Cytometry 
Bulk, EV+, and EV- CM from Panc- or BM-MSC were analyzed for the number of 
microparticles/𝜇l. 20𝜇l of each concentrate was diluted to 300𝜇l with 0.22um-filtered 
PBS at room temperature. Microparticles secretion were detected using the A-50 
nanoscale flow cytometer (Apogee), capable of multi-parametric analyses on 
microparticles between 150nm-1000nm diameter 24. 150𝜇l of diluted CM was injected 
and analyzed at 10.5𝜇l/min for 1 minute. The size of secreted microparticles was 
estimated using silca beads ranging 110nm-1300nm using properties of large-angle light 
scatter (LALS) and small-angle light scatter (SALS). Silica beads provide a refractive 
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index (λ=1.42) that is similar to cells (λ=1.35-1.39). The resolution of exosomes 
(<100nm) or large protein complexes compared to background noise was not reliably 
attained based on the limitations of the A-50 nanoscale flow cytometer.    
5.2.8 Atomic Force Microscopy 
EV+ and EV- CM fractions were washed with 0.22um filtered PBS twice, diluted 1:20, 
and CM fractions were pipetted as 10uL microdroplets onto sterile glass coverslips and 
allowed to dry at room temperature in a sterile biological safety cabinet in preparation for 
atomic force microscopy (AFM) imaging. AFM measurements were performed using a 
BioScope Catalyst AFM (Bruker) equipped with NCL tips (NanoWorld) and Nanoscope 
software. Images were recorded in noncontact mode at a line rate of 0.5 Hz and processed 
using post-acquisition software Gwyddion.  
 
5.2.9 Visualization of EVs derived from Panc-MSC 
CM generated by BM-MSC or Panc-MSC was incubated for 40 minutes at room 
temperature with 1uM of Cell Tracker CTMPX, a fluorescent dye that becomes a 
membrane intercalated product. CTMPX-labelled CM was used to visualize EVs and 
semi-quantify uptake by HMVEC using flow cytometry and confocal imaging. 
Specifically, CTMPX-labelled CM was processed to generate EV+ and EV- CM. EV- 
CM was used as a negative control, as this fraction is devoid of membrane structures that 
retain CTMPX fluorescence. CMPTX+ EVs were visualized using oil immersion 
confocal imaging at 63X with 4x digital zoom (Leica TSP8).  
 
5.2.10 EV Uptake by Human Endothelial Cells 
To confirm EV- CM was devoid of EVs, HMVEC were cultured in EBM-2 with equal 
volumes of CMTPX labelled CM separated into EV+ and EV- fractions. Geometric mean 
fluorescent intensity (MFI) was measured at 0.5, 1, and 12 hours using a LSRII flow 
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cytometer. Furthermore, CTMPX-labelled EV+ CM uptake was spiked at increasing 
doses into single-cell suspensions of 1.0 x 106 HMVEC and immediately measured using 
MFI via flow cytometry. 
Additionally, CTMPX+ EV uptake was visualized by adding CTMPX+ EV+ or 
EV- CM to serum-free HMVEC cultures for up to 12 hours. Confocal images were 
acquired at 1 or 12 hours after CFMPM-labelled HMVEC were fixed using 10% formalin 
and counterstained with DAPI. EV and CMPTX internalization were visualized through 
the Z-plane at 0.1𝜇m increments under 63x oil immersion and 2x digital zoom (Leica 
TSP8).   
5.2.11 HMVEC Tubule Formation 
To assay for tubule forming function in vitro, 1.2x105 HMVEC were cultured on growth 
factor-reduced Geltrex matrices (LifeTechnologies) in EGM-2, EBM-2 or EBM-2 
supplemented with 30ug of bulk, EV+ or EV- CM generated by BM-MSC or Panc-MSC.  
After 24 hours, four photo-micrographs were taken per well, and complete tube formation 
was quantified by manual counting in a blinded fashion using open-source Fiji Image 
Analysis Software.   
5.2.12 Femoral Artery Ligation and Transplantation 
Unilateral hind limb ischemia was induced in anesthetised (100mg/kg ketamine/xylazine, 
maintain with 2% isoflurane, 0.8L/min) NOD/SCID mice via surgical ligation and 
cauterization of the femoral artery and vein (FAL), as previously described 39. Mice with 
unilateral hind-limb ischemia (perfusion ratio <0.1), were transplanted 24-hours after 
surgery (Day 0) with 40𝜇g total protein intramuscularly (i.m) injected (20𝜇L) at 3 sites in 
the thigh muscle and one site in the calf muscle. As a vehicle control, mice received i.m.-
injections of 80𝜇l of basal AminomaxTM C100 media.  
5.2.13 Laser Doppler Perfusion Imaging 
Anesthetised mice were warmed to 37ºC for 5 minutes and hindlimb blood perfusion was 
measured using Laser Doppler perfusion imaging (LDPI) as previously described 39. 
189 
Recovery of blood flow was quantified on 3-, 7-, 14- and 21-days post-transplantation by 
quantifying the perfusion ratio (ischemic/non-ischemic limb) of transplanted mice.  
5.2.14 Endothelial Cell Density 
Adductor muscle from ischemic and non-ischemic thighs were harvested at Day 28, 
embedded in OCT, and cryosectioned (14𝜇m) to obtain three sections per slide ≥100𝜇m 
apart. Cryosections were fixed in 10% formalin (Sigma) and blocked with 5% serum. 
CD31+ area was quantified at 21-days post-transplantation using rat anti-mouse CD31 
(BD Biosciences; 1:100) detected with alkaline phosphatase-labelled rabbit anti-rat 
secondary antibodies (Vector; 1:200) stained with Vector Blue (Vector). CD31+ cell area 
was enumerated using 3 randomly selected fields of view per section, totaling 9 images 
per limb. Images were converted to RBG stack and threshold of was set between 180-210 
using Fiji Image Analysis Software.  
5.2.15 Statistical Analyses 
Analysis of significance was performed by one-way ANOVA with Tukey’s multiple 
comparisons tests for all in vitro or in vivo experiments and enumeration of histological 
analyses. Outliers were identified using Grubb’s test; *p<0.05. 
 
5.3 Results 
5.3.1 The secretome of Panc-MSC was enriched for proteins that 
contribute to vascular development, wound response, and 
chemotaxis 
We recently demonstrated Panc-MSC express tissue-specific MSC characteristics, 
however, the therapeutic potential of Panc-MSC is currently undetermined. We 
considered BM-MSC as the gold-standard of therapeutic MSC and utilized the secretome 
of BM-MSC as a comparator for the secretome of Panc-MSC. Using label-free mass 
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spectrometry we detected >1700 proteins in bulk CM generated by both MSC-types 
(Figure 1A), and 540 proteins were considered secreted effectors based on GO-
terminologies. 343 of the 540 secreted proteins were detected at equivalent levels in both 
MSC subtypes (Figure 1B), referred to herein as the shared MSC secretome. GO-pathway 
enrichment analyses determined the majority of shared MSC secretome (182/343) were 
associated with wound response, vascular development, and/or inflammation 
(Supplemental Figure 1A-B). Specifically, 54 of these 182 proteins were associated with 
overlapping (>1) GO-pathway annotation (Figure 1B), and 12 proteins were associated 
with all 3 GO-pathway terminology and included pleiotropic signals including WNT5A, 
TIMP1, HGF, TGFB1, IL-6 and CCL2. Alternatively, Panther pathway enrichment 
analysis determined the shared MSC secretome was enriched with proteins associated 
with integrin signaling and angiogenesis (Supplemental Table 1-2). 
 Of the 540 shared secreted proteins, 115 and 82 were significantly upregulated 
(total=197 differentially expressed) in the secretome of Pan-MSC or BM-MSC, 
respectively (Figure 1C; Supplemental Figure 1C). GO-pathways enrichment analyses 
suggested there was a significant representation (95/197=48%) of differentially expressed 
proteins that have functional contributions towards wound response (GO:0009611), 
chemotaxis (GO:0006935), and/or blood vessel development (GO:0001568). 54 of these 
proteins were exclusively associated with a single GO-pathway annotation term (Figure 
1D), 27 of which were significantly upregulated in Panc-MSC. Moreover, 41 differential 
proteins were associated with 2 or more GO-pathway annotations (Figure 1E), 27 which 
were significantly enriched in the secretome of Panc-MSC.  Specifically, the secretome 
of Panc-MSC was significantly enriched with proteins that contribute to chemotaxis and 
blood vessel development (i.e. Platelet-derived Growth Factor D/PDGFD).  
 We previously demonstrated the secretome of BM-MSC with high ALDH-
activity can stimulate robust endothelial cell recruitment in a murine model of endothelial 
cell chemotaxis 23. Accordingly, we used the directed in vivo angiogenesis assay 
(DIVAA) methodology to assess the capacity of BM-MSC or Panc-MSC to recruit 
endothelial cells in vivo (Figure 1F). Interestingly, BM-MSC or Panc-MSC seeded in 
angioreactors did not stimulate endothelial cell recruitment, compared to vehicle controls. 
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In contrast, concentrated CM generated by Panc-MSC significantly stimulated the 
recruitment of murine endothelial cells, compared to vehicle controls (Figure 1G). 
Collectively, these results suggest the secretome of Panc-MSC is enriched for proteins 
involved in chemotaxis, wound response and vascular development compared to BM-
MSC; however, there exists a comparable functional capacity to stimulate endothelial cell 
chemotaxis in vivo. 
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Figure 5.2 The secretome of Panc-MSC was enriched for pro-vascular proteins that 
stimulate endothelial cell recruitment in vivo.  Conditioned Media (CM) generated by 
BM-MSC or Pan-MSC was analyzed by label-free mass spectrometry. (A) Mass 
spectrometry identified 1912 and 1872 unique proteins in the secretome of BM-MSC and 
Panc-MSC, respectively. Identified proteins filtered using GOCC analysis identified 540 
secreted proteins were shared in the secretome of BM-MSC and Panc-MSC. Of the 
secreted proteins identified, 343 secreted proteins were equally expressed, 115 secreted 
proteins were upregulated in the secretome of Panc-MSC, whereas 82 secreted proteins 
were upregulated in the secretome of BM-MSC (*p<0.05). (B) Of the 343 shared 
proteins, 182 were associated with Inflammation, Response to Wounding, or Blood 
Vessel Development. Specifically, 8 of the 182 shared proteins were associated with all 3 
GO-terms. (C) Differentially expressed proteins cross referenced to GO-pathway 
database revealed a significance enrichment of pro-vascular proteins in the secretome of 
Panc-MSC. Specifically, (D) differentially expressed proteins associated with one GO-
pathway annotation or (E) multiple annotations were enriched in Panc MSC CM. (F) 
Schematic of 2.5 x105 MSC or 20µg MSC CM-loaded DIVAA angioreactor implantation 
into NOD/SCID mice. (G) Panc-MSC CM significantly increased endothelial cell 
recruitment compared to vehicle or cellular controls. Data represented as Mean ± SEM 
(*p<0.05; N=3, n=3). Statistical analyses were determined by one-way ANOVA with 
Tukey’s post-hoc test. 
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Figure 5.3 GO-Pathways Analysis of Panc-MSC and BM-MSC Conditioned Media. 
Label-free mass spectrometry was performed on concentrated conditioned media 
generated by human BM-MSC or Panc-MSC. (A) Pathways networks and (B) pathway 
enrichment analyses demonstrate the secretome of both MSC-types are enriched with 
proteins that have functional roles in wound response, blood vessel development and 
chemotaxis. 
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Table 5.1 Protein enrichment analysis on the secretome of of Panc-MSC cross-
referenced to the Panther 2016 Database. 
 
Table 5.2 Protein enrichment analysis on the secretome of BM-MSC cross-
referenced to the Panther 2016 Database. 
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5.3.2 Panc-MSC CM increased HMVEC proliferation and survival. 
Blood vessel regeneration requires fine-tuned orchestration of endothelial cell 
recruitment, proliferation, and tube formation. We have previously demonstrated the 
secretome of BM-MSC can support HMVEC survival, proliferation, and tube formation 
in vitro 23. Accordingly, we sought to investigate whether CM generated by Panc-MSC 
similarly supported HMVEC survival and/or proliferation under serum and growth 
factor-starved conditions in vitro. After 48 hours culture under starvation conditions in 
EBM-2 without serum or growth factors, HMVEC supplemented with 40𝜇g of CM 
generated by BM-MSC or Panc-MSC demonstrated increased cell survival (**p<0.05, 
Figure 2A) and proliferation (**p<0.01; Figure 2B). The frequency of HMVEC 
undergoing apoptosis (Annexin V+/7-AAD-) was reduced when EBM-2 was 
supplemented with BM-MSC or Panc-MSC CM (**p<0.01; Figure 2C). Moreover, the 
frequency of dead cells (Annexin V+/7-AAD+) was also reduced when HMVEC were 
supplemented with BM- or Panc-MSC generated CM (Figure 2D). As a result, the total 
number of viable HMVEC was significantly increased after 48 hours, when HMVEC 
cultures were supplemented with BM- or Panc-MSC CM under starvation conditions 
(**p<0.01; Figure 2E). Collectively, these results demonstrated the capacity of Panc-
MSC CM to support HMVEC survival and proliferation in vitro was comparable to BM-
MSC CM. 
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Figure 5.4 Panc-MSC CM promoted endothelial cell survival and proliferation 
under growth-factor and serum-starved conditions in vitro. HMVEC were cultured up 
to 48 hours in EBM-2 without serum or growth factors with or without 40µg of BM-MSC 
CM or Panc-MSC CM. As a control for optimal HMVEC growth, HMVEC were also 
cultured under EGM-2 conditions. (A) Panc-MSC increased the frequency of EdU+ 
HMVEC after 48 hours. Panc-MSC CM increased (B) viable HMVEC frequency by 
decreasing the frequency of (C) apoptotic and (D) dead HMVEC after 48 hours. (E) Total 
viable HMVEC cell number was increased after 48 hours.  Data represented as Mean ± 
SEM (*p<0.05; n=3). Statistical analyses were determined by one-way ANOVA with 
Tukey’s post-hoc test 
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5.3.3 Panc-MSC CM contains extracellular vesicles 
We have recently demonstrated using custom fabricated nano-hole trapping and surface 
enhanced Ramen-spectrometry that the secretome of Panc-MSC contains vesicle-like 
structures with packaged cargo including proteins, lipids, and nucleic acids 18. Because 
this technique does not assess vesicle size or distinguish the identity of common markers 
in the EV membrane (i.e. CD9, CD63, or CD81), we identified an enrichment of proteins 
associated with exosomes within bulk Panc-MSC generated CM, according to the 
ExoCarta database (exocarta.org) and FunRich (funrich.org) functional enrichment 
analyses (Figure 3A).  Accordingly, we detected a high abundance of the EV membrane 
markers CD9, CD63, and CD81 in the secretome of Panc-MSC (Figure 3B). EV-
associated proteins such as Pyruvate Kinase M1/2 (PKM) or Tumor susceptibility gene 
101 (TSG101) were also detected. The detection of EVs by conventional flow cytometry 
is limited by resolution of particle size and obscuration from sample debris, 
underestimating EV concentrations in analyzed samples 24. To address this, we employed 
nanoscale flow cytometry to measure microparticle content in EV-enriched (EV+) and 
EV-depleted (EV-) CM (Figure 3C).  The number of detectable microparticles (170nm-
1𝜇m) was increased above media control only in EV+ CM, whereas the number of events 
in EV- CM did not exceed background measurements (Figure 3D). Interestingly, the 
majority of total protein by mass for both BM-MSC and Panc-MSC was contained within 
the EV- CM fraction (Figure 3E). The majority of microparticles detected were relatively 
small (170-250nm) and aligned with the size range of microparticles (Figure 3F). Atomic 
force microscopy (AFM) was used to visualize the enrichment of EVs after ultrafiltration 
(Figure 3G). EV+ CM contained many vesicle-like structures demonstrating appropriate 
microparticle dimensions and morphology, whereas vesicle-like structures were not 
observed in EV- CM. Collectively, these results demonstrate Panc-MSC secrete EVs and 
ultrafiltration is sufficient to segregate EVs from vesicle-free proteins. 
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Figure 5.5 Panc-MSC secrete extracellular vesicles that can be detected by nano-
scale flow cytometry. (A) Mass spectrometry analysis identified 1298 unique proteins in 
the secretome of Panc-MSC and BM-MSC that were associated with exosomes using 
FunRich enrichment analysis. (B) Mass spectrometry detected proteins associated with 
extracellular vesicles, including CD63, CD81, CD9, PKM or TSG101 in the secretome of 
both BM-MSC and Panc-MSC. (C) Representative nanoscale flow cytometry plots, 
acquired using Apogee A-50 and calibrated using silca beads ranging from 178 to 
1300nm, demonstrated only bulk and EV+ CM fractions exhibited detectable 
microparticle detection. (D) On the other hand, levels of microparticles in EV- CM was 
not detectable above background levels observed with media (horizontal dashed line). (E) 
Total protein measured by 660nm spectrophotometry revealed the majority of bulk mass 
was contained within EV-CM. Tot. Vol = Volume of CM after typical ultrafiltration 
when 10mL of CM was concentrated. (F) Size distribution of EVs detected by nanoscale 
flow cytometry. (G) Representative atomic force microscopy image demonstrating 
enrichment of EVs within EV+ CM. Data represented as Mean ± SEM (*p<0.05; n=3-4). 
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5.3.4 HMVEC demonstrate uptake of EVs generated by Panc-MSC 
EVs contain bioactive cargo enclosed by a plasma membrane that can up taken by target 
cells either through endocytosis or fusion with the plasma membrane 25. To assess 
whether endothelial cells were competent to EVs generated by Panc-MSC, we incubated 
cell-free CM with a fluorescent label (CMTPX red) that is metabolized to a membrane 
impermeable by-product (Figure 4A). This approach ensures that only vesicles with 
enzymatic activity would retain CTMPX and free CTMPX(<3kDa) would be removed 
during CM concentration and purification into EV+ and EV- subfractions.  CTMPX+ 
vesicle-like structures were observed using oil-immersion confocal microscopy and 
diameters validated EV sizes detected by nanoscale flowcytometry and AFM (Figure 
4B). HMVEC cultured with CMTPX-labelled EV+ CM demonstrated distinct 
accumulation of CMTPX after 12 hours whereas, HMVEC supplemented with EV- CM 
did not accumulate CTMPX fluorescence above non-supplemented HMVEC controls 
(Figure 4C). Furthermore, rapid accumulation of CMTPX+ fluorescence was observed 
within 400ms of exposure to labelled EV+ CM, and accumulation of CMTPX 
fluorescence occurred in a dose-dependent manner (Figure 4D). Next, we wanted to 
determine whether CTMPX+ accumulation in HMVEC was a result of vesicle 
internalization or vesicle fusion to the plasma membrane. Accordingly, HMVEC were 
first labelled with CMFPR (green) to define cytoplasmic contents and incubated with 
either CMTPX-labelled EV+ or EV- CM. Robust CMTPX internalization was observed 
after HMVEC were cultured with EV+ CM for 1 hour, suggesting active EV uptake in 
HMVEC via an endocytotic mechanism. In contrast, CMTPX internalization was not 
observed in HMVEC cultured with EV- CM for up to 12 hours (Figure 4E). High 
resolution oil-immersion confocal microscopy detected the presence of CMTPX+ vesicle-
like structures in both the plasma membrane and cytoplasm of HMVEC (Figure 4F). 
Thus, HMVEC EV uptake demonstrated characteristics consistent with EV 
internalization to the cytoplasm and fusion at the plasma membrane. 
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5.3.5 Classical EV-markers were exclusively detected in EV+ CM 
It is well established that EVs contain specific cargo distinct from the parent cytoplasm. 
However, currently undetermined is the identities of proteins exclusively released within 
EVs versus conventional vesicle-free exocytosis from the parent cell. We employed an 
additional label-free mass spectrometry screen on EV+ versus EV- CM generated by 
Panc-MSC to investigate proteomic make-up of each compartment.  Although we have 
previously demonstrated EV- CM contained the majority of bulk protein content based on 
660nm spectrophotometry, we determined the EV+ CM fraction contained a significantly 
more protein diversity compared to EV- CM. Specifically, we detected 1458±63.02 
versus 877.30±78.19 proteins in EV+ CM versus EV- CM, respectively (Figure 5A). 
PCA analysis demonstrated a clear distinction between the proteomic profile of EV+   
 
Figure 5.6 HMVEC uptake EVs generated by Panc-MSC. (A) Panc-MSC and BM-
MSC CM was stained with Cell Tracker CTMPX, allowing for the labelling of EVs. (B) 
Representative oil immersion confocal photomicrograph of Panc-MSC EV+ CM 
labelled with Cell Tracker CTMPX. (C)  Representative flow cytometry plots 
demonstrate that only the EV+ CM fraction was able to increase the Cell Tracker 
CTMPX fluorescence in HMVEC, as measured by geometric mean fluorescence 
intensity (MFI).   (D) HMVEC in single cell suspension were exposed to increasing 
amounts of CTMPX-labelled EVs and immediately analyzed for CMTPX accumulation 
up to 400s by MFI. (E) CMTPX-labeled EVs were detected within HMVEC at 1 hour 
and (F) visualized in the Z-plane using oil immersion confocal imaging at 63x oil and 
2x digital zoom. Data represented as Mean ± SEM (*p<0.05; n=3). 
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Figure 5.7 Panc-MSC EV+ CM demonstrates a diverse proteomic profile with 
exclusive enrichment of EV-associated proteins. Panc-MSC CM was processed into 
EV+ CM and EV- CM and analyze by mass spectrometry.  (A) ~1450 and 870 proteins 
were quantified in EV+ or EV- CM, respectively. (B) PCA analysis demonstrates distinct 
composition between EV+ and EV- CM. (C) Specifically, expression levels of 1047 
proteins were equally detected, whereas 637 proteins were exclusively detected in at least 
1 EV+ CM. On the other hand, 74 proteins were exclusively detected in at least 1 EV- 
CM. (D) Volcano plot of comparably detected proteins. EV+ CM was significantly 
enriched for ECM molecules, such as FN1, and POSTN. (F) Of the 637 proteins 
exclusive to 1 of 3 EV+ CM, 142 were detected in 3 of 3 EV+ CM samples. (G) Of the 
74 proteins exclusive to EV- CM, 18 were detected in 3 out of 3 EV- CM. Data 
represented as Mean ± SEM (*p<0.05; n=3). 
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versus EV- CM (Figure 5B). Although 1047 common proteins were detected in both EV+ 
or EV- CM (Figure 5C), 322 of these proteins were significantly enriched in the EV+ CM 
fraction, whereas 180 proteins were significantly enriched in the EV- CM fraction (Figure 
5D). Proteins with increased abundance in EV+ CM included several ECM   
molecules (i.e. COL1A2, COL6A2, COL5A, FN1) and two isoforms of Periostin 
(POSTN). On the other hand, EV- CM was significantly enriched for proteins including 
SERPINB6/7, CD201/PROCR, and Tissue Factor/TF.  
 Next, we investigated which proteins were robustly and exclusively detected in 
each CM fraction. 637 proteins were detected in at least 1 of 3 EV+ CM sample and 
exclusively absent from 3 out of 3 EV- CM samples. We filtered these 637 unique 
proteins to include only those which were detected in 3 out of 3 EV+ CM samples. These 
subsequent analyses identified 142 proteins that are robustly expressed and exclusively 
detected in the Panc-MSC EV+ CM fraction (Figure 5E). Proteins exclusive to EV+ CM 
included classical EV markers such as CD9, CD81, CD63 and PKM; and 
regenerative/pro-angiogenic proteins ALDH1A1, ANGPT1, and WNT5A. In contrast, 74 
proteins detected in at least one EV- CM sample and excluded from EV+ CM were 
identified. We filtered these 74 unique proteins to only those detected in 3 of out 3 EV- 
CM samples, in return identifying 18 proteins with robust expression that exclusively 
detected in EV- CM (Figure 5F). Collectively, these results confirmed the segregation of 
EVs using ultrafiltration and provide novel insight into proteins which may be 
exclusively secreted within EVs by Panc-MSC.  
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5.3.6 HMVEC tubule formation was enhanced by CM fractions 
generated by Panc-MSC 
CM generated by Panc-MSC supported endothelial cell proliferation and survival (Figure 
2). To determine whether Panc-MSC CM could support HMVEC tubule formation, 
HMVEC in seeded on Geltrex media and treated with Panc-MSC CM subfractions in 
vitro. After 24 hours, we observed a significant increase in the number of tubules formed 
by HMVEC supplemented with Panc-MSC bulk CM (Figure 6A), compared to EBM-2 
without supplements (*p<0.05). Furthermore, when Panc-MSC CM was segregated into 
EV+ CM and EV- CM, both subfractions enhanced tubule formation compared to EBM-2 
conditions (*p<0.05; Figure 6A). Collectively, the soluble and EV secretome 
compartments from Panc-MSC equally supported endothelial tubule formation under 
serum-deprived culture conditions in vitro.  
 
5.3.7 Intramuscular-injection of Panc-MSC EV+ CM enhanced recovery 
of blood perfusion in mice with hindlimb ischemia 
Although MSC demonstrate diverse pro-regenerative functions in vitro, transplantation of 
MSC has produced modest and often inconsistent results due to culture-induced 
functional heterogeneity, poor cell engraftment and transient cell survival. We recently 
demonstrated direct injection of MSC-generated CM can facilitate tissue regeneration in 
a model of 𝛽-cell regeneration, eliminating the requirement for cell transfer to stimulate a 
regenerative cascade 12. Therefore, we investigated the vascular regenerative potential of 
Panc-MSC CM following direct intramuscular injection and determined if vascular 
regenerative stimuli were contained in EV+ and/or EV- CM compartments. Mice with 
unilateral hind-limb ischemia received 4 x 20𝜇g injections of bulk, EV+ or EV- CM 
(Figure 6B) 24 hours following femoral artery/vein ligation and excision. Specifically, 
two injections were proximal to site the site of ligation, one immediately distal to 
ligation, and one into the calf muscle. Unconditioned media of equal volume was injected 
as a vehicle control. Interestingly, only EV+ CM significantly increased blood perfusion 
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(days 14 and 21), compared to vehicle control (*p<0.05; Figure 6C). Recovery of blood 
perfusion (Figure 6C, insert), measured by area under the curve (AUC), was significantly 
improved in mice that received bulk (*p<0.05) or EV+ CM (**p<0.01). Accelerated 
recovery of perfusion was not observed in mice that received i.m. injections of EV- CM 
and was statistically comparable to the injection of vehicle control. Collectively, these 
results provide foundational evidence that the secretome of Panc-MSC contains vascular 
regenerative stimuli contained primarily within extracellular vesicles. 
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Figure 5.8 Panc-MSC CM supports HMVEC tubule formation in vitro and supports 
the recovery of hindlimb blood perfusion in vivo.  (A) Representative 
photomicrographs at 24-hours of HMVEC tubule formation following culture with 
(30µg) of bulk, EV+, or EV- CM generated by either Panc-MSC or BM-MSC. Panc-
MSC bulk, EV- and EV+ CM significantly increased HMVEC tubule formation under 
EBM-2 conditions. (B) Schematic of femoral artery ligation (x) and cauderization (c) 
sites and laser doppler perfusion imaging following intramuscular transplantation of 
Panc-MSC CM fractions into NOD/SCID mice. (C) Intramuscular injection of bulk or 
EV+ CM significantly improved hindlimb perfusion over 28 days (insert). Specifically, 
EV+ increased hind limb blood perfusion at days 14 and 21 post-transplantation. Data 
represented as Mean ± SEM (*p<0.05; n=3-6). Statistical analyses were determined by 
one-way ANOVA with post-hoc tukey’s t-test. 
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5.3.8 Injection of Panc-MSC CM increased vessel density in ischemic 
thigh muscle. 
Microvascular density was assessed in the thigh muscles of mice 28 days after Panc-MSC 
CM injection (Figure 7A). Consistent with improved perfusion induced by Panc-MSC 
subfractions, mice I.M.-injected with bulk or EV+ CM showed significantly increased 
CD31+ cell area (3.13±0.46 or 3.53±0.40 CD31+ % of area, respectively), compared to 
mice injected with unconditioned media control (1.83 ± 0.35 CD31+ % of area; Figure 
7B). In contrast, mice injected with EV- CM fraction did not demonstrate significant 
recovery of blood vessel area (2.39 ± 0.28 CD31+ % of area). Collectively, bulk and EV+ 
CM generated by Panc-MSC stimulated the recovery of hind-limb blood perfusion which 
coincided with increased vessel density in the ischemic thigh muscles of NOD/SCID 
mice with femoral artery ligation-induced unilateral hindlimb ischemia.  
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Figure 5.9 Revascularization of thigh muscle tissue is stimulated after i.m. injection 
of Panc-MSC CM. Thigh muscles were harvested at Day 28 from NOD/SCID mice with 
hindlimb ischemia that received intramuscular injections of Panc-MSC CM. (A) 
Representative photomicrographs demonstrate Panc-MSC bulk and EV+ CM 
significantly increased CD31+ area in ischemic thigh muscles, compared to vehicle 
control. Conversely, i.m. injection of EV- CM did not significantly increase CD31+ area, 
compared to vehicle control. Data represented as Mean ± SEM (*p<0.05; N=5). 
Statistical analyses were determined by one-way ANOVA with post-hoc tukey’s t-test. 
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5.4 Discussion 
MSC hold notable therapeutic potential and can be isolated from a diverse selection of 
tissue sources. However, it is currently undetermined whether a pro-vascular secretome is 
uniform across MSC isolated from different tissue types. We provide novel evidence that 
human Panc-MSC possess a unique secretome containing vascular regenerative stimuli, 
primarily packaged into EVs, that demonstrates proangiogenic function when injected 
into ischemic muscle. These characteristics combined with ease of MSC expansion after 
cadaveric islet harvest suggests that Panc-MSC CM may serve as a biotherapeutic agent 
to support vascular regenerative therapy. We demonstrated: 1) Panc-MSC generate a 
secretome composition distinct to BM-MSC, albeit CM generated by BM MSC also 
demonstrated pro-vascular functions in vitro and in vivo; 2) EVs generated by Panc-MSC 
contained a diverse portfolio of protein cargo that supported the recovery of blood 
perfusion and stimulated revascularization after im-injection into ischemic murine 
hindlimbs. Collectively, this study has provided foundational knowledge to further 
understand proteomic and functional characteristics which may be uniform across MSC 
from different tissue-types. In addition, we provide proof-of-concept and continuing 
evidence that the cell-free delivery of MSC biotherapeutics (i.e. MSC CM) may represent 
a useful tool for applications of regenerative medicine. 
 We recently characterized the total proteome of human Panc-MSC and conducted 
a parallel molecular and functional comparison with BM-MSC in vitro, demonstrating 
Panc-MSC were enriched for cell division protein machinery and depleted for proteins 
involved in lipid metabolism compared to BM-MSC. Panc-MSC also demonstrated 
phenotypic differences such as reduced ALDH1A3 and CD146 expression and 
adipogenic competency compared to BM-MSC. Considering, the secretome of both Panc- 
and BM-MSC harbour pro-vascular stimuli and demonstrated comparable functions in 
vitro and in vivo, the phenotypic differences previously reported (i.e. CD146 or ALDH-
activity) may not correlate with a pro-vascular secretome 23. Other MSC subtypes, 
including adipose-derived MSC, have also demonstrated the secretion of pro-vascular 
stimuli alongside differential cell surface phenotypes 26. Whether the production of pro-
angiogenic stimuli is a uniform characteristic across tissue specific MSC subtypes 
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remains to be established. However, fibroblasts from several tissues did not demonstrate 
pro-vascular effects in a comparable in vitro or in vivo model 15,27, therefore future 
studies are warranted. 
 Extracellular vesicles contain a diverse range of cargo that ‘communicate’ with a 
target cells at levels of transcriptional, translational, or directly as ligands to activate 
target receptors 20. Panc-MSC generated extracellular vesicles with diverse protein 
content compared to EV- CM, despite representing <50% of the bulk protein mass 
secreted. Nonetheless, cargo within Panc-MSC EVs was readily incorporated by 
HMVEC and stimulated endothelial tubule-formation in vitro. Importantly, EV+ CM 
generated by Panc-MSC accelerated the recovery of hindlimb blood perfusion after 
femoral artery ligation in vivo. We cannot conclude that proteomic stimuli were 
exclusively responsible for the pro-vascular effects observed in this study. Losordo and 
colleagues recently demonstrated that human CD34+ hematopoietic progenitors 
generated exosomes that transfer miR-126-3p to reduce SPRED1 mRNA and increase 
revascularization in a murine model of hind-limb ischemia 28. The potential role of 
miRNA content within Panc-MSC EVs was not assessed in this study. Moreover, several 
studies have demonstrated secreted MSC signals alter the infiltration hematopoietic cell 
populations, such as promoting a pro-regenerative M2 macrophage recruitment opposed 
to pro-inflammatory M1 macrophages 29. Thus, future studies are needed to investigate 
the functional role of nucleic acid content within EVs and to elucidate the roles of 
infiltrating hematopoietic cell populations in angiogenesis. Nonetheless, we demonstrate 
a relatively uncostly method to concentrate and enrich EVs from MSC in an injectable 
volume (<100ul). Future work designed to investigate the functional role of protein 
stimuli that exert pro-vascular benefits in a pre-clinical models of critical limb ischemia 
are needed. 
 Utilizing the secretome of vascular regenerative MSC subtypes, we envision the 
creation of a cell-free biotherapeutic ‘tailored’ to combat a pathological condition. For 
instance, stimuli with known pro-regenerative functions were detected in MSC CM 
and/or exclusively in the EV+ CM fraction. Wnt5a signals through both the canonical and 
non-canonical signaling pathways to activate pro-angiogenic pathways in vivo through 
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endothelial cells or through M2-polarization of infiltrating monocytes 30,31. Likewise, 
VEGF-A, ANGPT1 and POSTN have also demonstrated pro-angiogenic and regenerative 
function in previous studies 32-34.  Although we did not assess the contribution of 
individual proteins, or defined protein mixtures detected in EV+ CM to the recovery of 
hind-limb blood perfusion, this study provides a foundation to explore targetable 
pathways during MSC expansion to ‘tailor’ the secretome towards a specific regenerative 
response. For example, we have recently demonstrated activation of canonical Wnt-
signaling during BM-MSC expansion (via GSK3-inhibition) can enhance islet 
regenerative secretory function in vivo 12. Other studies have demonstrated genetic 
modification 35 or hypoxic priming 36 may improve the regenerative or proangiogenic 
functions of MSC respectively. Therefore, our future studies will address whether 
pharmaceutical or genetic manipulation of specific MSC subtypes can enhance the pro-
vascular secretome of MSC to generate therapeutics for vascular regenerative therapies. 
 In conclusion, this study provides foundational insight to elucidate vascular 
regenerative potential of MSC-generated CM. Moreover, we further defined the central 
role of EVs generated by Panc-MSC and conducted two proteomic screens that identified 
future biological targets. Collectively, vascular regenerative medicine has demonstrated 
pre-clinical potential to treat macro- and micro-vascular pathologies, however direct cell 
transplantation has endured several setbacks during translation to clinical studies. Our 
recent studies suggest regenerative MSC populations may be used as ‘biofactories’ to 
generate a cell-free biotherapeutics, although future research is crucial to determine the 
‘therapeutic ceiling’ of these approaches. 
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Chapter 6 
6 Pancreatic MSC secrete islet regenerative stimuli* 
*This chapter was primarily incorporated to supplement Chapters 4 and 5 as foundational 
evidence to 1) establish a common multifaceted secretome across MSC populations 2) 
demonstrate the therapeutic potential of cell-free biotherapeutics for complex tissue 
regeneration. Additionally, this chapter provides preliminary experimental evidence to 
establish discussion points in Chapter 7.  
6.1 Introduction 
We have recently demonstrated that the secretome of BM-MSC harbours bioactive 
stimuli capable of supporting beta-cell proliferation and survival in vitro1. Notably, 
intrapancreatic (iPan) injection of concentrated BM-MSC CM stimulated complex islet 
regenerative programs, including characteristic consistent with the induction of islet 
neogenesis, increased β-cell proliferation, and accelerated 𝛽-cell maturation in STZ-
induced hyperglycemic NOD/SCID mice2. Currently, we are utilizing this reproduceable 
injection platform combined with thorough secretome analyses to identify stimuli that 
mediate islet regenerative processes in pre-clinical models which may be translated to 
human application for diabetes treatment2,3. To this end, mass spectrometry-based 
analyses of BM-MSC revealed active canonical Wnt-signaling was a conserved 
characteristic of islet-regenerative BM-MSC that significantly lowered hyperglycemia 
following intravenous cell transplantation3.  Inhibition of GSK3 activity (CHIR99021), 
resulting in the stabilization of β-catenin during ex vivo cell expansion led to enrichment 
of islet regenerative effectors in the secretome of BM-MSC that could be injected as a 
cell-free biotherapeutic to reverse hyperglycemia in NOD/SCID mice. Taken together, 
these studies suggested that 1) the secretome of MSC may determine islet regenerative 
functions in vivo and 2) cell-biotherapeutics can be ‘tailored’ to enhance the induction of 
islet regenerative programs.  
Considering Panc-MSC are derived from the islet microenvironment, I hypothesized that 
Panc-MSC will generate a secretome that demonstrates islet regenerative function after 
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direct iPan-delivery. In chapter 6, I present functional evidence that the Panc-MSC 
secretome of also capable of inducing islet recovery and reducing STZ-treated 
hyperglycemic mice, similar to BM-MSC. The knowledge acquired within this chapter 
will serve as preliminary proof-of-concept for future studies aiming to utilize the 
secteome of Panc-MSC as a cell-free biotherapeutic for the treatment of diabetes.  
6.2 Methods 
6.2.1 BM-MSC and Panc-MSC Isolation and Culture 
BM-MSC: 
Human BM aspirates were obtained from healthy donors with informed consent from the 
London Health Sciences Centre (London, ON). BM-MSC were established and cultured in 
Amniomax-C100 media + C100 supplement (Life Technologies) as previously described 
in Chapter 4. 
Panc-MSC: 
Ricordi-chamber isolated human islets were obtained through the Integrated Islet 
Distribution Program (IIDP) funded by the National Institute of Diabetes and Digestive 
and Kidney Diseases (NIDDK). Panc-MSC were established by plastic adherence during 
islet suspension cultures and expanded in Amniomax-C100 media + supplement as 
previously described in Chapter 4. 
6.2.2 Enrichment of EVs from Panc-MSC CM 
Conditioned media (CM) was generated by culturing BM-MSC and Panc-MSC to ~80% 
confluency, rinsed twice with pre-warmed PBS, switched to basal Aminomax C100 
media without supplement and media was collected after 24-hours culture. CM was 
subsequently processed in one of three ways (Supplemental Figure 2). 1) Cell-free CM 
was concentrated (~20-fold by volume) by centrifugation in 3kDa centrifuge filter unit 
for 45 minutes at 2800g. This fraction contained both EVs and soluble proteins >3kDa 
and is referred to as bulk CM. 2) Cell-free CM was concentrated in 100kDa centrifuge 
filter units for 20 minutes at 2800g. This fraction (EV+) was enriched with EVs and 
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proteins complexes larger than 100kDa This fraction was referred to as EV+ CM or EV-
enriched CM. 3) CM which passed through the 100kDA filter was centrifuged in 3kDA 
centrifuge filter units for 40 minutes at 2800g to concentrate soluble proteins between 
>3kDa and <100kDA size. This fraction was referred to as EV- CM or EV-depleted CM 
(also see Chapter 5 Methods). 
6.2.3 Intrapancreatic or Intravenous Transplantation of Panc-MSC in 
hyperglycemic NOD/SCID mice 
Pancreatic β-cell ablation was induced in NOD/SCID mice aged 8- to 10-weeks by 
intraperitoneal injection of STZ (35 mg/kg/ day) for 5 consecutive days. All animal 
procedures were approved by the Animal Care Committee at Western University Canada 
(AUP 2015-033). On day 10, hyperglycemic (15–25 mM) mice were sublethally 
irradiated (300 cGy) prior to intrapancreatic transplantation of 5.0x105 Panc-MSC (20µl). 
Alternatively, 5.0x105 Panc-MSC were intravenously infused within 500ul of Basal 
Aminomax C-100 via tail vein injection. Equal volumes of Basal Aminomax C-100 were 
used as vehicle control for both injection modalities. Systemic blood glycemic levels 
were monitored in a blinded fashion weekly for 42 days.  
6.2.4 Intrapancreatic or Intravenous Injection of MSC-derived CM in 
hyperglycemic NOD/SCID mice 
Hyperglycemic NOD/SCID mice, generated as described above were transplanted on day 
10 by intrapancreatic or intravenous injection of MSC-derived CM fractions. 
Specifically, hyperglycemic mice received a single intrapancreatic injection of bulk, EV+, 
EV- CM (6μg total protein in 20ul) derived from Panc-MSC or bulk CM (6μg total 
protein 20µl) derived from BM-MSC. In addition, STZ-treated NOD/SCID mice received 
i.v. injection of 100μg total protein of Panc-MSC CM via the tail vein, as described 
above. Equal volumes of Basal Aminomax C-100 were used as vehicle control for both 
routes of CM injection. Systemic blood glycemic levels were monitored in a blinded 
fashion weekly for 42 days.  
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6.3 Results 
6.3.1 Intravenous or intrapancreatic transplantation of Panc-MSC did not 
reduce hyperglycemia in STZ-treated mice 
We have previously demonstrated that BM-MSC can lower hyperglycemia and stimulate 
islet regeneration when infused into the systemic circulation4-6. However, regenerative 
functions were variable and donor specific. Furthermore, direct intrapancreatic -
transplantation of islet-regenerative UCB ALDHhi cells augmented the reduction in 
hyperglycemia7, compared to intravenous transplantation. Therefore, I sought to 
investigate if Panc-MSC could stimulate islet regeneration following intravenous infusion 
or after intrapancreatic transplantation. Accordingly, we demonstrated that neither 
intravenous or intrapancreatic transplantation of Panc-MSC reduced hyperglycemia in 
STZ-treated NOD/SCID mice (Figure 6.1), compared to mice injected with vehicle 
control.  
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Figure 6.1  Intravenous or Intrapancreatic-injection does not reduce hyperglycemia 
in STZ-treated NOD/SCID mice. 8-10-week-old NOD/SCID mice were injected with 
STZ days 0-5 to induce β-cell ablation. On day 10, hyperglycemic mice (>15mmol/mL) 
received 5.0x105 Panc-MSC by either intravenous (i.v.) infusion or intrapancreatic (iPan) 
transplantation. Basal Aminomax C-100 was injected as vehicle control. (A) i.v. or iPan 
transplantation of Panc-MSC did not significantly reduce blood glucose levels in 
NOD/SCID mice, compared to vehicle injected control mice. Data represented as Mean + 
SEM (n=3-4 mice per group). Statistical analyses were performed by two-way ANOVA 
with Tukey’s post-hoc test. 
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6.3.2 Panc-MSC CM reduced hyperglycemia in STZ-treated NOD/SCID 
mice after intrapancreatic-injection but not after intravenous 
injection 
STZ-treated mice injected with concentrated CM generated by BM-MSC demonstrated 
reduced hyperglycemia via the stimulation of potent islet regenerative and islet neogenic 
programs following direct injection into the pancreas2. However, it has yet to be 
determined if the intravenous infusion of CM generated by MSC could similarly 
stimulate islet regeneration. Accordingly, I sought to determine if 1) intrapancreatic 
injection of Panc-MSC CM could stimulate islet regeneration similar to BM-MSC and 2) 
if intravenous infusion of Panc-MSC CM via tail-vein injection could stimulate islet 
regeneration in hyperglycemic NOD/SCID mice.  
First, I injected hyperglycemic mice with CM (3 or 6μg total protein) generated by BM-
MSC or Panc-MSC. To serve as a vehicle control, non-conditioned media was iPan 
injection. Compared to vehicle control, 6𝜇g CM generated by both BM-MSC and Panc-
MSC significantly reduced (*p<0.05) hyperglycemia in STZ-treated NOD/SCID mice 
(Figure 6.2). In contrast, 3μg of BM-MSC or Panc-MSC CM did not reduce 
hyperglycemia in vivo, compared to vehicle control. To assess whether secreted stimuli 
could induce murine islet from distant sites, I tested whether tail vein-injection of 100μg 
total protein of Panc-MSC CM could reduce hyperglycemic in STZ-treated mice. 
Compared to vehicle control, intravenous-infusion of Panc-MSC CM did not 
significantly decrease hyperglycemia in vivo (Figure 6.3). Collectively, I demonstrated 
CM generated by Panc-MSC reduced hyperglycemia in NOD/SCID mice, albeit direct 
injection into the pancreas was required.   
 
 
 
227 
A 
  
B 
228 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2 Intrapancreatic injection of MSC-derived CM reduced resting 
blood glucose levels in STZ-treated NOD/SCID mice. 8-10-week-old 
NOD/SCID mice were rendered hyperglycemic by STZ-induced β-cell ablation 
between days 0-5. On day 10, hyperglycemic mice (>15mmol/mL blood glucose) 
received 3 or 6𝝁g of Panc-MSC or BM-MSC derived CM. Basal Aminomax C-
100 served as vehicle control. (A) Collectively, iPan transplantation of 6ug CM 
derived from Panc-MSC or BM-MSC significantly reduced resting blood glucose 
levels, (B) as measured by area under the curve (AUC). Conversely, 3μg of 
Panc-MSC CM did not demonstrate hyperglycemic reduction.  Data represented 
as Mean +/- SEM (n=5-8).  Statistical analyses performed by one-way ANOVA 
with post-hoc Tukey’s t test (*p<0.05). 
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Figure 6.3 Intravenous infusion of Panc-MSC CM did not reduce 
hyperglycemia in STZ-treated NOD/SCID mice. 8-10-week-old NOD/SCID 
mice were treated with STZ for 5 consecutive days to induce β-cell ablation 
between days 0-5. On day 10, hyperglycemic mice (>15mmol/mL blood glucose) 
received 100ug total protein of Panc-MSC by either intravenous (i.v.) infusion. 
500𝝁l of basal Aminomax C-100 served as vehicle control. (A) i.v. infusion of 
Panc-MSC CM did not significantly reduce resting blood glucose levels in 
NOD/SCID mice, compared to vehicle control. Data represented as Mean + SEM 
(n=3-4 mice / group). Statistical analyses were performed by one-way ANOVA 
with Tukey’s post-hoc test. 
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6.3.3 Islet regenerative stimuli are haboured throughout the secretome of 
Panc-MSC 
In Chapter 5, I demonstrated that EVs generated by Panc-MSC contained pro-angiogenic 
stimuli able to stimulate the recovery of hindlimb blood perfusion in mice with femoral 
artery ligation induced hindlimb ischemia. To investigate the role of Panc-MSC secreted 
EVs in islet regeneration, EV+ and EV- CM was generated in a similar fashion as 
described in Chapter 5. Interestingly, intrapancreatic injection of both the EV+ and EV- 
CM fractions reduced hyperglycemia in NOD/SCID mice compared to vehicle control 
and the extent of hyperglycemia reduction was comparable after EV+ and EV- CM 
injection, suggesting islet regenerative stimuli were found in the soluble fraction of the 
Panc-MSC secretome and in EV-bound vesicles secreted by Panc-MSC.  
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Figure 6.4 Islet regenerative stimuli contained in the soluble and EV+ fractions 
generated by Panc-MSC.  8-10-week-old NOD/SCID mice were rendered 
hyperglycemic by STZ-induced β-cell ablation between days 0-5. On day 10, 
hyperglycemic mice (>15mmol/mL blood glucose) received iPan-injection of 6ug EV- 
CM or EV+ CM generated by Panc-MSC. Basal Aminomax C-100 served as vehicle 
control. (A) Collectively, iPan transplantation of both EV- and EV+ CM was able to 
significantly reduce resting blood glucose levels, (B) as measured by area under the 
curve (AUC). Conversely, iPan-injection of 3ug of Panc-MSC CM did not induce 
hyperglycemia reduction.  Data represented as Mean +/- SEM (n=4-8 mice per group).  
Statistical analyses were performed by one-way ANOVA with post-hoc Tukey’s t test. 
(*p<0.05). 
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6.4 Discussion 
Endogenous regeneration of β-cells may hold the promise of providing sustained glucose 
control without exogenous insulin in patients with diabetes8-10. We have previously 
shown to islet regeneration could occur in response to the direct injection of BM-MSC 
CM2. Using an alternative source, we predicted Panc-MSC may provide a ‘fine-tuned’ 
secretome for islet regeneration, albeit islet regenerative stimuli could also be a 
conserved characteristic ‘common’ to the secretome MSC populations from different 
tissue sources. Herein, I provide preliminary evidence that islet regenerative stimuli are 
contained within both BM-MSC and Panc-MSC CM with comparable capacity to reduce 
hyperglycemia in STZ-treated NOD/SCID mice. Thus, these data suggest that secretion 
of pro-regenerative stimuli may be a shared characteristic across different MSC from 
different tissue sources. 
Furthermore, I demonstrated islet regenerative stimuli were contained within both EV+ 
and EV- CM fractions of the Panc-MSC secretome. Further studies are needed to 
elucidate specific stimuli contained within either fraction, or whether similar regenerative 
proteins were present in both EV+ and EV- CM. Conversely, it remains possible that EV- 
and EV+ CM contain unique stimuli which activate a common regenerative mechanism. 
In addition to proteins, EVs may also contain nucleic acid or lipid effectors that can 
influence recipient cell populations (Figure 1.11). Losordo and colleagues demonstrated 
that EVs isolated from CD34+ HPC could activate VEGF pathways in recipient 
endothelial cells through the transfer of miRNA that repressed translation of VEGF-
pathway inhibitors11. Collectively, future studies will need to characterize a vast array of 
stimuli collectively responsible for the activation of biological pathways in recipient 
cells.  
 Nonetheless, islet regeneration only occurred when stimuli generated by Panc-MSC were 
delivered directly to the site of injury (intravenous versus intrapancreatic) at a high 
therapeutic dose (3μg versus 6μg). The results highlight the generation of a “therapeutic 
islet microenvironment” that may tip the balance in favour of regeneration versus 
inflammation and destruction12-14. In continuation with Chapter 4 and 5, Chapter 6 
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supports the thesis that Panc-MSC generate a multifaceted secretome with potential as a 
cell-free biotherapeutic. This work will lead us to better unravel the mechanisms of islet 
regeneration using transgenic model systems to identify activated cell populations 
resident within the pancreas, discussed below.  
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Chapter 7 
7 Summary of Objectives 
The global objective of this thesis was to investigate scalable biotherapeutic approaches 
of regenerative medicine utilizing post-natal progenitor cells to stimulate endogenous 
islet regeneration and/or revascularization of ischemic tissue. In Chapters 2 and 3, I 
focused on enhancing the ex vivo expansion of human UCB ALDHhi hematopoietic cell 
progeny that retain vascular and islet regenerative functions after transplantation. 
Furthermore, I provide the first comprehensive proteomic and regenerative function 
analyses of human Panc-MSC (Chapter 4) demonstrating extracellular vesicles generated 
by Panc-MSC harbor vascular (Chapter 5) and islet regenerative protein cargo (Chapter 
6). Below, I briefly summarize the significant findings of each chapter to highlight the 
contributions of this work to the field of regenerative medicine and to outline intellectual 
and technical limitations encountered throughout these studies. Subsequently, I propose 
future experimentation required to further refine the breadth of knowledge obtained 
within this thesis. Finally, I will discuss the implications of these findings, with specific 
focus on regenerative medicine strategies to treat diabetes and related cardiovascular 
pathologies.  
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7.1 Summary of Findings 
In chapter 2, I determined that expanded hematopoietic progeny from UCB ALDHhi cells 
retained a characteristic of pro-angiogenic secretome, despite reduced capacity to 
stimulate angiogenesis in vivo. Moreover, I discovered that UCB ALDHhi cells will 
primarily differentiate towards the megakaryocyte lineage during expansion as primitive 
progenitor cell phenotype is diminished in vitro. Accordingly, I demonstrated that 
preventing HPC differentiation by temporally inhibition of RA-production (via DEAB-
treatment) enhanced the expansion of hematopoietic progeny retaining primitive 
phenotype in vitro and vascular regenerative function in vivo (Figure 7.1). Mass 
spectrometry analyses suggested the inhibition of ALDH-activity enriched the proteome 
of expanded HPC with a pro-survival signature which coincided with improved cell 
engraftment. In chapter 3, I sought to determine if expanded hematopoietic progeny 
reselected for high ALDH-activity (ALDHhi) after DEAB-treatment culture conditions 
retained islet regenerative function, analogous to freshly-isolated UCB ALDHhi cells. 
Surprisingly, only ALDHlo cells reselected after culture demonstrated islet regenerative 
stimuli, despite ALDHhi cells retaining progenitor cell characteristics. DEAB-treated 
ALDHlo cells were significantly enriched for cells of the megakaryocyte-lineage, albeit 
the mature hematopoietic cell marker CD38 was significantly reduced.  
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Figure 7.1 Inhibition of Retinoic Acid Production Enhances the Expansion of 
Hematopoietic Progeny with Multifaceted Regenerative Functions. 
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In chapter 4, I characterized the proteome on an understudied MSC population 
from human pancreatic tissue, Panc-MSC (Figure 7.2). In this study, I conducted a direct 
comparison of Panc-MSC versus BM-MSC using mass spectrometry, flow cytometry, 
and functional differentiation assays in vitro. The proteome of Panc-MSC was enriched 
with increased pro-mitotic protein expression, coinciding with accelerated growth 
kinetics in vitro. Adipogenic pathways were restricted within Panc-MSC, whereas the 
proteome of BM-MSC was ‘primed’ for adipogenic differentiation, lipid metabolism, and 
RA-induced differentiation. Nonetheless, I detected 15 differentially expressed CD 
markers between Panc- and BM-MSC as candidates for future investigation to reduce the 
heterogeneity of potentially therapeutic MSC subpopulations based on surface marker 
expression (i.e. CD146+ versus CD146- Panc-MSC). In Chapter 5 and 6, I demonstrated 
the secretome of Panc-MSC was enriched for pro-regenerative stimuli capable of 
promoting vascular or islet regeneration in vivo. Furthermore, extracellular vesicle 
protein content of Panc-MSC proved pro-regenerative and provided a foundation for the 
development of cell-free biotherapeutics employing Panc-MSC as mini ‘bio-factories’ for 
regenerative medicine applications. 
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Figure 7.2 Human Pancreas-derived Multipotent Stromal Cells Secrete 
Multifaceted Pro-Regenerative Stimuli.  
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In summary, I have demonstrated human HPC and MSC possess multifaceted therapeutic 
functions in murine models of vascular or islet regeneration. Unfortunately, previous 
clinical use of autologous therapeutic cell populations has led to modest efficacy in 
patients with critical limb ischemia presumably limited by poor cell engraftment in the 
ischemic limb post-transplantation and/or a diminished pro-regenerative secretome 
following extensive expansion ex vivo. Thus, allogenic cell sources such as healthy BM 
or UCB combined with cell-free biotherapeutic approaches may help circumvent many of 
the limitations of autologous cell transplantation. Further understanding of central 
regenerative pathways and functional synergies through future research is warranted. 
Towards this end, improving the capacity to expand therapeutic cell populations while 
retaining regenerative secretory function is essential to refining our current regenerative 
medicine approaches for treating diabetes and cardiovascular comorbidities.  
 
7.1.1 Limitations of Progenitor Cell Isolation and Hematopoietic Cell 
Expansion  
In chapter 2 and 3, I isolated and expanded ALDHhi cells from UCB mononuclear cell 
samples in serum-free conditions supplemented with TPO, FLT-3L, SCF. Leading up to 
transplantation, several notable limitations were encountered with UCB ALDHhi cell 
expansion. Firstly, lineage-depletion of UCB samples was achieved with a tetrameric 
antibody system that binds multiple mature hematopoietic cell surface markers and 
allows for depletion of mature cell populations during mononuclear cell isolation. After I 
discovered that expanded ALDHhi cells preferentially differentiate towards the 
megakaryocyte lineage, it was established this methodology did not deplete cells of the 
megakaryocyte lineage using an antibody for CD41 or CD42. At the time of this study, 
the initial enrichment of Lin- cells may have biased UCB ALDHhi cells towards 
megakaryopoiesis by indirectly enriching for cells expressing these megakaryocyte-
lineage markers. This limitation can easily be addressed in future studies by performing a 
secondary depletion of CD41+ cells during FACS or simply using current lineage-
depletion kits that include depletion of CD41+ cells.  
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Paradoxically, TPO is a known driver of megakaryopoiesis1,2 and through pleiotropic 
functions is also required for maintenance for human HSC pool3,4. Furthermore, HPC 
express the thrombopoietin receptor Mpl, and can be directed to a megkaryocyte fate 
when cultured with TPO in vitro4. I demonstrate in chapters 2 and 3 that exogenous TPO 
drives UCB ALDHhi cell expansion, albeit at the cost of progenitor cell differentiation 
(Figure 7.3). Developing megakaryocytes also secrete additional factors that further 
promote progenitor cell differentiation in vitro. Given that UCB ALDHhi cells are 
enriched with megakaryocyte-precursors and culture under conditions supplemented with 
known drivers of megakaryopoiesis, the outcome of HPC expansion observed in this 
study were likely predisposed by the aforementioned factors. Future studies will need to 
individually address the influence of Lin- selection and culture conditions utilized for the 
expansion of therapeutic ALDHhi cells. 
Throughout this thesis, ex vivo expansion of UCB ALDHhi cell was performed in static 
suspension culture and bulk media changes were performed every 3 days. Integration of 
additional technologies, such as real-time bioreactor expansion chambers developed by 
Zandstra and colleagues5-8, is expected to further enhance the expansion therapeutic HPC 
by permitting a dynamic and control of culture conditions. Nevertheless, knowledge 
acquired within this study provides insight towards targetable pathways that further 
enhance the expansion of therapeutic HPC for applications of regenerative medicine.   
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Figure 7.3 UCB ALDHhi cell Expansion and Differentiation is Paradoxically driven 
by TPO. 
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7.1.2 Elucidating the Complexity of ALDH-activity and Retinoic Acid 
Signaling Pathways 
Retinoic acid signaling exerts regulatory functions through the complex network of 
upstream cytosolic effectors and nuclear receptors9-12, each containing distinct and 
redundant isoforms. For example, genetic deletion of ALDH1A1 within transgenic mice 
is rescued by increased ALDH1A3 expression and leads to normal fetal and adult 
hematopoiesis13. An intellectual limitation encountered in chapter 2 was we did not 
directly quantify the abundance of individual ALDH isoforms which contribute to 
cannonical RA-signaling. Instead, we measured ALDH-activity using AldefluorTM 
substrate which acts as a substrate for multiple ALDH isoforms. ALDH-activity is also 
regulated through post-translation modifications, such as acetylation or deacetylation. 
Thus, further quantification of specific ALDH isoforms will be needed to support future 
studies utilizing AldefluorTM. Furthermore, ALDH-activity also measures a regulatory 
function independent of RA-production, including the reduction of ROS production and 
detoxification of reactive aldehydes14. DEAB-inhibition in chapters 2 and 3 inhibits 
several isoforms of ALDH15,16, thus future studies using selective inhibitors or siRNA 
interference would be better suited to address individual roles of ALDH isoforms and 
subsequent ROS production during UCB ALDHhi cell expansion.  
RA can be produced in cis- or trans- isoforms and is capable of activating receptors aside 
from canonical RAR/RXR heterodimers, such as the PPAR17,18 or RAR-related orphan 
receptors isoforms11,12,19. Likewise, the canonical RAR/RXR heterodimer complex can be 
activated by additional ligands that selectively bind sites on either RAR or RXR subunits 
bound to RA response elements11,20. RAREs are genetic loci of canonical RAR/RXR 
regulatory complexes and exists at 100s of genes throughout the human genome, thus 
active RA-signaling networks can provide a considerable amount of transcriptional and 
epigenetic regulation within expanding ALDHhi cells21. Collectively, these properties 
highlight the complexity of the RA-signaling network, that was largely understudied in 
Chapters 2 and 3 as a result of technical limitations. Specifically, the future use of global 
transcriptional (microarray or RNAseq) and proteomic analyses would provide more 
fruitful insight into the ability of DEAB-supplementation to modify the complete RA-
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signaling network. To this end, concurrent manipulation of additional effectors and/or 
receptors of may provide further regulation of complex RA-signaling networks in vitro. 
7.1.3 Current Limitations of Murine Model of CLI 
In Chapter 2 and 5, I utilized a murine model of hindlimb ischemia to assess distinct 
biotherapeutic approaches to stimulate revascularization. Hindlimb ischemia in this 
model is induced by surgical removal of the femoral artery and vein to induce acute 
localized ischemia22,23. Unfortunately, acute ischemia induced in healthy NOD/SCID 
mice does not fully reflect the pathogenesis observed in human patients with severe 
atherosclerosis developed over a prolonged cardiometabolic imbalance24-26. Specifically, 
the surgical model employed in this study does not reflect the gradual atherosclerotic 
occlusion of peripheral arterioles that leads to distal tissue ischemia, inflammation and 
necrosis in human patients. Therefore, inducing cardiometabolic imbalances within 
preclinical models will improve translation of novel regenerative medicine approaches 
towards reproduceable clinical efficacy in human patients.  
Mice are highly resistant to atherosclerosis when fed a high-fat ‘Western’ diet, 
thus modeling PAD/CLI in a standard rodent model is nearly impossible without genetic 
perturbation. Single or dual transgenic knockouts of Apolipoprotein E/APOE or 
Lipoprotein Lipase/LPL in mice provide models for the pathogenesis of atherosclerosis27-
30, albeit even these genetic models do not entirely reflect the pathophysiology or 
secondary complications of human CVD. Additional exogenous insults would be 
necessary to model concurrent cardiometabolic syndromes such as diabetes. Ultimately, 
the physiology of murine models limit our capacity to accurately model human PAD/CLI 
with or without concurrent cardiometabolic syndromes. The physiology of large animals, 
such as porcine or non-human primates, more accurately reflect human physiology, 
although financial and logistical limitations must be considered with these models31-34. 
Furthermore, the necessity of using immunodeficient models to study human cell 
transplantation limits the relevance of an intact immune system that would likely require 
larger animal models combined with immunosuppressive therapies. Later in this chapter, 
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I will briefly discuss the theoretical use of human organoids as a complimentary model to 
study human PAD/CLI.  
7.1.4 Limitations of Using Mouse and Human Tissues to Elucidate Islet 
Regenerative Mechanisms 
In chapters 3 and 6, we employed a murine model of hyperglycemia induction through 
STZ-induced 𝛽-cell ablation in immune deficient NOD/SCID mice that permit the 
survival of transferred human cells35-37. Pathogenesis in this model was induced by the 
administration of STZ, a glucose analog which specifically targets and damages β-cells 
with high Glut2 expression. Therefore, autoimmune pathogenesis of human Type 1 DM 
is not accurately reflected in the murine model employed38. Furthermore, NOD/SCID 
mice provide a functional platform for human cell transplantation studies39, however the 
lack of functional lymphocytes responsible for autoimmune destruction of β-cell in 
human subjects. The initiation of autoimmunity is proceeded by a chronic infiltration of 
inflammatory cells (insulitis) that will change the inflammatory microenvironment within 
islets38. Future studies will need to employ more immunocompetent mice to better model 
T1D and to assess the critical question whether β-cell regeneration can occur in the face 
of ongoing autoimmunity?  NOD mice spontaneously develop diabetes through a 
pathogenic insulitis similar to human subjects40-42, however β-cell regeneration may not 
be feasible without immunosuppression or reversal or autoimmunity. Our future studies 
aim to explore whether human-derived cell-free biotherapeutics can be injected into 
autoimmune NOD mice as described in chapter 6. If proof-of-concept can be established, 
cell-free biotherapeutic delivery would be required to address whether islet regeneration 
can occur in the face of autoimmunity and whether biotherapeutics generated by Panc-
MSC can also dampen local autoimmunity in pre-clinical models of Type 1 DM.  
The molecular and morphogenic mechanisms underlying endogenous islet regeneration 
observed in Chapter 3 and 6 remain elusive. Specifically, putative signal-receiving cells 
within the NOD/SCID pancreas can only be inferred through antibody-based histological 
analyses following euthanasia, thus lacking fate-mapping capabilities captured using 
current transgenic reporter systems (i.e. lineage-tracing). Several mechanisms for 
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endogenous islet regeneration have been proposed and each require inducible lineage-
specific transgenic systems to fully determine the origin of regenerating islet cells. For 
example, the Melton laboratory used a tamoxifen-inducible transgenic human placental 
alkaline peroxidase-reporter system driven by the insulin-promoter to suggest that mature 
β-cell duplication was the primary source of regenerated β-cell mass following partial 
pancreatomy43. In contrast, several cell alternative populations within rodent and human 
pancreata have been suggested to possess a facultative capacity to transdifferentiate to β-
cells (α cells, exocrine cells, ductal epithelial cells) following specific pancreatic injury 
(partial pancreatectomy, ductal ligation, STZ-treatment) to generate new 𝛽-cell mass 
during pregnancy or early stages of Type 2 DM44-51. The ductal epithelium has been 
repletely suggested to dedifferentiate into a bipotent progenitor cell that transiently 
expresses NEUROG3 prior to endocrine cell neogenesis52,53. For example, the Collombat 
lab used inducible expression of PAX4 to expand β-cell mass through the 
transdifferentiation of Glucagon+ or Somatostatin+ cells cells54-57. Accordingly, 
replacement of depleted glucagon cell populations was also suggested by this group to 
occur through ductal epithelial cell transdifferentiation through a peusdo-mesenchymal 
state. These novel findings demonstrate endocrine plasticity within the adult mouse 
pancreas is possible, however further studies are required to determine the functional 
relevance of this phenomea in humans without genetic manipulation. Liu et al recently 
demonstrated inducible dual-lineage fate-mapping system, utilizing Dre- and Cre-
recombinase, to identity a multipotent stem cell population within the lungs activated 
after injury58. With this system in mind, future fate-mapping studies investigating islet 
regeneration can be designed using MSC-derived biotherapeutic approach in 
sophisticated lineage-tracing models that selectively label cells with ‘transitional’ 
phenotype (i.e. Insulin/Glucagon; see Figure 7.4).  
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Figure 7.4 Working model of Dual-lineage transgenic system utilizing Cre- and 
Dre-recombinase to labelled potential cells with polyhormonal expression. 
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7.1.5 EV isolation and transplantation to identify pro-regenerative sub-
fractions 
Several approaches are currently used to effectively purify EVs60-62, however I employed 
a simple ultrafiltration fractionation in chapters 5 and 6 to enrich for EVs from CM 
generated by Panc-MSC. I demonstrated ultrafiltration was sufficient to separate EVs 
from soluble proteins of 3-100kDa using biological validation by mass spectrometry and 
physical validation using nanoscale flow cytometry and atomic force microscopy. As 
such, the purity of EVs within EV+ CM was limited by co-enrichment with large ECM 
molecules (i.e. fibronectin) or large protein complexes. Generally, ECM components are 
typically integrated as large heteromeric complexes selectively bound to additional 
proteins63,64. Therefore, ECM molecules and large proteins complexes would be 
concentrated with EVs using the ultrafiltration employed in chapters 5 and 6. Potential 
contamination with large protein/complexes within the EV+ CM subfraction limited the 
ability to demonstrate regenerative pathway stimulation in vivo was exclusive to EVs 
secreted by Panc-MSC. Proteomic analysis of Panc-MSC CM encountered similar 
limitations, such that effectors detected within the EV-enriched fraction were ‘most 
likely’ contained within the lumen or membrane of EVs.  Future studies would benefit by 
using ultrafiltration to obtain pure EV preparations prior to transplantation64,65. 
Alternatively, the implementation of siRNA interference or CRISPR-mediated genetic 
modifications to Panc-MSC would provide insight towards the effectors secreted by 
Panc-MSC that may provide multifaceted regenerative functions in vivo. 
 
7.2 Clinical Applications 
Throughout my thesis, I have demonstrated that both HPC and MSC demonstrate 
multifaceted therapeutic potential using two pre-clinical models. Likewise, HPC and 
MSC have been used previously in clinical trials for vascular or islet regenerative 
applications66-68. Unfortunately, current clinical efficacy using these progenitor cell 
population in the autologous has been modest at best. Several primary explanations for 
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the lack of translational efficacy have been postulated including: (1) autologous 
progenitor cells exposed to a harsh microenvironment shaped by chronic disease have 
shown diminished therapeutic function and decreased engraftment following 
transplantation69, and (2) extensive expansion ex vivo is often required to generate 
sufficient cell numbers for transplantation yet expansion paradoxically drives the loss of 
progenitor cell identify and therapeutic functions in vivo70, Thus, refinement of expansion 
protocols to generate high cell number with therapeutic functions provide the greatest 
clinical benefit. Results obtained in chapters 2 and 3, provide insight towards targetable 
pathways (i.e. RA-signaling) to enhance expansion of regenerative progeny retaining 
multifaceted therapeutic functions; potentially through the enrichment of pro-survival 
signaling pathways which improves engraftment after transplantation.  
Transplantation of biotherapeutic stimuli holds potential to activate specific 
regenerative signaling pathways without many of the regulatory limitations encountered 
by direct cell transplantation71,72. MSC demonstrate multifaceted regenerative functions 
primarily mediated by a paracrine secretion of regenerative stimuli. Thus, MSC have 
been previously used in numerous clinical trials68,73 for their secretory profile, however 
clinical efficacy utilizing direct MSC transplantation into tissues has been limited by low 
engraftment in an unfamiliar or harsh microenvironment. In chapters 4-6, I provide the 
first in-depth and functional characterization of human Panc-MSC. Within the context of 
clinical applications, I demonstrated Panc-MSC are an accessible cell population with 
robust expansion kinetics and a pro-regenerative secretome. Future studies are now 
warranted to determine whether cell-free biotherapeutics generated by Panc-MSC can be 
used to directly stimulate endogenous regeneration or to better support regenerative cell 
types after transplantation into relevant pre-clinical models. 
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7.3 Future Studies and Proposed Experimentation 
7.3.1 Enhancing the Engraftment of Therapeutic HPC 
UCB provides a readily accessible source of allogenic progenitor cells used for 
regenerative medicine applications74,75. Although efficacy following transplantation is 
often limited by transient engraftment, in chapter 2, I identified that DEAB-treatment 
during culture expansion enriched for HPC that generated proteins associated with pro-
survival functions. To further elucidate the functional roles of these proteins, I would 
implement siRNA interference prior to intramuscular transplantation to knockdown 
identified proteins effectors in UCB ALDHhi cells expanded under DEAB-treated 
conditions. Histological analyses performed shortly after transplantation would provide 
insight into pathways that influence the engraftment of transplanted cell populations. 
Alternatively, proteins of interest could also be upregulated through ectopic vector 
expression or pharmaceutical activation of up/downstream effectors. 
 
7.3.2 Do cells of the megakaryocyte-lineage possess multifaceted 
therapeutic potential? 
It was discovered in chapters 2 and 3 that UCB ALDHhi cell expansion was biased 
towards generation of progeny from the megakaryocyte lineage. Interestingly, expanded 
cells with low ALDH-activity were enriched for committed megakaryocytes with 
previously unrecognized islet regeneration in vivo. Unfortunately, I was not able to 
determine potential contribution of megakaryocytes to islet regeneration, although FACS 
purification based on CD41 and/or CD42 could be employed to enrich for cells at 
different stages of megakaryopoiesis. Direct FACS purification of megakaryocyte-related 
cell populations could be transplanted into murine models of Type 1 diabetes or severe 
CLI utilized throughout this thesis. Furthermore, platelet-rich plasma (PRP) has recently 
emerged as a source of pro-angiogenic or anti-inflammatory stimuli with therapeutic 
benefit for treating articular cartilage osteoarthritis in early clinical trials76-80. Platelets are 
anucleated fragments generated by megakaryocyte burst is essential for wound healing 
and vascular homeostasis81-83. Notably, it has been recently demonstrated that platelets 
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can transfer potent vascular and tissue regenerative stimuli to exposed cell 
populations77,84. Thus, future research would benefit from investigation of the therapeutic 
potential culture-generated platelets transplanted into pre-clinical models of Type 1 DM 
or PAD/CLI.  
 
7.3.3 Identification of Panc-MSC during human pathology and 
regeneration 
The true phenotype of MSC in human tissues remains controversial and represents a 
persistent limitation to the advancement of regenerative medicine approaches using 
MSC85. Further fate-mapping studies are necessary to elucidate MSC hierarchies within 
human tissues, however clinical use of native human Panc-MSC will ultimately rely on 
elucidating unique functional benefits not demonstrated by BM-derived MSC. Here, I 
demonstrated Panc-MSC demonstrated a unique proteome and enriched expression 
progenitor cell markers, such as vimentin and nestin. Furthermore, I provided a surface 
marker profile of Panc-MSC, including over 70 CD markers which may potentially serve 
as candidate markers for further subset purification and functional analyses (Figure 7.5). 
As observed in this study, heterogenicity is a current limitation of MSC culture. Until this 
heterogeneity is minimized, functional variation between tissue-specific MSC will limit 
consistent therapeutic benefit. Fibrosis following wounding is mediated by MSC-like 
progeny, such that fibroblasts or myofibroblasts, robustly deposit ECM components that 
comprise scar tissue and formation of an inflammatory microenvironment that generally 
inhibits regeneration of functional cell populations86-88. Other groups have demonstrated 
that tissue-specific MSC exist using fate-mapping in mice, however their multipotency 
was facultative to injury and potency was restricted to fibroblast or adipocyte-lineages 
when exposed to a pro-inflammatory microenvironment88. In the context of diabetes, the 
BM niche becomes populated with MSC-derived adipocytes due to local metabolic 
imbalances89,90. Although mesoderm-derived BM-MSC effectively differentiates into 
adipocytes within this thesis, I demonstrated human Panc-MSC were restricted from 
adipogenic differentiation in vitro. Adipocyte formation can occur within the pancreas; 
however, the origin of these adipocytes remains elusive and requires further 
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investigation. Lastly, several groups have proposed that select MSC populations may not 
be derived from a mesodermal origin during embryogenesis91-96, but are 
developmentally-derived from the neural crest. Collectively, future studies will need to 
investigate the pathogenesis of human Panc-MSC during established Type 1 and Type 2 
diabetes. Moreover, fate-mapping studies using pluripotent ESCs or iPSCs may be 
required to elucidate the developmental origins of human Panc-MSC and their 
contributions to endogenous islet regeneration.  
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Figure 7.5 Working model to elucidate the phenotype and function of Panc-MSC in 
situ in humans and mice. Pancreas concurrently harvested from (Ai) human or (Aii) 
murine donors would be used to isolate single cells from (Bi) whole pancreas digests or 
(Bii) dissociated islet preps. (C) Single cells would be FACS purified based on CD 
candidates identified in Chapter 4 and (D) tested for single- cell colony formation and 
MSC characteristics in vitro. MSC-like cells would be subjected to further molecular and 
functional experimentation. (E) Transgenic mouse models could be created based on 
relevant MSC-phenotypes, albeit (F) refinement of purification strategies may be 
required.  (G) Ultimately, the pathological role and therapeutic function of Panc-MSC 
could be tested in stitu and used to develop of Panc-MSC could be tested in clinical trials 
for regenerative medicine applications. 
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7.3.4 Elucidating the pro-regenerative microenvironment generated by 
cell-free biotherapeutics 
The recent advancement in human organoid generation and culture may provide 
an sustainable high-throughput platform to accurately model human disease in vitro and 
after organoid implantation in vivo97,98. Furthermore, iPSC technologies offer the 
opportunity to assess genetic and epigenetic differences encountered between human 
patients with a given pathology. As eluded to in Chapter 1, designer cells would allow for 
patient-specific organoids that reflect complex and concurrent pathogenesis, such as Type 
2 DM or atherosclerosis. Although these technologies hold undoubtable potential, 
standardized generation of human organoids is in its infancy and further development is 
necessary before organoids are routinely used as translational models of disease. The 
Penniger lab recently demonstrated the generation of human vascular organoids which 
effectively modelled diabetes-induced vasculopathy in a multi-well culture system97. In 
theory, we could use a cell-free biotherapeutics generated from ‘designer’ MSC and test 
regenerative functions on similar organoid systems to elucidate targetable pathways that 
reverse pathogenesis99. For example, periostin and Wnt5a was significantly enriched 
within EV+ CM generated by Panc-MSC. Results for previous studies suggest Wnt5a100-
103 and periostin104-106 has proangiogenic and islet proliferative functions, respectively100-
103. Additionally, global proteomic analyses and biotherapeutic agent transfer into 
immunocompetent or inducible lineage-specific lineage tracing models suggested in this 
thesis could provide additional insight towards understanding how ECM and 
microenvironmental architecture influences both vascular and islet regenerative 
mechanisms. It is essential to consider the signaling contribution of the 3D 
microenvironment, as many studies have demonstrated the role of the extracellular matrix 
on progenitor cell survival and differentiation8,107-109. Ultimately, the success of 
biotherapeutic approaches, aiming to stimulate endogenous regeneration, will rely on the 
ability to generate and sustain a ‘development-like’ microenvironment in the face of 
chronic disease. 
 
257 
References  
1 Hitchcock, I. S. & Kaushansky, K. Thrombopoietin from beginning to end. British 
journal of haematology 165, 259-268 (2014). 
2 Majka, M. et al. Stromal-derived factor 1 and thrombopoietin regulate distinct aspects of 
human megakaryopoiesis. Blood 96, 4142-4151 (2000). 
3 Fox, N., Priestley, G., Papayannopoulou, T. & Kaushansky, K. Thrombopoietin expands 
hematopoietic stem cells after transplantation. The Journal of clinical investigation 110, 
389-394 (2002). 
4 Yoshihara, H. et al. Thrombopoietin/MPL signaling regulates hematopoietic stem cell 
quiescence and interaction with the osteoblastic niche. Cell stem cell 1, 685-697 (2007). 
5 Csaszar, E., Chen, K., Caldwell, J., Chan, W. & Zandstra, P. W. Real‐time monitoring 
and control of soluble signaling factors enables enhanced progenitor cell outputs from 
human cord blood stem cell cultures. Biotechnology and bioengineering 111, 1258-1264 
(2014). 
6 Csaszar, E. et al. Rapid expansion of human hematopoietic stem cells by automated 
control of inhibitory feedback signaling. Cell stem cell 10, 218-229 (2012). 
7 Kirouac, D. C. & Zandstra, P. W. Understanding cellular networks to improve 
hematopoietic stem cell expansion cultures. Current Opinion in Biotechnology 17, 538-
547 (2006). 
8 Madlambayan, G. J. et al. Dynamic changes in cellular and microenvironmental 
composition can be controlled to elicit in vitro human hematopoietic stem cell expansion. 
Experimental hematology 33, 1229-1239 (2005). 
9 Chanda, B., Ditadi, A., Iscove, N. N. & Keller, G. Retinoic acid signaling is essential for 
embryonic hematopoietic stem cell development. Cell 155, 215-227 (2013). 
10 Chen, Y. et al. Retinoic acid signaling is essential for pancreas development and 
promotes endocrine at the expense of exocrine cell differentiation in Xenopus. 
Developmental biology 271, 144-160 (2004). 
11 Mark, M., Ghyselinck, N. B. & Chambon, P. Function of retinoid nuclear receptors: 
lessons from genetic and pharmacological dissections of the retinoic acid signaling 
pathway during mouse embryogenesis. Annu. Rev. Pharmacol. Toxicol. 46, 451-480 
(2006). 
12 Rhinn, M. & Dollé, P. Retinoic acid signalling during development. Development 139, 
843-858 (2012). 
13 Levi, B. P., Yilmaz, Ö. H., Duester, G. & Morrison, S. J. Aldehyde dehydrogenase 1a1 is 
dispensable for stem cell function in the mouse hematopoietic and nervous systems. 
Blood 113, 1670-1680 (2009). 
14 Ma, I. & Allan, A. L. The role of human aldehyde dehydrogenase in normal and cancer 
stem cells. Stem cell reviews and reports 7, 292-306 (2011). 
15 Moreb, J. S. et al. The enzymatic activity of human aldehyde dehydrogenases 1A2 and 2 
(ALDH1A2 and ALDH2) is detected by Aldefluor, inhibited by 
diethylaminobenzaldehyde and has significant effects on cell proliferation and drug 
resistance. Chemico-biological interactions 195, 52-60 (2012). 
16 Luo, M., Gates, K. S., Henzl, M. T. & Tanner, J. J. Diethylaminobenzaldehyde is a 
covalent, irreversible inactivator of ALDH7A1. ACS chemical biology 10, 693-697 
(2015). 
17 Kliewer, S. A., Umesono, K., Noonan, D. J., Heyman, R. A. & Evans, R. M. 
Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways 
through heterodimer formation of their receptors. Nature 358, 771 (1992). 
18 Noy, N. in The Biochemistry of Retinoid Signaling II     179-199 (Springer, 2016). 
258 
19 Cook, D. N., Kang, H. S. & Jetten, A. M. Retinoic acid-related orphan receptors (RORs): 
regulatory functions in immunity, development, circadian rhythm, and metabolism. 
Nuclear receptor research 2 (2015). 
20 Bastien, J. & Rochette-Egly, C. Nuclear retinoid receptors and the transcription of 
retinoid-target genes. Gene 328, 1-16 (2004). 
21 Gudas, L. J. & Wagner, J. A. Retinoids regulate stem cell differentiation. Journal of 
cellular physiology 226, 322-330 (2011). 
22 Niiyama, H., Huang, N. F., Rollins, M. D. & Cooke, J. P. Murine model of hindlimb 
ischemia. JoVE (Journal of Visualized Experiments), e1035 (2009). 
23 Limbourg, A. et al. Evaluation of postnatal arteriogenesis and angiogenesis in a mouse 
model of hind-limb ischemia. Nature protocols 4, 1737 (2009). 
24 Zaragoza, C. et al. Animal models of cardiovascular diseases. BioMed Research 
International 2011 (2011). 
25 von Scheidt, M. et al. Applications and limitations of mouse models for understanding 
human atherosclerosis. Cell metabolism 25, 248-261 (2017). 
26 McNeill, E., Channon, K. & Greaves, D. Inflammatory cell recruitment in cardiovascular 
disease: murine models and potential clinical applications. Clinical science 118, 641-655 
(2010). 
27 Olszanecki, R. et al. Effect of curcumin on atherosclerosis in apoE/LDLR-double 
knockout mice. Journal of physiology and pharmacology: an official journal of the 
Polish Physiological Society 56, 627-635 (2005). 
28 Nakashima, Y., Plump, A. S., Raines, E. W., Breslow, J. L. & Ross, R. ApoE-deficient 
mice develop lesions of all phases of atherosclerosis throughout the arterial tree. 
Arteriosclerosis and thrombosis: a journal of vascular biology 14, 133-140 (1994). 
29 Ko, K. W., Paul, A., Ma, K., Li, L. & Chan, L. Endothelial lipase modulates HDL but has 
no effect on atherosclerosis development in apoE−/− and LDLR−/− mice. Journal of lipid 
research 46, 2586-2594 (2005). 
30 Carmeliet, P. & Collen, D. Transgenic mouse models in angiogenesis and cardiovascular 
disease. The Journal of pathology 190, 387-405 (2000). 
31 Worthley, S. G. et al. High-resolution ex vivo magnetic resonance imaging of in situ 
coronary and aortic atherosclerotic plaque in a porcine model. Atherosclerosis 150, 321-
329 (2000). 
32 Veseli, B. E. et al. Animal models of atherosclerosis. European journal of pharmacology 
816, 3-13 (2017). 
33 McDonald, T. O. et al. Diabetes and arterial extracellular matrix changes in a porcine 
model of atherosclerosis. Journal of Histochemistry & Cytochemistry 55, 1149-1157 
(2007). 
34 Getz, G. S. & Reardon, C. A. in Animal Models for the Study of Human Disease     205-
217 (Elsevier, 2017). 
35 Herr, R. R., Jahnke, H. K. & Argoudelis, A. D. Structure of streptozotocin. Journal of the 
American Chemical Society 89, 4808-4809 (1967). 
36 Lenzen, S. The mechanisms of alloxan-and streptozotocin-induced diabetes. 
Diabetologia 51, 216-226 (2008). 
37 Hess, D. et al. Bone marrow–derived stem cells initiate pancreatic regeneration. Nature 
biotechnology 21, 763 (2003). 
38 Van Belle, T. L., Coppieters, K. T. & Von Herrath, M. G. Type 1 diabetes: etiology, 
immunology, and therapeutic strategies. Physiological reviews 91, 79-118 (2011). 
39 Seneviratne, A. K. et al. Expanded hematopoietic progenitor cells reselected for high 
aldehyde dehydrogenase activity demonstrate islet regenerative functions. Stem Cells 34, 
873-887 (2016). 
259 
40 Nakayama, M. et al. Prime role for an insulin epitope in the development of type 1 
diabetes in NOD mice. Nature 435, 220 (2005). 
41 Kodama, S., Kühtreiber, W., Fujimura, S., Dale, E. A. & Faustman, D. L. Islet 
regeneration during the reversal of autoimmune diabetes in NOD mice. Science 302, 
1223-1227 (2003). 
42 Rees, D. & Alcolado, J. Animal models of diabetes mellitus. Diabetic medicine 22, 359-
370 (2005). 
43 Dor, Y., Brown, J., Martinez, O. I. & Melton, D. A. Adult pancreatic β-cells are formed 
by self-duplication rather than stem-cell differentiation. Nature 429, 41 (2004). 
44 Ye, L., Robertson, M. A., Hesselson, D., Stainier, D. Y. & Anderson, R. M. Glucagon is 
essential for α cell transdifferentiation and beta cell neogenesis. Development 142, 1407-
1417 (2015). 
45 Bergemann, D. et al. Pancreatic Beta Cell Regeneration: Duct Cells Act as Progenitors in 
Adult Zebrafish.  (2016). 
46 Ben-Othman, N. et al. Long-term GABA administration induces α cell-mediated beta-
like cell neogenesis. Cell 168, 73-85. e11 (2017). 
47 Rieck, S. & Kaestner, K. H. Expansion of β-cell mass in response to pregnancy. Trends 
in Endocrinology & Metabolism 21, 151-158 (2010). 
48 Liu, Y. et al. Proliferating pancreatic beta-cells upregulate ALDH. Histochemistry and 
cell biology 142, 685-691 (2014). 
49 Kim, H. et al. Serotonin regulates pancreatic beta cell mass during pregnancy. Nature 
medicine 16, 804 (2010). 
50 Butler, A. et al. Adaptive changes in pancreatic beta cell fractional area and beta cell 
turnover in human pregnancy. Diabetologia 53, 2167-2176 (2010). 
51 Jacovetti, C. et al. MicroRNAs contribute to compensatory β cell expansion during 
pregnancy and obesity. The Journal of clinical investigation 122, 3541-3551 (2012). 
52 Lee, J. et al. Expansion and conversion of human pancreatic ductal cells into insulin-
secreting endocrine cells. Elife 2, e00940 (2013). 
53 Bonner-Weir, S. et al. β-cell growth and regeneration: replication is only part of the story. 
Diabetes 59, 2340-2348 (2010). 
54 Collombat, P. et al. The ectopic expression of Pax4 in the mouse pancreas converts 
progenitor cells into α and subsequently β cells. Cell 138, 449-462 (2009). 
55 Collombat, P. et al. Opposing actions of Arx and Pax4 in endocrine pancreas 
development. Genes & development 17, 2591-2603 (2003). 
56 Druelle, N. et al. Ectopic expression of Pax4 in pancreatic δ cells results in β-like cell 
neogenesis. J Cell Biol 216, 4299-4311 (2017). 
57 Blyszczuk, P. et al. Expression of Pax4 in embryonic stem cells promotes differentiation 
of nestin-positive progenitor and insulin-producing cells. Proceedings of the National 
Academy of Sciences 100, 998-1003 (2003). 
58 Liu, Q. et al. Lung regeneration by multipotent stem cells residing at the 
bronchioalveolar-duct junction. Nature genetics, 1 (2019). 
59 Yoneda, S. et al. Predominance of β-cell neogenesis rather than replication in humans 
with an impaired glucose tolerance and newly diagnosed diabetes. The Journal of 
Clinical Endocrinology & Metabolism 98, 2053-2061 (2013). 
60 van Niel, G., D'Angelo, G. & Raposo, G. Shedding light on the cell biology of 
extracellular vesicles. Nature reviews Molecular cell biology 19, 213 (2018). 
61 Shao, H. et al. New technologies for analysis of extracellular vesicles. Chemical reviews 
118, 1917-1950 (2018). 
62 Raposo, G. & Stoorvogel, W. Extracellular vesicles: exosomes, microvesicles, and 
friends. J Cell Biol 200, 373-383 (2013). 
260 
63 Hay, E. D. Cell biology of extracellular matrix.  (Springer Science & Business Media, 
2013). 
64 Yuana, Y., Levels, J., Grootemaat, A., Sturk, A. & Nieuwland, R. Co-isolation of 
extracellular vesicles and high-density lipoproteins using density gradient 
ultracentrifugation. Journal of extracellular vesicles 3, 23262 (2014). 
65 Nordin, J. Z. et al. Ultrafiltration with size-exclusion liquid chromatography for high 
yield isolation of extracellular vesicles preserving intact biophysical and functional 
properties. Nanomedicine: Nanotechnology, Biology and Medicine 11, 879-883 (2015). 
66 Perin, E. C. et al. Evaluation of cell therapy on exercise performance and limb perfusion 
in peripheral artery disease: the CCTRN PACE trial (patients with intermittent 
claudication injected with ALDH bright cells). Circulation 135, 1417-1428 (2017). 
67 Perin, E. C. et al. Rationale and design for PACE: patients with intermittent claudication 
injected with ALDH bright cells. American heart journal 168, 667-673. e662 (2014). 
68 Squillaro, T., Peluso, G. & Galderisi, U. Clinical trials with mesenchymal stem cells: an 
update. Cell transplantation 25, 829-848 (2016). 
69 Kornicka, K., Houston, J. & Marycz, K. Dysfunction of mesenchymal stem cells isolated 
from metabolic syndrome and type 2 diabetic patients as result of oxidative stress and 
autophagy may limit their potential therapeutic use. Stem Cell Reviews and Reports 14, 
337-345 (2018). 
70 Putman, D. M. et al. Expansion of umbilical cord blood aldehyde dehydrogenase 
expressing cells generates myeloid progenitor cells that stimulate limb revascularization. 
Stem cells translational medicine 6, 1607-1619 (2017). 
71 Konala, V. B. R. et al. The current landscape of the mesenchymal stromal cell secretome: 
a new paradigm for cell-free regeneration. Cytotherapy 18, 13-24 (2016). 
72 Kim, H. O., Choi, S.-M. & Kim, H.-S. Mesenchymal stem cell-derived secretome and 
microvesicles as cell-free therapeutics for neurodegenerative disorders. Tissue 
Engineering and Regenerative Medicine 10, 93-101 (2013). 
73 Barry, F. P. & Murphy, J. M. Mesenchymal stem cells: clinical applications and 
biological characterization. The international journal of biochemistry & cell biology 36, 
568-584 (2004). 
74 Putman, D. M., Liu, K. Y., Broughton, H. C., Bell, G. I. & Hess, D. A. Umbilical cord 
blood‐derived aldehyde dehydrogenase‐expressing progenitor cells promote recovery 
from acute ischemic injury. Stem cells 30, 2248-2260 (2012). 
75 Bell, G., Putman, D., Hughes-Large, J. & Hess, D. Intrapancreatic delivery of human 
umbilical cord blood aldehyde dehydrogenase-producing cells promotes islet 
regeneration. Diabetologia 55, 1755-1760 (2012). 
76 Thurston, G. et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. 
Nature medicine 6, 460 (2000). 
77 Marx, R. E. Platelet-rich plasma: evidence to support its use. Journal of oral and 
maxillofacial surgery 62, 489-496 (2004). 
78 Kon, E. et al. Platelet-rich plasma intra-articular injection versus hyaluronic acid 
viscosupplementation as treatments for cartilage pathology: from early degeneration to 
osteoarthritis. Arthroscopy: The Journal of Arthroscopic & Related Surgery 27, 1490-
1501 (2011). 
79 Foster, T. E., Puskas, B. L., Mandelbaum, B. R., Gerhardt, M. B. & Rodeo, S. A. Platelet-
rich plasma: from basic science to clinical applications. The American journal of sports 
medicine 37, 2259-2272 (2009). 
80 De Vos, R. J. et al. Platelet-rich plasma injection for chronic Achilles tendinopathy: a 
randomized controlled trial. Jama 303, 144-149 (2010). 
81 Davì, G. & Patrono, C. Platelet activation and atherothrombosis. New England Journal of 
Medicine 357, 2482-2494 (2007). 
261 
82 Verheul, H. et al. Platelet: transporter of vascular endothelial growth factor. Clinical 
cancer research 3, 2187-2190 (1997). 
83 Ruggeri, Z. Von Willebrand factor, platelets and endothelial cell interactions. Journal of 
Thrombosis and Haemostasis 1, 1335-1342 (2003). 
84 Zhao, Y. et al. Platelet‐derived mitochondria display embryonic stem cell markers and 
improve pancreatic islet β‐cell function in humans. Stem cells translational medicine 6, 
1684-1697 (2017). 
85 Caplan, A. I. Mesenchymal stem cells: time to change the name! Stem cells translational 
medicine 6, 1445-1451 (2017). 
86 Yates, C. C. et al. Multipotent stromal cells/mesenchymal stem cells and fibroblasts 
combine to minimize skin hypertrophic scarring. Stem cell research & therapy 8, 193 
(2017). 
87 Carlson, S., Trial, J., Soeller, C. & Entman, M. L. Cardiac mesenchymal stem cells 
contribute to scar formation after myocardial infarction. Cardiovascular research 91, 99-
107 (2011). 
88 Joe, A. W. et al. Muscle injury activates resident fibro/adipogenic progenitors that 
facilitate myogenesis. Nature cell biology 12, 153 (2010). 
89 Piccinin, M. A. & Khan, Z. A. Pathophysiological role of enhanced bone marrow 
adipogenesis in diabetic complications. Adipocyte 3, 263-272 (2014). 
90 Keats, E. C., Dominguez, J. M., Grant, M. B. & Khan, Z. A. Switch from canonical to 
noncanonical Wnt signaling mediates high glucose‐induced adipogenesis. Stem Cells 32, 
1649-1660 (2014). 
91 Xu, X. et al. Gingivae contain neural-crest-and mesoderm-derived mesenchymal stem 
cells. Journal of dental research 92, 825-832 (2013). 
92 Morikawa, S. et al. Development of mesenchymal stem cells partially originate from the 
neural crest. Biochemical and biophysical research communications 379, 1114-1119 
(2009). 
93 Miller, F. D. Riding the waves: neural and nonneural origins for mesenchymal stem cells. 
Cell Stem Cell 1, 129-130 (2007). 
94 Jinno, H. et al. Convergent genesis of an adult neural crest‐like dermal stem cell from 
distinct developmental origins. Stem cells 28, 2027-2040 (2010). 
95 Isern, J. et al. The neural crest is a source of mesenchymal stem cells with specialized 
hematopoietic stem cell niche function. Elife 3, e03696 (2014). 
96 George, E. L., Georges-Labouesse, E. N., Patel-King, R. S., Rayburn, H. & Hynes, R. O. 
Defects in mesoderm, neural tube and vascular development in mouse embryos lacking 
fibronectin. Development 119, 1079-1091 (1993). 
97 Wimmer, R. A. et al. Human blood vessel organoids as a model of diabetic vasculopathy. 
Nature (2019). 
98 Fatehullah, A., Tan, S. H. & Barker, N. Organoids as an in vitro model of human 
development and disease. Nature cell biology 18, 246 (2016). 
99 Cooper, T. T., Hess, D. A. & Verma, S. Vascular Organoids: Are We Entering a New 
Area of Cardiometabolic Research? Cell metabolism 29, 792-794 (2019). 
100 Rauner, M. et al. WNT5A is induced by inflammatory mediators in bone marrow stromal 
cells and regulates cytokine and chemokine production. Journal of bone and mineral 
research 27, 575-585 (2012). 
101 Miyoshi, H., Ajima, R., Luo, C. T., Yamaguchi, T. P. & Stappenbeck, T. S. Wnt5a 
potentiates TGF-β signaling to promote colonic crypt regeneration after tissue injury. 
Science 338, 108-113 (2012). 
102 Ekström, E. J. et al. WNT5A induces release of exosomes containing pro-angiogenic and 
immunosuppressive factors from malignant melanoma cells. Molecular cancer 13, 88 
(2014). 
262 
103 Arderiu, G., Espinosa, S., Peña, E., Aledo, R. & Badimon, L. Monocyte-secreted Wnt5a 
interacts with FZD5 in microvascular endothelial cells and induces angiogenesis through 
tissue factor signaling. Journal of molecular cell biology 6, 380-393 (2014). 
104 Smid, J. K., Faulkes, S. & Rudnicki, M. A. Periostin induces pancreatic regeneration. 
Endocrinology 156, 824-836 (2015). 
105 Kudo, A. Periostin in fibrillogenesis for tissue regeneration: periostin actions inside and 
outside the cell. Cellular and molecular life sciences 68, 3201 (2011). 
106 Dorn, G. W. Periostin and myocardial repair, regeneration, and recovery. New England 
Journal of Medicine 357, 1552 (2007). 
107 DeCarolis, N. A., Kirby, E. D., Wyss-Coray, T. & Palmer, T. D. The role of the 
microenvironmental niche in declining stem-cell functions associated with biological 
aging. Cold Spring Harbor perspectives in medicine 5, a025874 (2015). 
108 Huang, Y.-C., Leung, V. Y., Lu, W. W. & Luk, K. D. The effects of microenvironment in 
mesenchymal stem cell–based regeneration of intervertebral disc. The Spine Journal 13, 
352-362 (2013). 
109 Brissova, M. et al. Islet microenvironment, modulated by vascular endothelial growth 
factor-A signaling, promotes β cell regeneration. Cell metabolism 19, 498-511 (2014). 
 
 
 
 
 
 
 
 
 
 
 
 
263 
Appendices 
 
 
Appendix 1 Permission to reproduce Cooper et al. Stem Cells 
264 
 
AUP Number: 2015-033 
 
AUP Title: Transplantation of Novel Stem Cells for the 
Regeneration of B-Cell Function 
 
Yearly Renewal Date: 07/01/2019 
 
The YEARLY RENEWAL to Animal Use Protocol (AUP) 2015-033 
has been approved by the Animal Care Committee (ACC),  and 
will be approved through to the above review date. 
 
Please at this time review your AUP with your research team to ensure 
full understanding by everyone listed within this AUP. 
 
As per your declaration within this approved AUP, you are obligated to 
ensure that: 
 
1) Animals used in this research project will be cared for in alignment 
with: 
 
Appendix 2  Animal Use Protocol Ethics Approval: β-cell Regeneration 
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 a) Western's Senate MAPPs 7.12, 7.10, and 7.15                      
http://www.uwo.ca/univsec/policies_procedures/research.html  
 b) University Council on Animal Care Policies and related Animal 
Care Committee procedures                      
http://uwo.ca/research/services/animalethics/animal_care_and_use_p
olicies.html  
 
2) As per UCAC's Animal Use Protocols Policy 
 a) this AUP accurately represents intended animal use; 
 b) external approvals associated with this AUP, including permits 
and scientific/departmental peer approvals, are complete and accurate; 
 c) any divergence from this AUP will not be undertaken until the 
related Protocol Modification is approved by the ACC; and 
           d) AUP form submissions - Annual Protocol Renewals and Full 
AUP Renewals - will be submitted                        and attended to within 
timeframes outlined by the ACC.   
http://uwo.ca/research/services/animalethics/animal_use_protocols.ht
ml          
 
3) As per MAPP 7.10 all individuals listed within this AUP as having any 
hands-on animal contact will                       
 a) be made familiar with and have direct access to this AUP; 
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           b) complete all required CCAC mandatory training (  
training@uwo.ca); and                     
 c) be overseen by me to ensure appropriate care and use of 
animals.   
 
4) As per MAPP 7.15,                        
 a) Practice will align with approved AUP elements; 
           b) Unrestricted access to all animal areas will be given to ACVS 
Veterinarians and ACC Leaders;                     
 c) UCAC policies and related ACC procedures will be followed, 
including but not limited to:                                       
  i) Research Animal Procurement 
                      ii) Animal Care and Use Records                                    
  iii) Sick Animal Response 
                      iv) Continuing Care Visits       
 
5) As per institutional OH&S policies, all individuals listed within this AUP 
who will be using or potentially    exposed to hazardous materials will 
have completed in advance the appropriate institutional OH&S training, 
facility-level training, and reviewed related (M)SDS Sheets,  
http://www.uwo.ca/hr/learning/required/index.html    
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Submitted by: Copeman, Laura on behalf of the Animal Care Committee 
University Council on Animal Care 
 
The University of Western Ontario                                                         
Animal Care Committee / University Council on Animal Care                                                                         
London, Ontario Canada N6A 5C1                                                                
519-661-2111 x 88792 Fax 519-661-2028                                                 
auspc@uwo.ca� 
http://www.uwo.ca/research/services/animalethics/index.html 
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